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ABBREVIATIONS 
AD    Alzheimer's disease 
ARXAR model  bivariate causal model 
AUC   area under the curve 
BMI   body mass index 
BP    blood pressure    
BPV   blood pressure variability 
BR   baroreflex 
BRS   baroreflex sensitivity 
CA   cerebral autoregulation 
CBF    cerebral blood flow   
CBFV   cerebral blood flow velocity 
CCM   convergent cross mapping  
ChEI   cholinesterase inhibitors 
CIRS-G   cumulative illness rating scale for geriatrics 
CoV   coefficients of variation 
CRP   c-reactive protein 
CSH   carotid sinus hypersensitivity 
CSM   carotid sinus massage 
CVCI   cerebrovascular conductance index 
CVCI   cerebrovascular conductance index 
CVD   cardiovascular disease 
CVMR   cerebral vasomotor reactivity 
DPF   differential pathlength factor 
ECG   electrocardiogram 
FFT   fast Fourier transform 
fNIRs   functional near-infrared spectroscopy 
HbDiff   oxygenation index 
HF    high frequency   
HFO   high frequency oscillations 
[HHb]   deoxygenated haemoglobin concentration 
HR   heart rate 
HRV   heart rate variability 
IL-6   interleukin -6 
LF    low frequency 
LFOs   low frequency oscillations 
LPS   E. coli lipopolysaccharide 
MCA   middle cerebral artery 
MCI   mild cognitive impairment 
MUMC   Maastricht University Medical Center 
NIRS   near-infrared spectroscopy 
NR   not reported 
[O2Hb]   oxygenated haemoglobin concentration 
OH   orthostatic hypotension 
PPH   postprandial hypotension 
RMSSD-HRV  square root of the mean-squared difference of successive heart  
   beat intervals  
ROC   receiver operating characteristic 
ROC   receiver operating characteristic 
RRi   R-R interval; time between two successive heart beats 
RUNMC   Radboud University Nijmegen Medical Centre 
SBP   systolic blood pressure 
SDNN-HRV  standard deviation of all normal heart beat intervals  
TCD   transcranial Doppler 
TFA   transfer function analysis 
[tHb]   total haemoglobin concentration 
TNF-α   tumor necrosis factor alpha 
VLF    very low frequency    
VLFOs   very low frequency oscillations 
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BACKGROUND 
Cerebral perfusion 
The human brain is a complex organ that is critically dependent on its blood supply. It 
comprises only about 2 % of the total body weight. However, it consumes around 20 % of the 
total available oxygen for normal functioning [1]. This makes the brain one of the most highly 
perfused organs in the body. Unlike the kidney, liver or muscle, the brain is only able to 
withstand very short periods of inadequate oxygen supply. Insufficient blood flow and oxygen 
will result in cerebral ischemia, in which the neurons and other brain cells are damaged and 
lose their function. On the other hand, excessive blood perfusion may also have unfavourable 
consequences, such as intracranial hypertension or capillary damage. Maintenance of an 
adequate cerebral perfusion is therefore critical to ensure a sufficient delivery of oxygen and 
glucose and to avoid brain injury. As a result, regulatory mechanisms act to control systemic 
blood pressure and cerebral blood flow. This way, even under considerable external changes, 
an adequate blood- and oxygen supply to the brain is maintained in accordance with its 
underlying functional and metabolic needs. The most important aspects of the body’s 
perfusion regulation consist of the integrated control of systemic blood pressure and cerebral 
blood flow via the arterial baroreflex and cerebral autoregulation, respectively [3, 4]. 
However, literature shows that different pathological conditions, such as dementia, stroke 
and head trauma [5-9], may influence these highly important regulation systems. In subjects 
with a disturbed brain perfusion regulation, the brain may be excessively sensitive to 
fluctuations in blood pressure, which has been associated with increased morbidity and 
mortality [10, 11]. 
Maintaining safe levels of cerebral perfusion is thus essential to preserve cerebral function. 
Therefore, the ability to accurately quantify the quality of the perfusion regulation is of 
importance in clinical practice. Monitoring the quality of brain perfusion may be of benefit in 
the care of patients with brain injury, meningitis or stroke. But it may also be of importance 
for early detection of, for example, neurodegenerative diseases.  
The two mechanisms that act together to safeguard brain perfusion, blood pressure control 
(the baroreflex mechanism) and cerebral autoregulation, will be discussed below. 
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Blood pressure: the baroreflex 
The baroreflex is a reflex loop with cardiac, vascular and cerebral components involved in 
short-term blood pressure regulation [12]. The baroreflex works through the baroreceptors, 
which are stretch-sensitive fibres embedded primarily in the wall of the carotid arteries and 
aorta. Changes in blood pressure lead to changes in the arterial vessel wall, which are sensed 
by the baroreceptors and information is sent to the brainstem. Via the autonomic nervous 
system heart rate and vascular tone are changed to restore the blood pressure. A clinical 
example is the drop in blood pressure upon standing (Figure 1), which the baroreflex corrects 
by a rapid increase in heart rate (parasympathetic inhibition) followed by peripheral arterial 
vasoconstriction (sympathetic activation). Abnormalities in the vascular baroreceptors, the 
glosso-pharyngeal or vagal nerves, or the brain stem could lead to impairment of the 
baroreflex. Baroreflex failure may result in a significant dysregulation of blood pressure, 
leading to increased blood pressure variability. This may result in sudden pressure drops on 
shifting from supine to standing position as well as aberrant pressure rises with a major risk of 
fatal events such as myocardial infarction and stroke. The quality of the baroreflex function 
can, for example, be assessed by evaluating the relationship between variations in heart rate 
and blood pressure [13-15]. 
Figure 1. Example of blood pressure (grey area, the upper and lower borders corresponding to the systolic and 
diastolic blood pressures) and beat-to-beat heart rate (thin black line) of a healthy person before and after 
standing up. BP= blood pressure. HR = heart rate. 
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Cerebral autoregulation 
Cerebral autoregulation acts to maintain a relatively constant cerebral blood flow despite 
fluctuations in blood pressure. Cerebral autoregulation is achieved by changes in cerebral 
vascular tone in response to changes in intravascular pressure: when the blood pressure 
decreases the radius of the cerebral vessels increases (vasodilation; increasing the cerebral 
blood flow) and when the blood pressure increases the radius decreases (vasoconstriction; 
decreasing the cerebral blood flow). This autoregulatory mechanism was first proposed by 
Lassen et al. [4]. They proposed that cerebral autoregulation works within a certain range of 
blood pressures (≈ 60 to 150 mmHg). Outside this so-called autoregulatory range, vasomotor 
adjustments are exhausted and cerebral blood flow becomes pressure-passive and subjected 
to changes in blood pressure (Figure 2). Nowadays, this view on cerebral autoregulation is 
called ‘static autoregulation’ and is often studied using interventions inducing (large) blood 
pressure fluctuations, for example, by administering drugs that increase (phenylephrine) or 
decrease (sodium nitroprusside) blood pressure. 
Over the last two decades, techniques with a high temporal resolution (> 10 Hz) have been 
developed which allow analysis of the amplitude and time latencies of the cerebral blood 
 
Figure 2. Static autoregulation curve.  
During intact cerebral autoregulation, cerebral blood flow becomes only pressure passive when blood pressure 
comes below the lower limit or above the upper limit (based on [1]). 
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flow response to rapid (seconds) changes in blood pressure. One of these techniques is 
transcranial Doppler sonography, which uses a piezoelectric crystal probe placed on the 
temporal window of the skull. Ultrasound waves are sent through the skull and reflections of 
these waves on flowing blood result in a frequency shift of the sound. This frequency shift is 
used to quantify the cerebral blood flow velocity, which can be used as a surrogate for the 
cerebral blood flow. 
With high temporal resolution (> 10 Hz) techniques, such as transcranial Doppler, it was 
shown that sudden changes (elevation and reductions) in blood pressure are transmitted 
directly to the brain circulation under usual circumstances, but within a brief amount of time 
brain blood flow tends to return to its baseline value. This observation suggests that the 
relationship between cerebral blood flow and blood pressure within the autoregulatory range 
is not completely flat. The fast mechanisms that permit the restoration of cerebral blood flow 
after a perturbation in blood pressure are referred to as ‘dynamic cerebral 
autoregulation’ [16]. In subjects with a disturbed dynamic cerebral autoregulatory 
functioning, the brain may be excessively sensitive to short-term fluctuations in blood 
pressures. 
Several methods of analysis, involving a diversity of protocols, measurement techniques and 
data analysis approaches, have been developed for non-invasive assessment of dynamic 
cerebral autoregulation. These techniques can be split up into time domain (i.e. correlation 
index [17]), frequency domain (i.e. transfer function analysis [18]) and non-linear measures 
(i.e. Laguerre expansions of Volterra kernels [19]). 
1 
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AIM OF THIS THESIS 
Accumulating evidence indicates that, in clinical situations, information from baroreflex 
functioning and dynamic cerebral autoregulation is crucial for correct interpretation of the 
impact of severe interventions or events that may threaten the vulnerable brain 
tissue [5, 20-22]. Keeping the blood pressure at an adequately stable level, by careful 
monitoring and rapid correction, may be of great importance in such circumstances. 
Despite the importance of measuring the cerebral autoregulatory performance, currently no 
gold standard test of autoregulation exists that may be performed safely and easily in a wide 
sphere of clinical conditions. Many uncertainties exist with regard to the applied methods, 
making it difficult to replicate or compare the results of different studies, and this further 
hinders the applicability in clinical practice. 
In the first part of this thesis, we aim to obtain better insight into the quantification of 
cerebral autoregulation. A special focus is placed on the most often applied non-invasive 
technique for the analysis of cerebral autoregulation, namely transfer function analysis. The 
first main research question is: 
 
How is transfer function analysis applied  
for the quantification of cerebral autoregulation? 
 
By performing an extensive literature search and through debate with experts in the field, the 
current state of the art was reviewed. All this was done with the ultimate goal to come to a 
consensus agreement on how to quantify cerebral autoregulation. 
In the second part, the emphasis is shifted to haemodynamics in clinical practice. We aim to 
investigate whether perfusion regulation is changed in different pathophysiological 
conditions. Inspired by the clinical background of the department where this thesis research 
was performed, we chose conditions that are of relevance for an elderly population. The 
second main research question is : 
 
Is the perfusion regulation impaired  
in patients with Alzheimer’s disease, frail elderly and/or during systemic inflammation? 
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OUTLINE OF THIS THESIS 
The two general aims have been translated in a series of background studies, clinical 
experiments and retrospective analysis which are presented in the subsequent chapters of 
this thesis. 
Part 1. Quantification of cerebral autoregulation (Chapter 2 to 5) 
Research question: 
How is transfer function analysis applied for the quantification of cerebral autoregulation? 
Chapter 2 provides a systematic review on transfer function analysis, the most widely used 
method for the quantification of cerebral autoregulation based on spontaneous oscillations in 
blood pressure and cerebral blood flow velocity. The mathematical background of the 
method is described and an overview is given of how the method is applied by different 
researchers. One hundred thirteen articles were included and, specifically, the enormous 
heterogeneity in outcome values was addressed.  
Chapter 3 dives deeper into the variations found in the application of the transfer function 
analysis for quantification of cerebral autoregulation. A multi-centre study was performed to 
provide insight into the between-centre variation in transfer function outcomes. Next to the 
examination of clinical data, artificial datasets were used to examine the effect of different 
parameter settings on transfer function outcomes.  
Chapter 4 proposes a consensus for international guidelines on transfer function analysis for 
the quantification of cerebral autoregulation. 
Chapter 5 introduces a new non-linear method for the quantification of cerebral 
autoregulation. Despite the fact that transfer function analysis is the most used method in 
literature for the quantification of cerebral autoregulation, transfer function analysis may not 
be able to cover the whole process of cerebral autoregulation as it is based on the 
assumption that cerebral autoregulation is a linear process. However, it has been observed 
that the coherence function between blood pressure and cerebral blood flow is reduced 
below 0.07 Hz [23], indicating intrinsic non-linearities and/or non-stationarities in this 
frequency range [24]. This observation and the fact that the static autoregulation curve is 
non-linear make that one cannot confidently ascertain that cerebral autoregulation is not a 
1 
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non-linear process. The usage of non-linear methods may thus provide a broader notion of 
the mechanism pertinent to cerebral autoregulation [25]. This study investigates the usage of 
the non-linear analysis technique, convergent cross mapping, for the quantification of 
cerebral autoregulation.  
Part 2. Clinical application of haemodynamic analysis (Chapters 6 to 11) 
Part 2.1. Alzheimer’s disease 
Research question:  
Is the perfusion regulation impaired in patients with Alzheimer’s disease? 
Alzheimer’s disease, the leading cause of dementia, is a progressive neurodegenerative 
disorder. There is still a limited understanding of this disease and its underlying cause. A 
growing body of evidence points towards vascular pathology involvement in the disease. This 
vascular hypothesis states that systemic and cerebral vascular effects contribute to 
neurodegeneration and development of Alzheimer’s disease. 
Chapter 6 investigates the cerebral autoregulation in patients with Alzheimer’s disease. In 
addition to the transfer function analysis, cerebral autoregulation was assessed by 
investigating the effect of (repeated) sit-stand manoeuvres on blood pressure and cerebral 
blood flow velocity. Next to the cerebral autoregulation, the cerebral vasomotor reactivity 
was investigated, which is a mechanism that reflects the uniquely strong response of cerebral 
blood vessels to changes in arterial carbon dioxide concentration.  
Chapter 7 continues the research in the vascular hypothesis for Alzheimer’s disease. This 
study explores the role of the baroreflex functioning in the pathophysiology of Alzheimer’s 
disease.  
Part 2.2. Frail elderly 
Research question:  
Is the perfusion regulation impaired in frail elderly? 
Aging is associated with physiological changes of the vascular system. The systemic and 
haemodynamic regulation systems may be affected, creating a higher risk of cerebral 
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hypo- and hyperperfusion. 
Chapter 8 examines the effect of aging itself on cerebral haemodynamics. 
Hypertension affects 20% to 30% of the world population and is the most prevalent 
modifiable risk factor for stroke. Long-standing hypertension may result in structural changes 
of the cerebral vessels, such as thickening of the vessel walls with narrowing of the lumen and 
hyalinosis of the media resulting in stiffness.  
Chapter 9 describes how hypertension in elderly influences the baroreflex function, cerebral 
autoregulation and cerebral vasomotor reactivity. 
Also among elderly, the prevalence of orthostatic hypotension, postprandial hypotension and 
carotid sinus hypersensitivity is high. These disorders of blood pressure regulation may cause 
severe cerebral hypoperfusion, causing symptoms as weakness, dizziness and syncope. 
Orthostatic hypotension is predominantly seen as a disorder of autonomic failure and 
postprandial hypotension and carotid sinus hypersensitivity are classified as reflex or neurally 
mediated syncope. As the cardiovascular autonomic system plays an important role in the 
distribution of blood volume and the regulation of blood pressure, failure of this system 
might play an important role in the aetiology and pathophysiology of these hypotensive 
syndromes. 
Chapter 10 investigates whether orthostatic hypotension, postprandial hypotension and/or 
carotid sinus hypersensitivity are related to changes in heart rate variability, blood pressure 
variability and/or baroreflex functioning. 
Part 2.3. Inflammation 
Research question:  
Is the perfusion regulation impaired during systemic inflammation? 
Sepsis is a systemic host response to a severe bacterial infection, characterized by a 
widespread state of inflammation, often complicated by organ dysfunction or failure. It is a 
potentially deadly medical condition, often accompanied by irreversible acute cerebral 
dysfunction. Despite the fact that the exact pathophysiology remains unknown, many 
indicators, such as reduced global perfusion, disruption of the blood-brain barrier and 
1 
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cerebral edema, point towards a link between cerebral perfusion and brain dysfunction. 
Chapter 11 describes the use of purified E. coli lipopolysaccharide, as an established human in 
vivo model of the systemic inflammatory response that occurs during early sepsis, to assess 
the effect of the systemic inflammatory response on cerebral autoregulation functioning. 
General discussion and summary 
Chapter 12 provides a general discussion of the findings in this thesis. 
Chapter 13 provides a summary of the chapters in this thesis. 
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ABSTRACT 
Cerebral autoregulation (CA) is a key mechanism to protect the brain against excessive 
fluctuations in blood pressure (BP) and maintain cerebral blood flow. Analysing the 
relationship between spontaneous BP and cerebral blood flow velocity (CBFV) using transfer 
function analysis is a widely used technique to quantify CA in a non-invasive way. The 
objective of this review was to provide an overview of transfer function techniques used in 
the assessment of CA. 
For this review, 113 publications were included. This literature showed that there is no gold 
standard for the execution and implementation of the transfer function. There is a high 
diversity in settings and criteria used for transfer function analysis. Notable is also the high 
number of studies which report little on the settings. 
This disparity makes it difficult to replicate or compare the results of the different studies and 
further hinders the opportunity to make a distinction between intact and impaired CA in 
different patient groups. 
More research on the effects of different implementation techniques on outcomes for CA and 
optimization of the transfer function analysis is urgently needed. Furthermore, the results of 
this review show that international guidelines should be created to inform the minimal 
description of the applied technique and the interpretation of transfer function outcomes in 
scientific research. 
2 
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INTRODUCTION 
Cerebral autoregulation 
Cerebral autoregulation (CA), first introduced by Lassen et al. [8], refers to the intrinsic ability 
of the brain to stabilize cerebral blood flow despite changes in blood pressure (BP) [10, 11]. 
CA is a key protective mechanism of the brain, and has an important role during both 
physiological and pathological situations [12]. A reduction in CA has been reported in for 
example carotid artery disease [13], severe head injury [14], ischemic stroke [15], 
hypertension [16], Parkinson’s disease [19] and obstructive sleep apnoea [20]. In subjects 
with a disturbed CA, the brain may be excessively sensitive to fluctuations in BP. 
Autoregulation failure has been associated with increased morbidity and mortality [21]. 
However, the underlying mechanisms that cause the impairments in CA are not yet fully 
understood. 
Dynamic cerebral autoregulation  
For a long time, CA was considered as a static phenomenon [23], namely the regulation of 
cerebral blood flow during gradual changes (minutes – days) in BP. Evaluation of CA was 
performed by investigating the difference in cerebral blood flow before and after the 
autoregulatory response to a manipulation in BP. If the cerebral blood flow changed 
significantly, CA was said to be impaired. If cerebral blood flow remained nearly constant, CA 
was said to be intact [25]. Over the last two decades, the high temporal resolution of 
transcranial Doppler (TCD) sonography allowed analysis of the amplitude and time latencies 
of the cerebral blood flow velocity (CBFV) response to rapid (seconds) changes in BP [26]. It 
was shown that, under normal conditions, CBFV tends to return to its original value with a 
time constant of a few seconds. The evidence that cerebral blood flow, after a perturbation, 
requires a finite amount of time to return to its original value has led to the distinction 
between ‘static’ and ‘dynamic’ CA [28]. This dynamic approach quantifies the fast 
modifications in cerebral blood flow in relation to rapid alterations in BP within the upper and 
lower limits of static CA and reflects the latency and efficiency of the cerebral vasoregulatory 
system [35]. In contrast to static CA, dynamic CA allows differentiation of the CA responses to 
fluctuations in BP of different amplitudes and durations, representing daily life challenges for 
CA [25]. Non-invasive evaluation of CA could be a source of valuable information for clinical 
management. 
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Induced changes / challenges 
In order to induce changes in BP and CBFV, and thus to quantify dynamic CA, several methods 
have been developed. The traditional techniques assess CA by challenging the 
cerebrovascular systems using interventions such as the cold pressor test, squat-to-stand 
and/or sit-to-stand manoeuvres and the deflation of thigh cuffs [35-37]. These interventions 
induce (large) BP fluctuations; however, they require cooperation of patients and can be 
uncomfortable, making them unsuitable in cases of severe illness or in older or cognitively 
impaired persons. Furthermore, the interventions might affect other physiological 
subsystems (e.g. sympathetic activation with the cold pressor test) or parameters (e.g. pCO2 
with squat-to-stand and/or sit-to-stand [35]), confounding the results. This limits their value 
for daily practice in a clinical setting in a broad range of patients. 
Spontaneous changes 
Fortunately, several methods of analysis, involving a diversity of protocols, measurement 
techniques, and data analysis approaches, have been developed for non-invasive assessment 
of dynamic CA in the resting state [12]. These techniques use spontaneous fluctuations in BP 
and CBFV. The advantages of using spontaneous oscillations are that they do not need 
additional clinical manoeuvres, are less laborious and may be used in a wider range of 
patients, including those who are unstable or unable to cooperate with or tolerate the 
challenges required to provoke a haemodynamic response [12]. Moreover, they allow 
continuous, non-invasive monitoring for cerebrovascular function. Of all available methods to 
do this, the transfer function analysis is the most frequent method reported in literature to 
quantify CA using spontaneous fluctuations. The transfer function method, first carried out to 
quantify dynamic CA by Giller et al. [39], analyses the relationship between the oscillations in 
BP and CBFV in the frequency domain. 
Aim of this study 
The first objective of our investigation is to provide an overview of the variations in the 
transfer function technique as it is used in the scientific literature to assess dynamic CA for 
spontaneous oscillations in BP and CBFV. The hypothesis was that there were variations in 
transfer function methods between countries and between centres, and that these variations 
make direct comparisons between studies difficult if not impossible. The second objective 
was to assess the reproducibility and potential utility as a clinical test of the transfer function 
2 
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analysis for CA as reported by multiple investigators. Since previous studies on CA have used 
relatively small sample sizes, the aim was to combine results of multiple studies to investigate 
the inter-study variability in CA values for healthy subjects and to obtain insight into the 
discriminative power of the transfer function analysis between physiological and pathological 
conditions. 
METHODS 
Literature search 
To retrieve the studies that had used transfer function analysis to assess dynamic CA for 
spontaneous BP and CBFV oscillations, an online search of the literature (PubMed, Embase 
and WebOfScience) was conducted on October the 15th 2012, including only articles written 
in English. Search terms included are shown in Table 1. Two authors (AM, AB) independently 
assessed eligibility by reading abstracts and, if necessary, whole articles. The snowball 
method was used to manually identify relevant references from the reference lists of 
included articles. Animal studies or articles that used any manoeuvre or intervention to 
change BP and quantify CA were excluded from the search. The following data were extracted 
from the remaining articles: number of included subjects, health status, physiological 
condition used, status of CA and technical aspects of the transfer function analysis used to 
assess CA. 
Table 1. Search terms. 
 
 
   AND 

O
R
  
cerebral autoregulation TFA 
cerebral homeostasis transfer function 
cerebral blood flow autoregulation transfer-function 
cerebral pressure regulation transfer analysis 
cerebral pressure autoregulation   
cerebral blood pressure regulation   
cerebral blood pressure autoregulation   
cerebrovascular autoregulation   
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Transfer function analysis 
Evaluation of CA by transfer function analysis is based on the concept that CA minimizes the 
effect of spontaneous BP oscillations on CBFV. Without CA each spontaneous oscillation in BP 
would cause an oscillation of a similar duration, magnitude and frequency in CBFV. The 
method of transfer function analysis has already been used extensively in, for example, the 
investigation of cardiovascular control, respiratory sinus arrhythmia and renal auto-
regulation  [43-45]. Spectral analysis, such as performed with the fast Fourier transform (FFT), 
transforms time series of BP and CBFV to the frequency domain. Then, the transfer function 
between the two signals can be calculated as: 
H (f) = Sxy (f) / Sxx (f)    1. 
Where Sxx (f) is the autospectrum of the input signal, BP, and Sxy (f) is the cross spectrum 
between the input signal, BP, and output signal, CBFV [7]. With the transfer function the 
associated relative power (gain) and timing (phase) can be described using the real part HR (f) 
and the imaginary part HI (f) of the complex transfer function: 
gain: | H (f) | = √ {| HR (f) |2 + | HI (f) |2 }  2. 
phase: Ф (f) = tan-1[HI (f) / HR (f) ]   3. 
An estimate of reliability of the relationship between the two signals can be found as the 
squared coherence: 
coherence: MSC (f) = | Sxy (f)|
2 / [Sxx (f) Syy (f)]   4. 
where Syy (f) is the autospectrum of changes in CBFV. 
As representative of the linear association between the fluctuation in blood pressure and 
cerebral blood flow, the coherence is in some studies also used as a measure for CA. 
Coherence approaching zero indicates no relationship between BP and CBFV, whereas a 
coherence approaching unity suggests a linear relationship indicating CA impairment. 
In the first study of CA using the transfer function approach and spontaneous fluctuations in 
BP estimates of the amplitude frequency response (gain) and coherence were obtained, but 
not the phase frequency response [39]. The studies following after the first publication of 
2 
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Giller et al. all reported the transfer function in different ways, some calculating the gain 
and / or phase, and / or coherence, others using the transfer function to obtain the impulse 
and step responses from which autoregulation can be quantified using the autoregulation 
index or other measures [6, 28]. 
Different settings of transfer function analysis 
Despite the fact that the quantification of the transfer function seems straight forward, many 
different settings are used, such as the type of input data (CBFV, ABP, raw- or averaged over 
heart-beats), sampling frequency, detrending, normalization, interpolation, filtering, 
anti-leakage window, window length, superposition and spectral smoothing. Input data 
stands for the data that is used as input for the transfer function analysis, i.e. beat-to-beat BP 
in mmHg and CBFV in cm/s. The sampling frequency defines the number of times per second 
that the continuous signals are sampled and used for analysis. Some studies resampled their 
signals after storage, in those cases the resampling frequency is taken as sampling frequency 
for this review. Resampling is for example used to obtain equidistant time interval data for 
beat-to-beat data. Detrending, normalization, interpolation and filtering are four examples of 
pre-processing steps. Detrending means removing any linear or non-linear trends from the 
input data to avoid distortion of the low-frequency power. Normalization of BP and / or CBFV 
can be used to account for some inter-subject variability. An example of normalization is 
dividing the signal by its mean value, resulting in zero-mean signals which reflect relative 
changes in BP and/or CBFV [6]. Interpolation, a method of constructing new data points 
within the range of a discrete set of known data points, can be used to create equidistant 
time intervals (in case of beat-to-beat data) which is a prerequisite for transfer function 
analysis. Interpolation can also be used to downsample the data. Care must be taken to apply 
anti-alias filtering before downsampling. Filtering can be used to delete frequencies that are 
of no interest, such as very high frequencies or extremely low frequencies. For the estimation 
of the transfer function, the signal needs to be broken into overlapping segments (windows), 
to reduce the random errors in the estimates. However, this also leads to a distortion known 
as spectral leakage [57]. There are different kinds of anti-leakage windows, such as 
cosine-tapered window and Hanning window [58]. The window length represents the number 
of data points in that window, which will then define the frequency resolution of the transfer 
function estimates. Estimation errors in transfer function analysis are then reduced by 
averaging auto and cross-spectral estimates over the multiple data segments (Welch 
method). Further improvements can be achieved by spectral smoothing, by applying a 
low-pass filter to spectral estimates, before calculating the transfer function with equation 1 
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above. Usually triangular moving average filters are used for this purpose. 
Statistics 
The results of the articles were combined to obtain reference values for CA for all units used 
in the literature for calculating the transfer function. To obtain normal values for CA from the 
reported results, all the retrieved values were combined. The pooled mean and pooled 
standard deviation are calculated by weighting the individual values with the sample size of 
the corresponding study. 
RESULTS 
One hundred and ninety publications met the search criteria and were evaluated. Figure 1 
shows a flowchart of the literature review process. After reading abstracts and, if necessary, 
whole articles, 85 publications were excluded because the studies were performed in animals 
or they used any manoeuvre or intervention to quantify CA. By means of the snowball 
method four articles were added to the set of included articles. Hence, 113 publications were 
eligible for review. Table 2 lists the set of included publications. The term dynamic CA was 
introduced by Aaslid in 1989 [67] and the transfer function analysis was first used to quantify 
CA by Giller et al. in 1990 [39], therefore the articles included in this review were all published 
between 1990 and 2012 (Figure 2). Figure 2 shows the number of studies using spontaneous 
oscillations in BP and CBFV to assess dynamic CA for each year. Study details are discussed in 
the next sections. 
Figure 2. Number of included studies plotted against the year of publication. 
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Figure 1. Study inclusion diagram. 
A total of 85 (65+20) publications were excluded because they were animal studies or studies that used any 
manoeuvre or intervention to quantify CA. Through the snowball method (dashed line) four articles were 
added. All included publications were categorized in one or more groups: healthy subjects, pathology and/or 
physiology. The group ‘healthy subjects’ includes studies which used healthy subjects for their analysis. A 
subgroup is created for the studies which presented the numeric values for their CA results in their articles 
(box: present results). The group ‘Pathology’ includes studies which investigated CA in a pathological condition, 
further categorized as ‘(cerebro) vascular disease’ and ‘other’. The group ‘Physiology’ includes studies which 
obtained CA values in physiological situations, such as hypercapnia and exercise. This group is further 
categorized as ‘circumstantial situations’ and those investigating methodological issues (box: 
‘methodological’) . n is the number of studies found. 
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Variation in transfer function analysis parameter settings 
Figure 3 shows the overall heterogeneity in the use of transfer function of the studies. The 
percentage of studies (y-axis) using specific settings is shown for the ten most reported 
analysis parameters (x-axis): input data (beat-to-beat values or raw instantaneous CBFV and 
BP), sampling frequency, detrending, normalization, interpolation, filtering, anti-leakage 
window, window length, superposition, and spectral smoothing. It should be noted that not 
every study reported information on all of the ten analysis parameters. It is possible that 
some of the investigators thought no application of those were general and therefore not 
necessary to mention. 
As input data, the majority of the studies have used beat-to-beat BP and CBFV for their 
analyses (75 %), 23 % used the raw waveform data and 2 % did not report their setting. 
Regarding the sampling frequency, studies reported a wide range in different sample 
frequencies: the lowest sampling frequency was 0.5 Hz [72], the highest 100 Hz [73-75], 
whereas 28 % of the studies did not report sampling frequency. 
The vast majority of studies (85 %) did not report whether or not they had used detrending. 
When detrending was mentioned, 3 % did not specify the method used, 7 % used linear 
detrending, and 5 % applied non-linear functions to detrend the data. 
Regarding normalization of CBFV, 9 % of the included studies normalized the CBFV, 6 % 
normalized both BP and CBFV, and 84 % of the studies reported no normalization of the data. 
The different interpolation methods used by the studies can roughly be split up into two 
groups: linear- (32 %) or polynomial / spline (24 %) interpolation. Again, a substantial part of 
the studies (43 %) did not report whether or not they had used interpolation or not. 
Regarding filtering, 89 % did not mention using a filter, 7 % used low pass filtering, 2 % high 
pass filtering and 2 % used other types of filtering. 
Three types of anti-leakage windows were used: the Hamming or Hanning window (27 %), the 
cosine-tapered window (5 %) and the rectangular window (1 %). 
The window length was not reported in 68 % of the studies. The other 32 % of the studies 
showed a high diversity in window lengths ranging from 30 s to 256 s. Superposition was only 
mentioned in 31 % of the studies; most of those studies (23 %) used 50 % superposition. 
Spectral smoothing was only reported in 4 % of the studies. 
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Figure 3. The percentage of studies (y-axis) using specific settings for the quantification of the transfer function 
for the ten most reported analysis parameters (x-axis): input data, sampling frequency, detrending, 
normalization, interpolation, filtering, anti-leakage window, window length, superposition, spectral smoothing. 
NR is not reported, rect. is rectangular, poly. is polynomial. 
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Figure 4. Overview of the frequency distributions used in the different studies.  
The vertical axis represents the number of studies (n) who used the corresponding frequency bands. The 
dotted lines show frequency distributions used to represent the very low frequency range, the solid lines 
represent the low frequency range, and the dashed lines represent the high frequency range. The grey vertical 
lines indicate the average cut-off start frequency used in the studies for the very low-, low-, and high- 
frequency range, respectively. 
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Results of transfer functions analysis 
The transfer function analysis results in values of gain, phase and coherence. Since the 
transfer function contains frequency-specific information the gain, phase and coherence can 
be represented in graphs or as values for different frequency bands (using the mean, the 
integrated area or the maximal values). Figure 4 gives an overview of the frequency ranges as 
they were reported in the retrieved studies. A total of 92 studies reported their frequency 
ranges. 
Gain, phase and coherence results can be represented in different units, for example as     
cm/s/mmHg or %/% for gain. The units for gain used by the retrieved studies were              
cm/s/mmHg (64 %), %/% (15 %), %/mmHg (9 %), cm/s/% (2 %), dB (4 %), unit/mmHg (2 %) 
and no units (n.u.) (4 %). For the phase the following units were used: degrees (31 %), 
radians (69 %) and n.u. (2 %). For the calculation of reference values for phase in this study, 
degrees were converted to radians.  
Reference values 
From the search, 55 studies, with a total of 958 subjects, were included containing values for 
gain, phase and / or coherence of healthy adults. Concerning the differences in frequency 
ranges used, the data were sorted for very low frequency (VLF), low frequency (LF), and high 
frequency (HF) using the denominations as they were used in the articles. For example, 
Van Beek et al. used the frequency range 0.02 - 0.07 to represent the VLF, 0.07 - 0.2 to 
represent the LF, and 0.2 - 0.35 to represent the HF [79], consistent with the ranges proposed 
by Zhang et al. [35]. Reference values for the non-invasive determination of CA with transfer 
function analysis in healthy subjects are given in Table 3. In Figure 5 a graphical 
representation of the transfer function results for healthy subjects is given for the gain in   
cm/s/mmHg, the phase in radians and the coherence. The graph was obtained by 
extrapolating the mean values and standard deviations as quantified by each study, over the 
corresponding frequency band. Next the pooled mean and standard deviation for all the 
studies were calculated for each frequency point. 
Distinction of CA in physiology 
CA studies have been performed in different physiological conditions, such as 
hypercapnia [7], exercise [83], and head down tilt [85]. Hypercapnia, a model for impaired CA, 
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Figure 5. Graphical representation of the transfer function values found in the different studies.  
The graph shows the gain in cm/s/mmHg (A), the phase in radians (B), and the coherence (C). Results are 
represented by the pooled mean (black line) ± pooled standard deviation (grey lines).  
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Table 3. Reference values for the non-invasive determination of CA with transfer function analysis in healthy 
adults. The values for gain are represented for 6 different indices, cm/s/mmHg, %/%, %/mmHg, dB, unit/
mmHg, mmHg/cm/s, cm/s/%, and no units (n.u.), respectively. The phase is represented in radians.  
Frequency domain measurements 
Frequency 
band 
Gain     
Units n subjects n studies Value Std 
VLF cm/s/mmHg 422 23 0.77 0.34 
 %/% 89 4 0.74 0.21 
 %/mmHg 134 1 1.26 0.63 
 dB 16 2 -0.43 1.14 
 unit/mmHg 37 1 1.64 0.57 
 mmHg/cm/s 0 0 - - 
 cm/s/% 8 1 0.36 0.05 
 n.u. 30 1 1.59 0.72 
LF cm/s/mmHg 548 33 1.12 0.42 
 %/% 83 5 1.63 0.5 
 %/mmHg 232 4 1.46 0.4 
 dB 16 2 2.95 0.85 
 unit/mmHg 37 1 1.41 0.46 
 mmHg/cm/s 7 1 0.7 0.1 
 cm/s/% 8 1 0.45 0.03 
 n.u. 60 3 1.64 0.48 
HF cm/s/mmHg 299 24 1.33 0.43 
 %/% 0 0 - - 
 %/mmHg 88 2 1.36 0.15 
 dB 0 0 - - 
 unit/mmHg 37 1 1.26 0.48 
 mmHg/cm/s 7 1 0.8 0.1 
 cm/s/% 8 1 0.3 0.04 
  n.u. 30 1 1.9 0.43 
 Phase     
  Units n subjects n studies Value Std 
VLF radians 573 31 0.79 0.5 
LF radians 781 41 0.61 0.27 
HF radians 409 27 0.05 0.28 
Frequency 
band Coherence         
Units n subjects n studies Value Std 
VLF n.u. 799 29 0.49 0.16 
LF n.u. 834 35 0.67 0.15 
HF n.u. 558 25 0.44 0.17 
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is the most investigated physiological state in CA studies. During CO2 inhalation, elevations in 
PCO2 lead to vasodilatation of cerebral arterioles in the downstream bed and subsequently to 
an increase in cerebral blood flow [86]. This strong vasodilatation could impair the 
vasoconstrictive response to a blood pressure increase. Likewise, it could impair further 
dilatation in response to blood pressure decrease. These changes can result in lower phase 
and in an increased gain because there is less efficient damping of the effect of blood 
pressure fluctuations on the cerebral blood flow. However, the increased blood flow due to 
CO2 will also increase blood flow velocity, and unless relative flow-velocity changes are used 
to calculate gain, this higher absolute flow velocity will lead to higher gain estimates. In this 
case, a higher gain would not necessarily reflect impaired autoregulation. It is therefore 
important to consider changes in phase and gain together. This review has found four studies 
reporting results for CA during hypercapnia [7, 17, 87, 88]. Zhang et al. tested the hypothesis 
that hypercapnia impairs CA, by giving a gas mixture of 5 % CO2 and 21% O2 balanced with N2 
to their subjects [87]. They have found that transfer gain and coherence increased and phase 
decreased in the frequency range 0.07 - 0.20 Hz compared with baseline, suggesting an 
impairment of CA during hypercapnia. Edwards et al. investigated the effect of altered arterial 
PCO2 on CA [88]. Panerai et al. made recordings before, during and after breathing a mixture 
of 5 % CO2 in air [17]. During 5 % CO2, the coherence and the gain were significantly increased 
for frequencies below 0.05 Hz and the phase was reduced for the frequency range 
0.02 - 0.1 Hz. Ainslie et al. achieved incremental hypercapnia in 10 healthy male subjects 
through 4 - min administration of 4 % and 8 % CO2 [7]. In this study, hypercapnia caused a 
progressive increase in PCO2, but there were no evident changes in transfer function gain or 
coherence. However, the phase in the VLF range was reduced during the most severe level of 
hypercapnia. The results of the four studies for the gain, phase, and coherence are plotted 
against the averaged reference value graph for healthy subjects, quantified using the 55 
studies as described above, in Figure 6. While the four hypercapnia studies reported 
significant differences in CA gain, phase, and/or coherence between normal healthy state and 
hypercapnia, no evident differences are visible between the results of the hypercapnic 
studies and the calculated reference values of this review. 
Assessment of CA in pathophysiology 
CA studies using transfer function analysis are performed in specific clinical 
conditions (n = 43). This review showed that of the clinical studies, most were done in 
patients with carotid artery disease (n = 5) [5, 64, 66, 80, 100]. Patients with carotid stenosis 
may have several factors that affect the outcome of TFA of cerebral haemodynamics. First, 
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Figure 6. Graphical representation of the results found by the studies investigating the effect of hypercapnia on 
CA plotted against the average normal values (grey lines represent the pooled standard error of the mean). The 
average normal values are quantified using the 55 studies also presented as the area between the grey lines in 
Figure 5. The graph shows the gain in cm/s/mmHg (A), the phase in radians (B) and the coherence (C). Results 
are represented by the pooled mean for each study. The different studies are represented by the black lines.  
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Figure 7. Graphical representation of the results found by the studies investigating the effect of stenosis on CA 
plotted against the average normal values (grey lines represent the mean ± pooled standard deviation). The 
average normal values are quantified using the 55 studies also presented as the shaded area in Figure 5. The 
graph shows the gain in cm/s/mmHg (A) and the phase in radians (B). Results are represented by the pooled 
mean for stenosis of at least 50 %. The different studies are represented by different symbols (, , , , 
). 
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these patients may have higher systemic and cerebral vascular resistance (due to chronic 
hypertension that is often seen in such patients) and they may have increased vascular 
stiffness due to the combination of hypertension, vascular disease and aging. The increased 
cerebrovascular resistance could enhance effective damping of rises in BP. This could lead to 
lower gain values. Lower gain in hypertension was indeed observed by Zhang et al. [101]. 
With regard to the effects of the stenosis, there is post-stenotic vasodilatation (to 
compensate for the upstream stenosis). These changes may result in a lowered vasodilatory 
capacity, which could affect gain and phase values measured in the affected circulation. 
However, carotid stenosis may also lead to lower (post-stenotic) cerebral blood-flow velocity, 
and when absolute values are calculated for gain, this may lead to lower gain estimates that 
do not necessarily reflect autoregulation. Fritzsch et al. examined whether stenotic disease of 
the carotid affects both neurovascular coupling and CA [100]. They studied 10 patients with 
altogether 13 stenosed arteries (≥ 50 %) and found no relevant differences between controls, 
non stenosed sides and stenosed sides. In this group of patients with mainly moderate 
stenosis, CA seemed to be unaltered. Hu et al. enrolled eighty-three consecutive patients with 
various degrees of carotid stenosis [5] and found that patients with unilateral high-grade 
(greater than 90 % stenosis) carotid stenosis demonstrated significant reduction in LF phase 
angle and HF gain. Reinhard et al. investigated 168 patients with severe carotid stenosis or 
occlusion using the transfer function analysis for CA [64], 30 patients with severe bilateral 
carotid stenosis (≥ 75 %) or occlusion [66], and 58 patients with severe unilateral stenosis 
undergoing carotid endarterectomy or stenting [80]. They found that all CA parameters were 
clearly impaired ipsilateral to the stenosis, compared with contralateral sides. 
The results of these studies (for stenoses of 50 % and higher) for the phase and gain are 
plotted against the averaged reference value graph for healthy subjects in Figure 7. 
DISCUSSION 
Although disorders of CA may lead to unfavourable clinical outcomes, there is currently no 
standardized test of autoregulation that may be performed safely and easily in a wide sphere 
of clinical conditions. Non-invasive methods for the quantification of CA have been 
developed, but a gold standard is lacking. The objective of our investigation was to provide an 
overview of transfer function techniques used in the assessment of dynamic CA while using 
spontaneous oscillations. Our main findings are that a large number of studies have used 
transfer function analysis to quantify CA – indicating the importance of having a non-invasive 
method to quantify CA. One might have expected, from the popularity and wide-spread use 
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of this method, and from this large amount of published studies, that issues of 
methodological variation had been properly addressed. In contrast, we found that a strong 
diversity exists in transfer function analysis, that no standard protocol exists, and that most 
studies fail to report important settings that were used to calculate the transfer function. 
The high diversity in the implementation of the transfer function reported in this review, 
infers that it is difficult to replicate or compare the results of the different studies. A major 
cause of the broad diversity is the difference in frequency range definitions. Dynamic CA is a 
frequency dependent phenomenon, and transfer function analysis actually makes use of this 
by quantifying frequency dependent changes in phase and gain. Therefore, it is obvious that 
changing the frequency definitions in a study prohibits direct comparison of that study’s 
results with those using other definitions. This makes it all the more surprising, if not 
worrisome, that we encountered such wide variety in frequency ranges in this field. 
Several other factors also contribute to this diversity, for example the differences in data 
pre-processing, such as detrending, normalization, interpolation and filtering. It is not yet 
known what effect the use of those different settings has on the outcome of transfer function 
analysis. Gommer et al. compared raw data pre-processing by mean subtraction with 
smoothness priors detrending [112]. They found no significant difference between these 
settings. However, the effect of other settings, for example the type of anti-leakage window 
used, have not yet been studied. 
Despite this broad diversity in CA values, pooling the data of the different studies led to 
encouraging results. Even though there was the expectedly large between-centre variability, 
the pooled data revealed multi-centre frequency plot trends for phase and gain that were 
consistent with the original high pass filter model for dynamic CA [35], with higher values for 
phase in the lower frequencies, decreasing with increasing frequency, and lower values for 
gain in the lower frequencies, increasing with higher frequency. 
The results of CA in the pathophysiological condition of carotid artery stenosis show that, in 
most cases, phase is below average but remains within one standard deviation of values for 
healthy controls, implicating that it is difficult to distinguish normal from impaired CA due to 
stenosis. However, gain differences do exceed this one standard deviation limit, suggesting 
that gain could be a possible parameter to distinguish between impaired CA due to stenosis 
and normal CA. The physiological condition of hypercapnia showed that only for the 
coherence around 0.1 Hz all studies differed more than one standard deviation from 
2 
53  
Transfer fu
n
cti
o
n
 an
alysis fo
r th
e assessm
en
t o
f ce
reb
ral au
to
regu
lati
o
n
  
reference values. However, for gain, phase and coherence a large inter-study variability was 
found, causing high standard deviations which make that a result needs to lie further from 
the average reference value before it can be indicated as aberrant. Overall, for hypercapnia 
and carotid stenosis it was difficult to distinguish between normal and impaired CA. However, 
a limitation of this comparison of individual studies with large population averages is that 
different subgroups of data of a variety of populations and collected in different conditions 
are compared. This may indicate that results are incompatible between different estimators. 
Still, we envisage that if we succeed in standardizing transfer function analysis, this will make 
it possible to have less dispersion in the normal values for CA, and therefore make it easier to 
distinguish between normal and impaired CA. 
Regarding the possibility of different transfer function analysis settings causing the diversity in 
results, there are also other possible causes that should be considered. An important factor 
to consider in transfer function analysis is the potential presence of non-stationarities in the 
data, which could lead to distorted results. Rigorously, CA is a non-linear phenomenon due to 
the modulation of cerebrovascular resistance. Next to the potential presence of 
non-stationarities, other physiological variables can affect the blood flow and its regulation, 
such as PCO2 [115], brain metabolic activity, haematrocrit, and sympathetic tone [117]. 
Despite demonstration that for small changes in BP and CBFV, as observed during 
spontaneous fluctuations, the linear model provides an acceptable approximation [33], it is 
possible that non-stationarities cause a high spread in the results. 
Furthermore, all studies measured CBFV in the middle cerebral artery (MCA) using TCD, 
rather than cerebral blood flow. Changes in CBFV reflect changes in cerebral blood flow only 
if the MCA diameter remains constant. Numerous studies have shown that MCA diameter in 
humans remains relatively constant under a variety of haemodynamic conditions [118-120]. 
However, there is a possibility that the measurement quality differs between the centres [65], 
leading to a higher spread in transfer function outcomes. 
The outcome and conclusion of this review raises several important research questions: first 
what is the reason for the fact that different centres apply transfer function in different ways? 
An explanation could be the misinterpretation and insufficient documentation concerning the 
settings for transfer function analysis in previous studies.  
Second, how is the outcome of the transfer function influenced by different settings? To 
answer this question a multi-centre study is needed, comparing the results of different centre 
methodologies for transfer function analysis all analysing the same datasets [122]. 
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Third, is there a method to differentiate between intact and impaired CA? In the literature, 
numerous ways of differentiating between impaired and intact CA are presented, but it is 
unknown which one is most robust. In this review, we only focused on the separate outcomes 
for gain, phase and coherence for the separate frequency bands, instead of looking at a 
method which particularly focuses on the differentiation between intact and impaired CA, 
i.e. by combining the gain, phase, and coherence value. 
The fourth question is whether the transfer function analysis is the optimal way to quantify 
CA, regardless of the fact that it is the most widely used method. Possibly, other methods, 
including non-linear alternatives, could provide better results. A study comparing the 
different methodologies is therefore also necessary. 
The fifth and maybe most important question is when do we speak of impaired CA. In 
pathological cases, such as carotid stenosis and brain injury, changes in cerebrovascular 
function are often confirmed with a complementary method of determining cerebral 
haemodynamics, i.e. CO2 reactivity. However, no generally accepted gold standard test for CA 
exists, making it difficult to ascertain whether a change in transfer function parameters 
reflects a better or worse CA. In addition, at this moment, no straightforward definition of 
impairment of CA has been reported. Studying the basics of CA and the effects of changes in 
CA on transfer function parameters is therefore of great necessity for the valid interpretation 
of results. 
Overall, despite considerable interest and urgency to bring autoregulation testing to the 
clinical arena, the overall heterogeneity of the studies, as reflected in this review, calls for 
standardization of the methodology of CA quantification. With the standardization of the 
methodology it may be possible to increase the reliability of the CA measurements, making it 
possible to create gold standard values for CA in healthy subjects. These normative values will 
make it possible to distinguish between normal and abnormal CA. Ultimately this may lead to 
international guidelines for the interpretation of CA indices, making it possible to start 
international multi-centre studies to determine the predictive clinical value. Furthermore, 
these guidelines for the interpretation of CA indices will make it possible to monitor patients 
CA in a standard manner. Such monitoring might help for example to identify patients at risk 
for ischemic events, but could also help optimizing BP management in uncontrolled 
hypertensive patients. 
In summary, there is a high need for extensive standardization and validation of the CA 
quantification method to improve the reliability and usefulness of CA in clinical practice. 
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Editor’s comment:  
This paper is a laudable joint initiative by a group of researchers in the Cerebral Autoregulation Research 
Network (CARNnet -http://www.car-net.org/) to assess one of the most commonly used techniques for the 
measurement of autoregulation (Transfer Function Analysis). Different groups internationally use slightly 
different variants of the methods, and this paper addresses the justified concern that small differences in 
analysis technique may be a confounding factor in comparing results of different studies. Considerable 
dispersion was indeed observed in results of analysing identical datasets in different groups (though inferences 
as to impairment of autoregulation were generally consistent). Of additional concern is the observation that 
even when all groups were using supposedly identical methods, results differed considerably. This highlights 
the need for quality control, more training and multidisciplinary collaboration to improve robustness of results 
and compatibility between studies, a lesson one hopes might be taken up by the wider research community.  
Richard Black, Editor in Chief  
Chapter 3. 
Between-centre variability in transfer function analysis: 
the CARNet study 
Medical Engineering & Physics. 2014 May ; 36(5): 620:-627      Aisha SS Meel-van den Abeelen 
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ABSTRACT 
Transfer function analysis (TFA) is a frequently used method to assess dynamic cerebral 
autoregulation (CA) using spontaneous oscillations in blood pressure (BP) and cerebral blood 
flow velocity (CBFV). However, controversies and variations exist in how research groups 
utilise TFA, causing high variability in interpretation. The objective of this study was to 
evaluate between-centre variability in TFA outcome metrics. For this study, 15 centres 
analysed the same 70~BP and CBFV datasets from healthy subjects (n = 50 rest; n = 20 during 
hypercapnia); 10~additional datasets were computer-generated. Each centre used their 
in-house TFA methods; however, certain parameters were specified to reduce a priori 
between-centre variability. Hypercapnia was used to assess discriminatory performance and 
synthetic data to evaluate effects of parameter settings. Results were analysed using the 
Mann-Whitney test and logistic regression. A large non-homogeneous variation was found in 
TFA outcome metrics between the centres. Logistic regression demonstrated that 11 centres 
were able to distinguish between normal and impaired CA with an AUC > 0.85. Further 
analysis identified TFA settings that are associated with large variation in outcome measures. 
These results indicate the need for standardisation of TFA settings in order to reduce 
between-centre variability and to allow accurate comparison between studies. Suggestions 
on optimal signal processing methods are proposed. 
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INTRODUCTION 
Oscillations in arterial blood pressure (BP) and cerebral blood flow velocity (CBFV) can be 
used for non-invasive assessment of the dynamic pressure-flow relationship of the cerebral 
circulation. Dynamic cerebral autoregulation (CA) is an important determinant of this 
pressure-flow relationship, and transfer function analysis (TFA) is a widely used linear 
approach to quantify CA. 
The transfer function method was first carried out to quantify dynamic CA by Giller et al. [1] 
analysing the relationship between oscillations in BP and CBFV in the frequency domain. 
Evaluation of CA by TFA is based on the concept that CA minimises the effect of dynamic BP 
fluctuations on CBFV, which is reflected by reduced low-frequency gain and phase-lead of 
CBFV over BP. Without CA, CBFV would passively follow BP, and TFA would show constant 
gain and zero phase across the low-frequency band. TFA has been employed to obtain 
quantification of CA during spontaneous oscillations in BP and CBFV. Using spontaneous 
oscillations to assess CA is often preferable to interventions which induce (larger) BP 
fluctuations, since these interventions require patient cooperation and/or can be 
uncomfortable; making them unsuitable in cases of severe illness or illness that reduces 
mobility. As a consequence, TFA is currently a widely used method in literature to quantify 
CA, both in basic physiological research and in clinical studies. However, there are large 
differences in TFA outcomes between studies. These differences may be due to large 
inter-subject variation in CA, even for healthy controls, but may also be due to 
methodological differences between centres. 
A systematic review on TFA found that most studies have used relatively small sample sizes, 
and were all done under different experimental conditions and for diverse research 
purposes [2]. Furthermore, this review showed a marked diversity in the signal processing 
methods used for TFA. This makes it difficult, if not impossible, to replicate or compare the 
results of the different studies or obtain normal values for healthy subjects. 
The objective of this multi-centre study was to evaluate the differences in transfer function 
gain, phase and coherence outcomes when the same datasets are analysed by different 
centres using their corresponding routine signal processing methods for TFA. Our study also 
investigated the effects of different parameter settings for the analysis on transfer function 
outcomes. Furthermore, our study evaluated the ability of TFA to identify the effects of 
hypercapnia [3]. 
 
72  
MATERIALS AND METHODS 
Multi-centre database 
Five different centres from the UK (authors DS, RB and MC), USA (author VN), and the 
Netherlands (author JC), provided datasets containing simultaneously recorded BP and CBFV 
of subjects during rest, to create a multi-centre database. Two centres also provided datasets 
recorded during 5 % CO2 breathing, a model known to alter transfer function outcome 
measures. One centre provided artificial datasets, using synthetic CBFV signals obtained by 
applying the models proposed by Tiecks et al. [4] to BP signals randomly selected from the 
available dataset. This Tiecks model provides the autoregulatory index (ARI), ranging 
from 0 to 9; in normal subjects ARI is approximately 5 with a standard deviation of 1. Ten 
signals were generated, one for each autoregulation index (ARI), covering the full range from 
‘absent’ (ARI = 0) to ‘fastest’ (ARI = 9) autoregulation. Since most centres use beat-to-beat 
data to analyse transfer function gain, phase, and coherence, in this study we chose to use 
beat-to-beat data only. The beat-to-beat data were created using peak detection to identify 
subsequent beats, obtaining average values for BP and CBFV (unilateral) for each heart beat, 
and storing this information together with the beat-to-beat interval. The consecutive 
beat-to-beat intervals were used to reconstruct a time series of 5 min. The time-series data 
were linearly interpolated and resampled at 10 Hz to create equidistant data sampling over 
time. In some datasets an alternative procedure, with low-pass filtering of the original data 
(cut-off frequency of 0.5 Hz, third order Butterworth filter applied in the forward and reverse 
direction for a zero-phase response) was used to generate the mean BP and CBFV signals. 
In total, the database contained 80 datasets (‘subjects’), 50 beat-to-beat baseline datasets 
(normal resting baseline conditions); 20 5 % CO2-breathing datasets (from 20 subjects who 
were also included in the baseline dataset); and 10 synthetic datasets. Data files were blinded 
to the analysing centres and presented in a randomised order. 
Participating centres 
The database was analysed by 15 centres and they returned their transfer function results to 
a central collecting site (AM, JC). These centres are included in the author affiliation section. 
3 
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Methods 
Centre routine 
All centres were first asked to report their normal routine settings for TFA in a predefined 
spreadsheet, including sampling rate, filtering or other pre-processing steps, and details on 
how the TFA was performed (e.g., type of window, window length, number of windows). 
Pre-specified settings for analysis 
Centres were asked to analyse the data using their own normal routine, however with some 
restrictions. This decision was made based on a review [2] as well as a pilot study that had 
revealed such profound between-centre differences in TFA settings (for example different 
frequency band definitions, different units) that comparison between centres was impossible. 
Therefore, centres were requested to analyse the datasets using the following pre-specified 
settings: mean value beat-to-beat data as input data, no detrending, no prefiltering, number 
of windows set at 5, window length ranging between 90 s and 100 s with 50% superposition, 
Hanning window as anti-leakage window, no spectral smoothing and no phase unwrapping. 
Centres were asked to report TFA parameter results as mean values, using standardised units 
for phase (radians) and gain (cm/s/mmHg) and apply pre-specified frequency band definitions 
(very low frequency (VLF): 0.02 - 0.07 Hz; low frequency (LF): 0.07 - 0.15 Hz; high 
frequency (HF): 0.15 - 0.4 Hz). Every centre reported their TFA gain, phase and coherence 
values for each of the frequency bands for every dataset. To compare the transfer function 
data across the entire frequency spectrum, all centres were also asked to provide data to 
reconstruct frequency plots for gain, phase and coherence for ten specified subjects in the 
database. 
Assessment of between-centre variability and comparison  
As descriptors of between-centre variability, the median, quartile and min-max values for the 
TFA parameters generated by the 15 centres were listed, and clustering between centres for 
parameter outcomes was tested using three-dimensional plots for phase, gain and coherence 
for each frequency band. 
Discriminatory power was assessed for each centre’s method by comparing TFA parameter 
differences between normocapnia and hypercapnia. Finally, phase and gain values for each 
frequency band in the generated datasets were used as the reference standards to allow 
between-centre comparison; deviation from these reference values was used to create a 
ranking of the centres’ method. 
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Effect of different transfer function settings 
The usual routines, as reported by the different centres, were then evaluated. The routines  
contained different transfer function settings, such as sample frequency, interpolation, 
detrending, number of windows, window length, choice of anti-leakage window, percentage 
of superposition, and the definition of the frequency bands. 
Explanation of these settings 
The sample frequency defines the number of samples per second in which the continuous 
signals are stored. Interpolation can be used to create equidistant time intervals (in case of 
beat-to-beat data), by constructing new data points within the range of a discrete set of 
known data points. Most signal processing methods, including TFA, require equidistant data 
points. Detrending reduces the contribution of signal trends to the low-frequency power by 
removing any linear or non-linear trends from the input data. Pre-filtering can be used to 
delete frequencies that are of no interest, such as very high frequencies or extremely low 
frequencies. Data segments are usually windowed to reduce a particular kind of distortion 
called spectral leakage [5]. There are different kinds of anti-leakage windows, such as the 
cosine-tapered or Hanning window [6]. The window length defines the frequency resolution 
of the transfer function estimates. Averaging of spectral estimates over consecutive 
overlapped windows (Welch method) is used to reduce estimation errors (variance) in TFA 
estimates. As an alternative (or in addition), spectral smoothing can be achieved by applying a 
low-pass filter to spectral estimates, before calculating the transfer function. Triangular 
moving average filters are typically used for this purpose. Phase unwrapping is the inference 
of absolute phase from modulo-2π phase [7]. A cut-off value for the coherence can be used to 
assure statistical reliability of the transfer function. This cut-off value is influenced by the 
number of windows (the value is lower for a higher number of windows) and smoothing of 
the frequency spectra using for example triangular moving averaging [8]. 
To evaluate how differences in usual routine settings of the centres might influence the 
outcome of the TFA, the following settings were compared using the artificial (generated) 
datasets: sample frequency (1, 5, 10, 20 and 50 Hz), type of interpolation (linear and spline), 
type of detrending (none, removal of the mean, linear and third order polynomial 
detrending), number of windows (1, 3, 5 and 10), window length (25, 50, 100 and 300 s), 
type of anti-leakage window (Hanning, Hamming, rectangular and Tukey), and percentage 
window superposition (25, 50 and 75 %). Furthermore, different frequency bands were 
evaluated. For the VLF, the following two sets were evaluated: 0.01 - 0.04 Hz and 
0.02 - 0.07 Hz. The LF was defined as 0.04 - 0.15 Hz, 0.07 - 0.15 Hz, and 0.07 - 0.2 Hz and the 
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HF as 0.15 - 0.4 Hz and 0.2 - 0.3 Hz. Since research has shown that some studies do not use 
three separate frequency bands [2], the outcomes for CA were also evaluated for 
0.02 - 0.5 Hz. 
For these comparisons, the actual values of gain and phase of the 10 ARI models were used as 
criterion standard. Next, using this same software, the effect of changing one of the settings 
as described above was investigated. The transfer function outcomes for VLF and LF gain and 
phase obtained for these different transfer function settings were compared by ranking the 
absolute deviation of the outcomes from the criterion standard values. 
STATISTICS 
Results are presented as median, min/max, and 1st and 3rd quartiles. Results were compared 
with the Mann-Whitney test. Logistic regression was used to construct a receiver operating 
characteristic (ROC) curve, in which the optimal sensitivity and specificity combination is 
visualised. The area under the curve (AUC) was quantified as a measure of quality of the 
classification model. A p-value < 0.05 was considered statistically significant. 
RESULTS 
Centre routine 
Participating centres 
The number of participating centres in this study was 15. The approach of centre 3 is distinct 
(Laguerre expansions [9]) from other frequency-domain approaches. Centre 14 did not report 
results for coherence. Table 1 and 2 (Supplement) give an overview of the normal routine 
settings of each centre and the settings used for this study, respectively. The centres differ in 
their signal processing methods for TFA in the following parameter settings: sample 
frequency, type of interpolation used, number of windows, window length, frequency 
resolution, type of spectral smoothing and phase unwrapping. Furthermore, centre 15 
reported to normalise the BP and CBFV data by the mean value during the 5-min period and 
subtracted by 1 before applying TFA. Table 1 and 2 (Supplement) show that not all centres 
were able to report all their settings (not reported, NR) used for the TFA. 
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Figure 1. Average transfer function results (gain (A), phase (B) and coherence (C)) of the centres found for one 
subject during normocapnia. Results are represented as median (black line), min/max (grey dashed lines), and 
1st/3rd quartile (grey solid lines) for the gain in cm/s/mmHg (top), phase in radians (middle),and coherence 
(bottom). 
Figure 2. Transfer function gain (A) and phase (B) of the artificial datasets ARI 0, 2, 4 and 6, analysed using one 
set of parameter settings for TFA. The specified parameter settings were: sample frequency = 10 Hz, window 
length = 95 s, anti-leakage window = Hanning, number of windows = 5, percentage of superposition = 50%, 
frequency bands were VLF: 0.02 - 0.07Hz; LF: 0.07 - 0.15Hz; HF: 0.15 - 0.4Hz. 
3 
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Figure 3. Relation between the average outcomes for phase (y-axis), gain (z-axis), and coherence (x-axis) of the 
centres for the very low frequency (A), low frequency (B), and high frequency (C). Vertical dashed lines indicate 
the projection of each point on the x-y plane. Centre 14 is excluded from the graph, because this centre did not 
report any values for the coherence. 
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Transfer function plots 
All centres were asked to present frequency plots, analysed using the pre-specified settings, 
for certain datasets. Figure 1 represents the average transfer function plots generated by the 
15 centres for a single subject under normocapnic baseline condition. These 15 plots are 
summarised as median (black line), 1st/3rd quartile (grey solid lines) and min/max (grey 
dashed lines). The transfer function plots for gain and phase of the generated datasets 
ARI = 0, 2, 4 and 6, generated when analysed using one set of parameter settings for TFA, are 
shown in Figure 2. The specified parameter settings were: sample frequency = 10 Hz, window 
length = 95 s, anti-leakage window = Hanning, number of windows = 5, percentage of 
superposition = 50%, frequency bands were VLF: 0.02 - 0.07 Hz; LF: 0.07 - 0.15Hz; 
HF: 0.15 - 0.4 Hz. 
Figure 4. Phase results in radians (y-axis) for each centre (x-axis) showing the differences found between 
normocapnia (dark boxes) and hypercapnia (light boxes). The spread between the results is represented using 
multiple box plots. On each box, the central mark is the median value, the edges of the box are the 25th and 
75th percentiles and the whiskers extend to the most extreme data points. Asterisks (*) indicate that the 
centre found a significant difference between normocapnia and hypercapnia (p < 0.05). The graphs show the 
phase results for the VLF (A), LF (B) and HF (C). 
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Differences between centre outcomes 
Table 3, 4 and 5 (Supplement) show the numerical values (median, 1st/3rd quartile, min, and 
max) for the results found for the 50 healthy subjects per centre. The relation between the 
data generated by the 15 centres for the 50 healthy subjects is presented in Figure 3. For all 
frequency bands, a cluster is formed by the following 9 centres: 1, 2, 4, 7, 8, 10, 11, 12 and 13. 
Hypercapnia 
Figure 4 and 5 show results for phase and gain in VLF (top), LF (middle), and HF (bottom) for 
each centre (represented on the x-axis) obtained in the 20 subjects under normal resting 
conditions (normocapnia) and for these same 20 subjects during 5% CO2 breathing 
(hypercapnia), using multiple box plots.  
Figure 5. Gain results in cm/s/mmHg (y-axis) for each centre (x-axis) showing the differences found between 
normocapnia (dark boxes) and hypercapnia (light boxes). The spread between the results is represented using 
multiple box plots. On each box, the central mark is the median value, the edges of the box are the 25th and 
75th percentiles and the whiskers extend to the most extreme data points. Asterisks (*) indicate that the 
centre found a significant difference between normocapnia and hypercapnia (p < 0.05). The graphs show the 
phase results for the VLF (A), LF (B) and HF (C). 
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Figure 6. ROC curves of the centre with the best ability to distinguish  (centre 3) between normocapnia and 
hypercapnia and the centre which is least able to distinguish  (centre 14). ROC curves are derived using logistic 
regression. Logistic regression was performed using the state of CA (normal = baseline, impaired = hypercapnia) 
as the outcome value and as predictor variables the phase VLF, phase LF, phase HF, gain VLF, gain LF, gain HF, 
coherence VLF, coherence LF and coherence HF. 
Figure 7. Gain (A), phase (B) and coherence (C) results (y-axis) for ARI 0, 2, 4 and 6. The spread between the 
centres is represented using multiple box plots. On each box, the central mark is the median value of the 
centres of the specific subject, the edges of the box are the 25th and 75th percentiles and the whiskers extend 
to the most extreme data points. Results are shown for the VLF, LF, and  HF. Asterisks (*) indicate the values for 
transfer function phase and gain that were obtained by the software (written in Matlab by DS) that was used to 
generate the datasets. 
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Logistic regression was performed using the two conditions of CA (normal = baseline, 
modified= hypercapnia) as outcome value, and as predictor variables the phase VLF, phase LF, 
phase HF, gain VLF, gain LF, gain HF, coherence VLF, coherence LF, and coherence HF. 
Figure 6 shows the ROC that were generated for all centres, describing their performance in 
separating normal from modified. The graph shows ROC curves for the best (centre 3 AUC: 
0.927), the worst (centre 14 AUC: 0.68), and the median of all centres. 
Artificial datasets 
Gain (top), phase (middle) and coherence (bottom) results (y-axis) for ARI 0, 2, 4 and 6 are 
shown in Figure 7. Results are shown as median, 1st and 3rd quartile, minimum and 
maximum values of the results of all centres for the VLF, LF and HF bands. The model for fully 
impaired autoregulation, ARI = 0, showed (as expected) a phase of nearly zero and a high 
gain (≈ 1 cm/s/mmHg). The model for intact CA, ARI = 6, shows a high phase (1.1 ± 0.4 rad) 
and a low gain (0.6 ±0.2 cm/s/mmHg) in the very low frequency. 
Figure 8. The transfer function results expressed in VLF gain, LF gain, VLF phase, and LF phase of ARI = 6 for 
three different parameter settings: sample frequency (1, 5, 10, 20 and 50 Hz) (A), window length (25, 50, 75 
and 95~s) (B), and different frequency bands (C). Standard indicates the actual values of gain and phase of the 
10 ARI models were used as criterion standard which were used as criterion standard value.  
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Effect of different transfer function settings 
The effect of three different parameter settings on transfer function gain and phase results 
for the ARI = 6 generated data are shown in Figure 8; sample frequency (1, 5, 10, 20 and 50 
Hz), window length (25, 50, 75 and 95 s), and different frequency bands. The best results are 
found for a sample frequency of 10 Hz (the sample frequency used to generate the data). The 
farther the sample frequency deviates from 10 Hz, the more the results deviate from the 
criterion value. Decimating the data produces larger deviations than up-sampling of the data. 
No differences were found in gain and phase estimates when different methods of 
interpolation were used (including spline versus linear interpolation), detrending versus no 
detrending (including removal of the mean, linear trend removal and third order polynomial 
detrending). Comparing the number of windows showed that using less than three windows 
resulted in less optimal results. 
Also using window lengths smaller than 75 s resulted in larger deviations from the criterion 
value, particularly in the VLF. Using the Hamming or Hanning anti-leakage window did not 
result in different outcomes, but rectangular and Tukey window showed different results 
compared to the Hamming and Hanning windows. The rectangular window yields inferior 
results in LF gain and VLF phase and the Tukey window distorts the gain and the phase in 
the VLF. Varying the percentage of superposition, using percentages of 25 %, 50 % and 75 %, 
did not affect the outcomes. The use of different frequency bands affected outcomes for 
phase in VLF and in LF. Using a frequency band of 0.02 - 0.5 Hz led to the strongest deviation 
from the criterion value. 
DISCUSSION 
Strong diversity exists in the signal processing methods for TFA used by the international 
research community in quantifying CA. The objective of this multi-centre study was to 
evaluate how this diversity in methods affects transfer function outcomes for CA. An 
important underlying question was whether these between-centre differences in how to 
perform TFA may contribute to the large variability in TFA outcomes in the literature. This 
objective was achieved by asking different centres that use different methodological 
approaches for TFA, to analyse the same dataset. Our main finding is that TFA analysis — of 
the same dataset — by these centres led to a large variability in metric outcomes. This large 
variability could in part be explained by the use of different parameter settings for TFA by 
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these centres, however part of the variability remains unexplained. This finding of large 
between-centre variability is in agreement with the results of a systematic review of 
published TFA studies [2]. Our study adds to this review by directly comparing multiple 
centres that analyse the same set of data. Furthermore, we systematically evaluated how 
different choices for the signal processing methods will affect outcomes. 
Non-invasive monitoring of CA is important, since disorders of CA may lead to adverse clinical 
outcomes such as cerebral hypoperfusion [10]. Currently, no gold standard test for the 
assessment of dynamic CA exists. TFA is the most widely used and reported method for 
non-invasive quantification of CA. However, no standardised form for the implementation of 
the transfer function exists, resulting in high diversity among studies [2]. Our study showed 
that the inter-centre variability is quite high, particularly for a procedure that is deemed 
rather straightforward and places restrictions on the choice of implementation parameters. 
Even though instructions were given to the centres that should have reduced variability, the 
observed high spread in CA outcomes was still due to diversity in TFA signal processing 
choices. Parameter settings that differed between the centres were: sampling frequency, type 
of interpolation, number of windows, window length, type of anti-leakage window, frequency 
resolution, type of spectral smoothing and phase unwrapping. Based on our analyses 
discussed below, we can conclude that these differences in settings are in part responsible for 
the high diversity in results from the different centres. Not all variance could however be fully 
explained by these settings. Nevertheless, despite the large variance, most centres showed 
good ability to distinguish between normal CA and modified CA (using hypercapnia). Even the 
poorest performing centre had a ROC AUC higher than 0.75. 
Effect of different parameter settings on TFA outcome  
To further investigate how different settings may affect TFA analysis, in a sub-study we used 
artificially generated datasets to systematically evaluate how different parameter settings 
affect transfer function outcome. These analyses were performed in a single centre. We did 
this by running repeated analyses of these artificial datasets, using analysis software written 
in Matlab® (by author DMS), each time changing a single parameter setting. These analyses 
showed that particularly the sampling frequency, number of windows, window length, type of 
anti-leakage window, and the definition of frequency bands influenced the results. Regarding 
the sampling frequency, we found that both decimating and up-sampling the data altered the 
results. A reduction of sample frequency resulted in a VLF phase decrease for the artificial 
data. When we compared the clustered centre data (1, 2, 4, 7, 8, 10, 11, 12 and 13) this VLF 
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phase decrease was confirmed by the results of centre 4 that used a sample frequency 
of 1 Hz. Also the centres 3, 9 and 14 used low sample frequencies and showed lower VLF 
phase. In the present study a sampling frequency of 10 Hz resulted in the best results. 
However, this could be due to the fact that the artificial datasets were created at 10 Hz. 
Therefore, a different sampling frequency may be optimal for biological signals of BP and 
CBFV; this awaits further investigation. Lowering the number of windows or the length of the 
window mainly affected the VLF outcomes, but this effect of increased VLF gain and 
decreased VLF phase with decreasing window length could not be confirmed by comparing 
the results in healthy subjects. However, since the pre-specified settings instructed the 
centres to use a window length of 90-100 seconds little between-centre variation in window 
length was present. Concerning the type of anti-leakage window, we found that the Hanning 
and Hamming window did not differ in outcome values. However, the use of a rectangular or 
Tukey window yielded inferior results. This can be explained by the fact that the rectangular 
window has excellent spectral resolution characteristics for sinusoids of comparable strength, 
but it is a poor choice for sinusoids of disparate amplitudes [6] and the Tukey window, also 
known as the tapered cosine window, has also relatively poor leakage protection. It should be 
pointed out that the analysis of synthetic data can only provide partial guidance into the 
optimal choices for estimator settings. For example, in the synthetic data, the input-output 
relationship was purely linear, and there was no noise present in the data. Thus the benefits 
of detrending or increased window-length present in signals recorded from human volunteers 
cannot be observed. 
Implications 
These results imply that standardisation of the parameter settings used to calculate the 
transfer function could substantially lower the inter-centre variability in transfer function 
outcomes. However, some methodological issues need to be considered. TFA is a linear 
method, while, in general, CA is considered to be a non-linear phenomenon. Therefore it is 
possible that other methods, i.e. non-linear approaches, may provide better estimates of CA . 
Although it is likely that variations in parameter settings may also influence metric outputs as 
observed here for TFA. We suggest that resolving the lack of methodological standardisation 
must take priority when new methods are proposed and implemented. Future studies should 
implement the approach taken in this study, with multiple centres analysing a central 
database, for a prospective study comparing different methods to analyse CA, to investigate 
whether non-linear methods are superior to TFA, while at the same time optimising 
standardisation of such methods. Another methodological issue is whether it is accurate to 
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assume that TFA wholly reflects dynamic CA. Although the relationship between cerebral 
perfusion pressure and flow are influenced by dynamic CA, it is important to recognise that 
other physiological factors such as baseline BP, PCO2 [11, 12], brain metabolic activity, and 
sympathetic tone are also influential. Because TFA considers only the BP (input) and 
CBF (output) relationship, the approach is clearly a simplification of a highly complex 
physiological system. In this context, the contribution of PCO2 as an additional input has been 
investigated by for example in [12, 13]. However, the exclusion of this (and other) inputs does 
not mean that the transfer function analysis has no clinical utility. Indeed, the medical 
literature is replete with examples of simplified measures that have been successfully applied 
as metrics for risk stratification and monitoring. A good example is the use of gait speed 
(measuring the time taken to walk 4 m) as a measure of the highly complex concept frailty, 
and even as a prediction of survival [14]. 
In conclusion, this study shows that there is an urgent need for detailed standardisation of 
the signal processing methods used for TFA. Without such standardisation, additional 
uncertainty is added to any comparison between studies of autoregulation carried out at 
different centres. 
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SUPPLEMENTARY APPENDIX 
Centre 1 2 3 4 5 6  7 8 9 10 11 12 13 14 15 
Input data beat to beat beat to beat beat to beat beat to 
beat 
raw wave-
form 
beat to beat  NR beat to beat beat to beat beat to beat raw wave-
form 
NR raw wave-
form 
raw wave-
form 
beat to beat 
Sampling frequency (Hz) 4 5 2 1 1000 1  NR 5 2 100 500 NR 50 50 5 
Type of interpolation in signal spline spline none none none none  NR none linear linear linear NR NR polyphase 
implemen-
tation, anti-
aliasing 
(lowpass) 
FIR filter 
linear 
Type of detrending spline spline none none none none  NR none polynomial 3rd order 
polynomial 
NR NR 2nd order linear none 
Number of windows spline spline none none none none  NR 4 to 10 depends on 
signal 
length 
5 NR NR NR depends on 
signal 
length 
4 
Window length in samples: 400 256 NR 64 128 depends on 
signal 
length 
 NR 512 128 128 NR NR 5000 depends on 
signal 
length 
256 
Type of anti-leakage window Hanning Hanning NR Hanning 512 Hamming  NR Hanning Hamming Hanning Hanning NR rectangle Hanning Hanning 
% of superposition 50 50 NR 50 50 50  NR 40 50 50 NR NR 50 50 50 
Frequency resolution (Hz) 0.01 0.0195 0.005 0.003 0.007 0.004  NR 0.098 NR 0.016 0.02 NR NR 5 0.02 
Type of Spectral smoothing NR triangular NR none none none  NR triangular none none triangular NR none none triangular 
Type of Phase unwrapping none arctan 
(mean (sin
(phi))/ 
mean( cos
(phi))) 
none Wrapped 
between -
pi and pi  
none none  NR remove 
negative 
values 
remove 
negative 
values 
none NR NR none none none 
Cut-off level for coherence  0.5 0.2 none none NR 0.5  NR 0.5 none none 0.5 NR 0.5 none none 
Table 1. Overview of the normal routine settings for transfer function analysis of each centre . NR is not 
reported. 
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Centre 1 2 3 4 5 6  7 8 9 10 11 12 13 14 15 
Input data beat to beat beat to beat beat to beat beat to 
beat 
raw wave-
form 
beat to beat  NR beat to beat beat to beat beat to beat raw wave-
form 
NR raw wave-
form 
raw wave-
form 
beat to beat 
Sampling frequency (Hz) 4 5 2 1 1000 1  NR 5 2 100 500 NR 50 50 5 
Type of interpolation in signal spline spline none none none none  NR none linear linear linear NR NR polyphase 
implemen-
tation, anti-
aliasing 
(lowpass) 
FIR filter 
linear 
Type of detrending spline spline none none none none  NR none polynomial 3rd order 
polynomial 
NR NR 2nd order linear none 
Number of windows spline spline none none none none  NR 4 to 10 depends on 
signal 
length 
5 NR NR NR depends on 
signal 
length 
4 
Window length in samples: 400 256 NR 64 128 depends on 
signal 
length 
 NR 512 128 128 NR NR 5000 depends on 
signal 
length 
256 
Type of anti-leakage window Hanning Hanning NR Hanning 512 Hamming  NR Hanning Hamming Hanning Hanning NR rectangle Hanning Hanning 
% of superposition 50 50 NR 50 50 50  NR 40 50 50 NR NR 50 50 50 
Frequency resolution (Hz) 0.01 0.0195 0.005 0.003 0.007 0.004  NR 0.098 NR 0.016 0.02 NR NR 5 0.02 
Type of Spectral smoothing  NR triangular NR none none none  NR triangular none none triangular NR none none triangular 
Type of Phase unwrapping none arctan 
(mean (sin
(phi))/ 
mean( cos
(phi))) 
none Wrapped 
between -
pi and pi  
none none  NR remove 
negative 
values 
remove 
negative 
values 
none NR NR none none none 
Cut-off level for coherence  0.5 0.2 none none NR 0.5  NR 0.5 none none 0.5 NR 0.5 none none 
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Centre 1 2 3 4 5 6  7 8 9 10 11 12 13 14 15 
Input data beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat  beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat 
Sampling frequency (Hz) 4 10 2 1 NR 10  10 5 2 10 10 10 NR 1 1 
Type of interpolation in signal none none none NR none none  none none linear linear linear none NR none none 
Type of detrending none none none none none none  none none none none none none none none none 
Number of windows 5 5 0 5 5 8  5 5 NR 5 5 5 5 5 5 
Window length in samples: 400 512 NR NR 256 NR  1000 512 NR 1024 NR 1000 1000 90 100 
Type of anti-leakage window Hanning Hanning NR Hanning Hanning Hamming  Hanning Hanning Hanning Hanning Hanning Hanning Hanning Hanning hamming 
% of superposition 50 50 NR 50 50 50  50 50 50 50 50 50 50 50 50 
Frequency resolution (Hz) 0.01 0.02 0.005 none NR NR  0.01 none none none NR 0.01 none 0.02 0.003 
Type of Spectral smoothing none none NR NR NR none  none none none none triangular none none none none 
Type of Phase unwrapping none arctan 
(mean (sin
(phi))/ 
mean( cos
(phi))) 
none NR NR none  none none none none NR none none none none 
Cut-off level for coherence  none none none none none none  none none none none none none none none none 
Table 2. Overview of the used settings for transfer function analysis by the centres for this study. NR is not 
reported. 
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Centre 1 2 3 4 5 6  7 8 9 10 11 12 13 14 15 
Input data beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat  beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat beat to beat 
Sampling frequency (Hz) 4 10 2 1 NR 10  10 5 2 10 10 10 NR 1 1 
Type of interpolation in signal none none none NR none none  none none linear linear linear none NR none none 
Type of detrending none none none none none none  none none none none none none none none none 
Number of windows 5 5 0 5 5 8  5 5 NR 5 5 5 5 5 5 
Window length in samples: 400 512 NR NR 256 NR  1000 512 NR 1024 NR 1000 1000 90 100 
Type of anti-leakage window Hanning Hanning NR Hanning Hanning Hamming  Hanning Hanning Hanning Hanning Hanning Hanning Hanning Hanning hamming 
% of superposition 50 50 NR 50 50 50  50 50 50 50 50 50 50 50 50 
Frequency resolution (Hz) 0.01 0.02 0.005 none NR NR  0.01 none none none NR 0.01 none 0.02 0.003 
Type of Spectral smoothing  none none NR NR NR none  none none none none triangular none none none none 
Type of Phase unwrapping none arctan 
(mean (sin
(phi))/ 
mean( cos
(phi))) 
none NR NR none  none none none none NR none none none none 
Cut-off level for coherence  none none none none none none  none none none none none none none none none 
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15 
14 
13 
12 
11 
10 
9 
8 
7 
6 
5 
4 
3 
2 
1 
C
e
n
tr
e
 
Phase (rad) 
0.7 
0.4 
0.8 
0.9 
0.7 
0.7 
0 
0.8 
0.8 
0.7 
0.2 
0.6 
0.7 
0.9 
0.7 
m
e
d
ia
n
 
Very low frequency 
0.5 
0.2 
0.5 
0.6 
0.4 
0.3 
0 
0.5 
0.5 
0.5 
0 
0.4 
0.3 
0.4 
0.4 
1
st
 q
u
ar
ti
le
 
1 
0.7 
1.1 
1.3 
1.1 
1.1 
0.1 
1.2 
1.1 
1 
0.2 
0.9 
1 
1.2 
1.1 
3
rd
 q
u
ar
ti
le
 
-0.3 
-0.5 
-0.4 
-0.1 
-0.8 
-0.7 
-0.3 
-0.2 
-0.6 
-0.2 
-0.7 
-0.3 
-0.4 
-0.7 
-0.7 
m
in
 
1.67 
1.62 
1.63 
7.69 
1.73 
1.84 
1.55 
1.58 
1.84 
1.58 
0.41 
1.4 
1.86 
1.8 
1.83 
m
ax
 
0.6 
0.4 
0.6 
0.6 
0.6 
0.6 
0.1 
0.6 
0.6 
0.4 
0.2 
0.6 
0.5 
0.6 
0.6 
m
e
d
ia
n
 
Low frequency 
0.5 
0.2 
0.5 
0.5 
0.4 
0.5 
0.1 
0.5 
0.5 
0.3 
0.1 
0.5 
0.4 
0.5 
0.5 
1
st
 q
u
ar
ti
le
 
0.8 
0.6 
0.8 
1 
0.7 
0.8 
0.2 
0.8 
0.9 
0.5 
0.4 
0.8 
0.7 
0.8 
0.7 
3
rd
 q
u
ar
ti
le
 
0.01 
-0.1 
-0.4 
0.14 
-0.2 
0.11 
-0 
0.16 
-0 
-0.1 
-0.9 
0.17 
-0.2 
0.31 
-0.2 
m
in
 
1.25 
1.11 
1.31 
7.26 
1.19 
1.41 
1.07 
1.36 
1.42 
0.91 
0.83 
1.31 
1.41 
1.28 
0.99 
m
ax
 
0.19 
0.11 
0.17 
0.22 
0.15 
0.2 
0.06 
0.19 
0.18 
0.13 
0.17 
0.15 
-0.1 
0.2 
0.13 
m
e
d
ia
 
High frequency 
0.07 
0.04 
0.05 
0.08 
0.06 
0.08 
0.03 
0.07 
0.09 
0.06 
0.01 
0.05 
-0.2 
0.08 
-0 
1
st
 q
u
ar
ti
le
 
0.3 
0.2 
0.3 
0.4 
0.3 
0.3 
0.1 
0.3 
0.3 
0.2 
1 
0.2 
0 
0.3 
0.3 
3
rd
 q
u
ar
ti
le
 
-0.3 
-0.2 
-0.3 
-0.7 
-0.3 
-0.3 
-0.1 
-0.4 
-0.4 
-0.1 
-1.3 
-0.3 
-0.4 
-0.2 
-0.4 
m
in
 
1 
1 
1 
8.75 
1 
1 
1 
1 
1 
1 
1.59 
1 
1 
1 
1 
m
ax
 
Table 3. The numerical values for the phase (median, 1st/3rd quartile, min, and max) for the results found for 
the 50 healthy subjects per centre. 
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 Table 4. The numerical values for the gain (median, 1st/3rd quartile, min, and max) for the results found for the 
50 healthy subjects per centre. 
15 
14 
13 
12 
11 
10 
9 
8 
7 
6 
5 
4 
3 
2 
1 
C
e
n
tr
e
 
Gain (cm/s/mmHg) 
0.89 
0.7 
0.76 
0.72 
0.71 
0.7 
0.88 
0.73 
0.71 
0.68 
0.76 
0.7 
0.64 
0.69 
0.67 
m
e
d
ia
n
 
Very low frequency 
0.68 
0.51 
0.57 
0.57 
0.54 
0.52 
0.64 
0.56 
0.52 
0.52 
0.63 
0.55 
0.54 
0.53 
0.52 
1
st
 q
u
ar
ti
le
 
1.2 
0.97 
0.92 
0.91 
1.0 
0.92 
1.0 
0.93 
0.97 
0.87 
0.96 
0.91 
0.91 
0.97 
0.93 
3
rd
 q
u
ar
ti
le
 
0.38 
0.29 
0.31 
0.27 
0.2 
0.25 
0.24 
0.28 
0.27 
0.27 
0.22 
0.29 
0.28 
0.25 
0.27 
m
in
 
2.1 
3.61 
3.4 
3.4 
3.7 
3.2 
2.04 
3.84 
3.25 
3.5 
2.6 
3.4 
3.4 
3.1 
3.3 
m
ax
 
1.1 
0.86 
0.93 
0.93 
0.93 
0.92 
0.86 
0.96 
0.93 
0.86 
0.76 
0.95 
0.9 
0.99 
0.96 
m
e
d
ia
n
 
Low frequency 
0.97 
0.68 
0.77 
0.77 
0.65 
0.75 
0.67 
0.76 
0.75 
0.71 
0.57 
0.75 
0.75 
0.73 
0.83 
1
st
 q
u
ar
ti
le
 
1.3 
1.06 
1.2 
1.2 
1.1 
1.1 
1.0 
1.2 
1.1 
1.02 
0.95 
1.1 
1.2 
1.2 
1.3 
3
rd
 q
u
ar
ti
le
 
0.64 
0.26 
0.34 
0.34 
0.3 
0.33 
0.27 
0.35 
0.35 
0.31 
0.19 
0.33 
0.45 
0.29 
0.31 
m
in
 
2.31 
3.7 
4.3 
4.3 
4.5 
4.3 
2.2 
4.3 
4.3 
3.4 
2.62 
4.3 
4.1 
4.3 
4.2 
m
ax
 
1.3 
0.92 
1.1 
1.1 
1.05 
1.1 
0.94 
1.1 
1.1 
0.91 
0.51 
1.1 
1.11 
1.1 
1.1 
m
e
d
ia
 
High frequency 
1.1 
0.79 
0.89 
0.89 
0.81 
0.9 
0.68 
0.91 
0.9 
0.79 
0.21 
0.88 
0.89 
0.87 
0.89 
1
st
 q
u
ar
ti
le
 
1.7 
1.3 
1.4 
1.4 
1.4 
1.4 
1.1 
1.37 
1.4 
1.2 
0.72 
1.4 
1.4 
1.4 
1.4 
3
rd
 q
u
ar
ti
le
 
0.67 
0.42 
0.5 
0.5 
0.43 
0.5 
0.37 
0.5 
0.5 
0.41 
-0.14 
0.39 
0.51 
0.48 
0.54 
m
in
 
2.8 
2.8 
3.3 
3.3 
3.9 
3.3 
2.1 
3.3 
3.3 
2.7 
1.8 
3.3 
3.9 
3.9 
3.1 
m
ax
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Table 5. The numerical values for the coherence (median, 1st/3rd quartile, min, and max) for the results found 
for the 50 healthy subjects per centre. 
15 
14 
13 
12 
11 
10 
9 
8 
7 
6 
5 
4 
3 
2 
1 
C
e
n
tr
e
 
Coherence 
0.49 
NR 
0.48 
0.5 
0.47 
0.45 
0.92 
0.53 
0.45 
0.47 
0.53 
0.52 
0.68 
0.5 
0.43 
m
e
d
ia
n
 
Very low frequency 
0.4 
NR 
0.39 
0.38 
0.34 
0.34 
0.85 
0.41 
0.35 
0.37 
0.33 
0.47 
0.52 
0.42 
0.34 
1
st
 q
u
ar
ti
le
 
0.63 
NR 
0.64 
0.64 
0.65 
0.64 
0.95 
0.62 
0.63 
0.58 
0.67 
0.66 
0.78 
0.62 
0.61 
3
rd
 q
u
ar
ti
le
 
0.3 
NR 
0.29 
0.29 
0.17 
0.2 
0.33 
0.3 
0.22 
0.23 
0.05 
0.28 
0.32 
0.22 
0.22 
m
in
 
0.79 
NR 
0.77 
0.77 
0.85 
0.78 
0.99 
0.84 
0.79 
0.79 
0.97 
0.83 
0.97 
0.83 
0.79 
m
ax
 
0.74 
NR 
0.75 
0.75 
0.75 
0.76 
0.85 
0.75 
0.75 
0.73 
0.59 
0.74 
0.88 
0.74 
0.76 
m
e
d
ia
n
 
Low frequency 
0.62 
NR 
0.6 
0.6 
0.58 
0.62 
0.8 
0.59 
0.63 
0.63 
0.42 
0.62 
0.79 
0.6 
0.63 
1
st
 q
u
ar
ti
le
 
0.82 
NR 
0.82 
0.82 
0.82 
0.81 
0.9 
0.83 
0.82 
0.8 
0.74 
0.82 
0.93 
0.83 
0.83 
3
rd
 q
u
ar
ti
le
 
0.27 
NR 
0.23 
0.23 
0.21 
0.3 
0.6 
0.23 
0.3 
0.38 
0.07 
0.28 
0.48 
0.18 
0.3 
m
in
 
0.92 
NR 
0.93 
0.93 
0.96 
0.92 
0.97 
0.93 
0.92 
0.89 
0.97 
0.91 
0.99 
0.93 
0.91 
m
ax
 
0.68 
NR 
0.67 
0.67 
0.64 
0.68 
0.9 
0.68 
0.69 
0.72 
0.4 
0.65 
0.82 
0.65 
0.67 
m
e
d
ia
 
High frequency 
0.57 
NR 
0.55 
0.54 
0.52 
0.58 
0.84 
0.56 
0.57 
0.64 
0.26 
0.56 
0.74 
0.53 
0.54 
1
st
 q
u
ar
ti
le
 
0.73 
NR 
0.74 
0.74 
0.76 
0.74 
0.93 
0.75 
0.74 
0.79 
0.59 
0.74 
0.91 
0.72 
0.74 
3
rd
 q
u
ar
ti
le
 
0.25 
NR 
0.23 
0.23 
0.17 
0.24 
0.67 
0.23 
0.25 
0.33 
0.09 
0.3 
0.51 
0.14 
0.23 
m
in
 
1 
NR 
1 
1 
1 
1 
1 
1 
1 
1 
0.96 
1 
1 
1 
1 
m
ax
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ABSTRACT 
The brain is highly dependent on a continuous supply of (oxygenated) blood. Cerebral 
autoregulation (CA) is a key mechanism to protect the brain against excessive fluctuations in 
blood pressure (BP) to maintain adequate cerebral blood flow. The ability to measure and 
monitor CA in a patient would provide clinically useful information and would possibly permit 
a more individualized physiologically based therapy aimed at reducing the risk of secondary 
brain injury. 
A widely used technique to quantify CA in a non-invasive way is analysing the relationship 
between spontaneous BP and cerebral blood flow velocity (CBFV) using transfer function 
analysis (TFA). Despite the frequent use of TFA, however, settings and qualifying terms for the 
interpretation of outcome metrics, for example criteria for “impaired CA”, have never been 
strictly defined, leading to limitations of comparison between existing literature, poor 
standardization and postponement of potential clinical benefits. 
The purpose of the present guideline is to establish a first consensus document on CA 
quantification using TFA with the use of BP and CBFV signals (obtained with transcranial 
Doppler ultrasonography (TCD)), to improve reproducibility and implementation of study 
results. 
The development of these guidelines was initiated by (but not confined to) The Cerebral 
Autoregulation Research Network (CARNet - www.car-net.org). This document reflects what 
is currently considered best practice in awake and cooperating patients with TCD monitoring. 
The proposed settings are not intended to necessarily indicate what is ‘best’ (by whatever 
criterion) and we emphasize that the discussion is ongoing, probably leading to future 
revisions in the light of new evidence. As a first step towards implementation, we encourage 
researchers to compare their practice to the settings as they are recommended in this 
consensus paper. 
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INTRODUCTION 
Perfusion of the human brain is more or less maintained by a set of control systems including 
chemo- and autoregulation, neurovascular coupling and probably a direct autonomic 
neurovascular influence. Myogenic mechanisms are traditionally represented by the brain’s 
capacity to autoregulate its own blood flow and cerebral autoregulation (CA) is accordingly 
defined as the intrinsic ability of the brain to maintain cerebral perfusion in the presence of 
blood pressure (BP) changes. As the brain is highly dependent on a continuous supply of 
(oxygenated) blood, reduced effectiveness of CA renders the brain more sensitive to both 
hypo- and hyperperfusion. In a variety of medical conditions, such as serious hypertension, 
diabetes, dementia, stroke, head trauma, subarachnoid haemorrhage as well as during 
surgical procedures [1-5], defect CA may play an important role in the pathogenesis of brain 
damage. Therefore, the ability to measure and monitor CA in a patient would provide 
clinically useful information and would possibly permit a more individualized physiological 
based therapy aimed at reducing the risk of secondary brain injury. 
The cerebral autoregulatory mechanism was first proposed by Lassen et al. [6]. They 
proposed that CA works within a certain range of BP (≈ 60 to 150 mmHg). Outside this, 
so-called autoregulatory range, vasomotor adjustments are exhausted and cerebral blood 
flow becomes pressure-passive and subjected to changes in BP. This view on CA is called 
‘static autoregulation’. Over the last two decades, techniques with high temporal resolution 
(e.g. transcranial Doppler ultrasonography (TCD)) have shown that the relationship between 
BP and cerebral blood flow (CBF) is more dynamic, with short-term reactions. The dynamic 
relationship between BP and CBF has been shown to function as a high pass filter [7]. High 
frequency oscillations (> 0.20 Hz) in perfusion pressure are passed along unimpeded, while 
slower frequency oscillations (< 0.20 Hz) are dampened by the cerebral arterioles. 
A large number of methods to assess the quality of CA have been proposed over the last 25 
years. Traditional techniques to assess CA use changes in BP to challenge the cerebrovascular 
system. These BP changes can be induced using pharmacological means or with manoeuvres 
such as the Valsalva manoeuvre, squat-to-stand and/or sit to stand and the deflation of thigh 
cuffs [8-10]. However, these interventions are most of the time unsuitable in clinical cases, 
such as in the severely ill or in older or cognitively impaired persons, because of the relatively 
large BP change, the requirement of cooperation of patients and the uncomfortable nature of 
the interventions. Furthermore, other physiological subsystems (e.g. sympathetic activation 
with Valsalva’s manoeuvre [11] and cortical activation with visual or acoustic stimuli [12]) or 
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parameters (e.g. pCO2 with squat- and/or sit to stand manoeuvres [9]) might be affected, 
potentially confounding the results. Therefore, different research groups have adopted 
methods that use spontaneous (e.g. physiological) instead of induced slow BP fluctuations to 
challenge CA. 
Because of the recognition of the potential clinical importance of CA, numerous methods 
have been developed for non-invasive assessment of CA [13], including for example 
correlation coefficient analysis, the autoregulatory index [14], transfer function analysis (TFA) 
[15], nonlinear analyses using Laguerre expansions of Volterra kernels or Principal Dynamic 
Modes [16], autoregressive [17], as well as multi-modal pressure-flow analysis [18]. 
With the existence of this multitude of methods, the choice of which method to employ to 
quantify CA remained a matter of personal choice. No single method has been universally 
accepted as the gold standard. 
Of all available methods, TFA is the most frequently used in the literature to quantify CA using 
spontaneous fluctuations in BP and CBF [19]. Transfer function analysis is based on analysis of 
frequency components of oscillations in BP and the resultant degree to which these 
oscillations are reflected in cerebral blood flow velocity (CBFV) [7]. One of the advantages to 
this method is that it only takes a baseline measurement without the need for any 
pharmacological or physiological manipulation of BP. Transfer function analysis starts with 
dividing the cross spectra between blood pressure and cerebral blood flow velocity by the 
auto spectra of the blood pressure. With the transfer function the associated relative power 
(gain), timing (phase) and the linear association (coherence) can be described. Evaluation of 
CA by TFA is based on the concept that CA minimizes the effect of dynamic BP fluctuations on 
CBFV, which is reflected by reduced low-frequency gain and phase-lead of CBFV over BP. 
Without CA, CBFV would passively follow BP and TFA would show constant gain and zero 
phase across the low-frequency band. To estimate the cross and power spectra several 
parameter settings need to be chosen, such as sample frequency, window length, overlap 
percentage and filtering. Despite the frequent use of TFA, however, settings and qualifying 
terms for the interpretation of outcome metrics, for example criteria for “impaired CA”, have 
never been strictly defined, leading to limitations of comparison between existing literature, 
poor standardization and postponement of potential clinical benefits. 
The purpose of the present guideline is to establish a first consensus document on CA 
quantification using TFA with the use of BP and TCD CBFV signals. The guidelines focus on TCD 
4 
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CBFV signals, as TCD CBFV is currently the most used non-invasive surrogate for CBF. It must 
be noted that the use of another surrogate, such as oxygenation index obtained with near-
infrared spectroscopy [20], may require different TFA settings. 
The development of these guidelines was initiated by (but not confined to) The Cerebral 
Autoregulation Research Network (CARNet - www.car-net.org). This document reflects what 
is currently considered best practice in awake and cooperating patients with TCD monitoring, 
although the discussion is ongoing, probably leading to future revisions in the light of new 
evidence. 
It should be noted that the choice for TFA in this document should not be seen as a statement 
that TFA is considered the best available method to quantify CA. 
METHOD 
Related  to the subject of the present paper, a systematic review of the TFA literature has 
been performed [21]. That paper (which includes details on search strategy and study 
inclusion) has identified a large diversity in the signal processing methods, experimental 
conditions and research protocols that have been used for TFA in previous publications, and 
the paper provides an overview of this heterogeneity in methods [21]. Following this review, 
a multi-centre study wherein a single, uniform database with healthy patients with BP and 
TCD recordings was analysed by different research centres, each using their own TFA settings 
(filters, frequencies, etc), which was initiated and carried out as part of CARNet. The results of 
the systematic review and multicenter study were discussed during the Second CARNet 
International Conference in Nijmegen, September 2012. To derive the guidelines, we then 
combined the results of the systematic review and the multi-centre study with other available 
evidence-based scientific literature and with expert opinions obtained from within CARNet. 
Next, the initial proposal for consensus guidelines was discussed during the 3rd CARNet 
International conference in Porto, May 2013. During this conference, the arguments in 
support of the consensus proposal were presented followed by an open discussion with all 
the participants, and the manuscript was amended accordingly. The CARNet consensus group 
on TFA listed at the end of the manuscript includes all those who contributed to the 
consensus process and the preparation of this consensus paper.  
The various topics related to the use of TFA for CA are divided into 3 different subjects: 
experimental procedure, TFA methodology and documentation of TFA results. 
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GUIDELINE PROPOSAL 
EXPERIMENTAL PROCEDURES 
Although the main purpose of the consensus document is to standardize TFA, consistent and 
reliable results cannot be obtained unless due care is given to data acquisition and 
measurement protocols. These include environmental conditions, body position, 
measurement technique and control of physiological covariates that can influence CA. 
Consensus statement 1 
Subjects should refrain from the ingestion of a heavy meal for at least 4 hours before 
examination. Exercise and caffeine and alcohol ingestion should also be avoided for a 
minimum of 12-hours. Supplement and various medications may also affect TFA and should 
be accounted for depending on the experimental question. If the resting state of CA is 
studied, visual or acoustic stimulation should be kept to a minimum (no disturbances by 
people entering or leaving the room). Sensory stimuli may however be applied in a controlled 
way if CA analysis is focusing on neurovascular coupling. Adequate explanation of the 
procedure to the subject will help to reduce fear and anxiety, especially in anxious individuals. 
End-tidal gases should be used to confirm the absence of hyperventilation, because of known 
diurnal variation in CA [22]. It is recommended that tests be conducted at a similar time of 
day for repeat assessments and, for between-group studies, assessment times should be 
standardized. 
Consensus statement 2 
BP can be measured invasively through an arterial line or non-invasively, through arterial 
volume clamping applied to a finger or via tonometry at the radial artery [23]. For the latter 
two methods, the finger should be supported at heart level or a height correction needs to be 
used. It is recommended that values of systolic and diastolic BP are obtained by standard 
sphygmomanometry prior to each recording, to ascertain reliable BP values. 
TCD CBFV can be measured non-invasively in the middle cerebral arteries (MCA) using 
transcranial Doppler ultrasonography, using ultrasound probes placed over the temporal 
window, or from other intracranial arteries such as the anterior cerebral artery (ACA) or 
posterior cerebral artery (PCA) [24]. The insonated artery should be identified according to its 
4 
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signal depth, velocity and wave characteristics [24]. 
Consensus statement 3 
Recordings of spontaneous fluctuations of BP and CBFV for TFA should last a minimum of 5 
minutes, assuming stationary physiological conditions and uninterrupted good quality data, 
to ensure that recordings can yield robust estimates of transfer function parameters and to 
improve frequency resolution as detailed in the following statements. For a resting state or 
baseline level of CA, BP and CBFV should be measured with uncrossed legs after a 15 min 
period of rest. All body positions should be clearly reported (e.g. supine with head 30° 
elevation).  
Consensus statement 4 
Given the strong effects of carbon dioxide pressure (PCO2) on dynamic CA and BP, it is 
important to incorporate its measurement simultaneously with BP and CBFV. This is often 
accomplished by recording the trend of end-tidal CO2 signal with infra-red capnography or 
mass spectroscopy. Any significant fluctuations in PCO2 (> 1 mmHg) during the recording 
should be reported and taken into consideration when interpreting results from TFA [25]. If 
intracranial pressure monitoring is performed pressure levels at which dynamic CA analysis is 
performed will have to be given as well. This is because intracranial hypertension may impair 
CA [26]. 
TFA METHODOLOGY 
TFA is usually computed by way of the fast Fourier transform (FFT) to obtain estimates of 
auto- and cross-spectra. Spectral estimates derived from a single data window show 
considerable scatter with coefficients of variation (CoV = standard deviation / mean) 
approximately equal to one [27]. To improve precision of spectral estimations, averaging or 
smoothing is required, often using Welch’s method [28] which breaks the total data length 
into separate segments or windows to obtain averaged auto- and cross-spectra. In addition to 
signal segmentation, spectra may also be smoothed using moving-average filters in the 
frequency domain. Due to the phenomenon of spectral leakage [27], a tapered window must 
be applied to each segment of data in the time domain, before calculation of the FFT. 
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Selecting optimal parameter settings 
The systematic review on TFA showed a marked diversity in the signal processing methods 
used for TFA [21]. Many different settings are used in the literature and variations are found 
in parameters such as type of data (raw or beat-averaged), sampling frequency, interpolation, 
detrending, normalization, filtering, length and type of window, and number and 
superposition of data segments when estimating power spectral densities [21]. Consensus 
recommendations for these parameters are provided below. Accurate reporting of TFA 
settings must be ensured, as it has been shown that small differences in settings may cause 
large variations in TFA outcomes, making results less comparable [19, 21]. 
Waveform vs. beat-to-beat data 
The format of the BP and CBFV time signal used for TFA, i.e. the raw waveform of recorded 
signals or beat-to-beat data provides two alternatives used in the literature. No studies have 
been performed to compare TFA outcomes between the use of full waveform time signals or 
beat-to-beat data. 
Consensus statement 5 
Since most studies report using beat-to-beat data to analyse TFA [21], for the purpose of 
standardisation the use of beat-to-beat data is recommended for future research. 
Sampling frequency 
The literature also shows a wide range of sampling frequencies (e.g. 10 and 200 Hz [21]), the 
number of times per second the data, used as input for TFA, is sampled. 
Consensus statement 6 
For recording the continuous BP and CBFV signals, a minimum sampling frequency of 50 Hz is 
recommended, following anti-alias filtering. For mean values of BP and CBFV obtained from 
each cardiac cycle (beat-to-beat data) the minimum resampling frequency should be 1 Hz 
after interpolation (to get uniform time-axis). In order to avoid aliasing, beat-to-beat data 
should be interpolated (see below) first to 5 or 10 Hz (greater than the heart-rate). Following 
this, an anti-alias filter with a cut-off frequency below half the intended sampling rate (e.g. 
0.4 times sampling rate) should be utilized, before resampling to the lower sampling rate. 
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Consensus statement 7 
Signals should always be visually inspected prior to analysis (preferably considering both raw 
and beat-averaged signals simultaneously), to ensure that they are free of excessive noise 
and artefacts (for example signal artefacts induced by motion of the subject). Short periods of 
strong artefact (up to 3 beats) should be removed and replaced by linear interpolation. When 
excessive artefact persists for longer periods, the data segment should be excluded from 
analysis. Sporadic ectopic beats can be included in analysis [29, 30]. 
Interpolation 
TFA supposes equidistant data points. Interpolation can be used to create equidistant time 
intervals (in case of beat-to-beat data), by constructing new data points within the range of a 
discrete set of known data points. Different types of interpolation, such as linear- and spline 
interpolation, are available, but it has been shown that this choice does not affect TFA 
outcomes considerably [19]. 
Consensus statement 8 
To standardize inter-centre procedures, it is recommended that spline (3rd order 
polynomials) are used to interpolate the time-series of mean BP and mean CBFV calculated 
for each cardiac cycle. 
Detrending 
Detrending reduces the amount of low-frequency power by removing any linear or non-linear 
trends from the input data. It has been shown that the type of detrending used (including no 
detrending, removal of the mean, linear trend removal and third order polynomial 
detrending) does not affect TFA outcomes [19, 31]. However, this was tested in computer-
generated (synthetic) data in which the input-output relationship was purely linear and no 
noise was present. This may explain why neither benefits nor disadvantages of detrending 
were observed, as may be seen for signals recorded from human volunteers. Further studies 
using synthesized data with added noise, including signal drifts, should be performed to 
confirm these observations. 
Consensus statement 9 
To standardize inter-centre procedures it is recommended that detrending is not used.  
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Units of measurement 
The coherence function is dimensionless. Regarding the units of TFA estimate phase, the 
literature shows an almost equal divide between the use of radians and degrees and changing 
from one to the other is straightforward (αdeg = αrad / π x180) , where αdeg refers to the angle 
in degrees and αrad to the angle in radians). However, when it comes to units of gain, the 
choice of which units to adopt is not so obvious. With measurements at rest, spontaneous 
fluctuations in CBFV and BP will normally be < 10% of their average value. For calculation of 
the FFT, it is normal practice to remove mean values (which should be reported as discussed 
later). This would reduce the inter-subject variability of the CBFV measure and therefore also 
of the gain. The existing options are to express both variables in absolute units or as relative 
values thus corresponding to cm.s-1.mmHg-1, %.mmHg-1, %/% or cm.s-1/% [21]. Ideally, the 
units adopted for gain should be those that would maximize sensitivity and specificity for 
various conditions, but unfortunately studies of this question are lacking. Because of the 
unknown insonation angle and inter-subject differences that can occur in these angles 
comparison of absolute values of CBFV is limited. Furthermore, BP changes, of for example 
10%, are physiologically very distinct for say a baseline mean BP of 90 or 150 mmHg. 
Therefore, expressing CBFV and BP as percentage changes with respect to their average value 
may be of preference. As a result, the choice would be between cm.s-1.mmHg-1 and %.%-1. 
Consensus statement 10 
Estimates of gain obtained by TFA should be expressed in both absolute units (cm.s-1.mmHg-1) 
as well as %/%.  
Filtering 
Filtering can be used to delete frequencies that are of no interest, such as very high 
frequencies or extremely low frequencies. Meel-van den Abeelen et al. reported that in the 
literature only a minority of studies reported the use of any kind of filtering (11 %) [21]. The 
effect of filtering on TFA outcomes has not yet been investigated. However, it is expected 
that , filtering in frequency bins outside the frequency range used for analysis has no effect on 
the results.  
Consensus statement 11 
For the purpose of standardization, filtering is not recommended. 
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Anti-leakage window 
Data segments need to be windowed to minimise a particular kind of distortion called 
spectral leakage [32]. A number of different shapes for anti-leakage windows, such as 
Hanning, Hamming and Tukey window [33], have been proposed and used. The multi-centre 
study, comparing the results of different centre methodologies for TFA, showed that there 
were no important differences in outcomes between using the Hamming or the Hanning 
anti-leakage window. In contrast, the use of a rectangular window (no anti-leakage) yielded 
inferior results in low frequency (0.07 - 0.15 Hz) gain and very low frequency (0.02 - 0.07 Hz) 
phase and the Tukey window distorted the gain and the phase in the very low frequency [19]. 
However, this was based on simulated noise-free signals and the impact on recorded signals 
has not been evaluated in the context of CA.  
Consensus statement 12 
Despite the lack of significant differences between the Hamming and Hanning anti-leakage 
windows, in the interest of standardization of results, the Hanning window is 
recommended  [33]. 
Window length when using the Welch algorithm 
The number of data points included in a window in combination with the sample frequency 
determines the window length in seconds, which will then define the frequency resolution of 
the transfer function estimates (Δf = 1 / T , where Δf is the frequency resolution in Hz and T 
the duration of the window, in seconds). It was shown in simulations that window lengths 
smaller than 75 seconds resulted in larger deviations from the expected values, particularly in 
the very low frequency range [19]. 
Consensus statement 13 
To allow sufficient frequency resolution, it is recommended to use window segments with a 
length of > 75 seconds. When recordings longer than 5 minutes are available, it is preferable 
to increase the number of windows, rather than the length of individual windows when using 
the Welch algorithm.  
 
 
 
108  
Number and superposition of data segments 
As described previously, the dominant technique in the literature for calculation of the 
auto- and cross-spectra is the use of the FFT, combined with Welch’s method [28] to improve 
its statistical reliability. This involves averaging spectral estimates from separate segments of 
data, which can be overlapped by variable degrees of superposition to maximize the degree 
of smoothing. Varying the percentage of superposition, using percentages of 25 %, 50 % and 
75 %, has been shown not to affect the outcomes of TFA [19], with 50% being the most 
common degree of superposition reported in the literature. 
Consensus statement 14 
A superposition of 50 % is recommended for overlapping data segments in conjunction with 
Welch’s method. Combining this recommendation with the minimum duration of the entire 
recording (minimum 5 min) and the window length (100 s) means that a minimum 
of 5 separate segments of data should be used with Welch’s method. When recordings longer 
than 5 minutes are available, the window length should not be increased, but rather the 
number of windows should increase.  
Phase wrap-around 
Estimates of phase require the calculation of the tangent (tg-1) of the ratio of the imaginary 
and real parts of the complex transfer function [27]. Unfortunately, the inverse tg-1 
calculation cannot differentiate values of phase between π and 2 π radians from 
corresponding negative angles. This indetermination of phase estimates, usually referred to 
as ‘wrap-around’ can obviously lead to major distortions if negative values are mixed with 
positive ones when averaging phase for a group of subjects or across frequencies. 
Consensus statement 15 
The complete phase frequency response for each subject needs to be visually inspected to 
check for the occurrence of ‘wrap-around’. When negative values of phase are detected for 
frequencies < 0.1 Hz, the particular recording should be removed [34]. 
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Reporting TFA results 
Next to accurate documentation of the settings used for TFA, it is important to report TFA 
outcomes in a standardized manner. In the earlier systematic review [5] it has been shown 
that TFA outcomes are presented in many different ways [21]. Overall, studies report the 
mean of the gain, phase and coherence over pre-defined frequency bands. Historically the 
most often used frequency bands for this purpose are 0.02 - 0.07 Hz for the VLF, 0.07 - 0.2 Hz 
for the LF and 0.2 - 0.3 Hz for the HF [35]. The upper limit for the VLF band was first defined 
by Zhang et al. [7], based on the observation that at ∼ 0.07 Hz, the coherence crossed 
above 0.5, indicating 50 % shared variance between BP and DBFV at frequencies > 0.07 Hz. 
However, evidence about their sensitivity and specificity in detecting impairment of CA in 
different patient groups and/or physiological conditions is lacking. 
Consensus statement 16 
When reporting results of TFA, it is important to present the complete frequency dependence 
of coherence, gain and phase in the range 0.0 - 0.4 Hz, as mean and SD values at each 
frequency. Until further evidence is available, statistical analyses should be based on 
averaged values for the VLF (0.02 - 0.07 Hz), LF (0.07 - 0.2 Hz) and HF (0.2 - 0.3 Hz). In 
addition, mean values of BP and CBFV and their intra-recording variability should also be 
reported. 
IMPLEMENTATION 
Translating guidelines into daily clinical practice and research remains a challenge. The 
principal goal of the present guidelines is to improve reproducibility and implementation of 
study results. Table 1 shows an overview of the above mentioned guidelines for TFA to 
quantify CA. 
As a first step towards implementation, we encourage researchers to compare their practice 
to the settings as they are recommended in this consensus paper. While some researchers 
may have strong arguments for not adopting the proposed settings, we strongly encourage all 
colleagues to present results with these settings (even if only as additional results), in order to 
facilitate comparison between studies and centres. Arguments against the use of the 
‘standard’ setting should be provided in order to help shape future (changed) guidelines. The 
proposed settings are not intended to necessarily indicate what is ‘best’ (by whatever 
criterion) and we emphasize that currently the evidence in support of some of the proposed 
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Table 1. Overview of the guidelines for transfer function analysis to quantify cerebral autoregulation from 
spontaneous fluctuation in blood pressure and cerebral blood flow velocity. 
Guidelines   
TFA parameter settings   
Input data beat-to-beat data  
Sample frequency ≥1 Hz 
Interpolation spline 
Detrending None 
Normalization None 
Filtering  None 
Anti-leakage window Hanning  
Window length ≥100 s 
Superposition 50% 
    
Reporting TFA results Report mean of the gain, phase and co-
herence over the complete frequency 
range of 0.0 -0.5 Hz using a frequency plot 
with mean and standard deviation curves. 
Plus averaged values of the gain, phase 
and coherence for the VLF (0.02-0.07 Hz), 
LF (0.07 -  0.2 Hz) and HF (0.2-0.3 Hz). 
    
Other outcome measures mean blood pressure 
  mean cerebral blood flow velocity 
  mean end-tidal CO2  
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settings is still weak, but standardization is considered preferable to a continued large 
variations between centres.  
DISCUSSION 
This paper provides guidelines for the use of TFA for the quantification of dynamic CA using 
the signals BP and TCD CBFV. 
The urgent need for guidelines was demonstrated by the evidence that a strong diversity 
exists within the international community in the signal processing methods used for TFA. 
Besides a multi-centre study which investigated the effect of several parameter settings on 
TFA outcomes, only a few studies have been published on the effect of different TFA settings 
[34]. Therefore, many areas of uncertainty exist in which more studies are still needed. 
Further optimization of the guidelines will be made possible by future research, taking 
advantage of the work that has already been done. 
When outlining the directions in which future research could be most useful, the following 
topics come to mind: 
1. More studies to investigate the effect of different TFA settings, such as the choice of 
data, normalization, window length and filtering. 
2. Application of an international standard protocol for the validation of the CBFV 
signal should be encouraged. Ensuring good signal quality will possibly also reduce 
the variability in TFA outcomes, making it easier to compare different studies. 
3. Studies to determine the reference values and diagnostic usefulness in specific 
populations, such as children, elderly and patients with specific clinical conditions.  
4. Determination of TFA standard decision criteria based on TFA outcomes. 
5. More attention should be paid to the experimental or clinical protocol. Investigating 
the question whether ‘rest’ is the best reference condition which body posture 
(supine/seated) and evaluate the usefulness of physiological manoeuvres. 
6. Similar studies for other analytical techniques, such as the time domain correlation 
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coefficient analysis [26], non linear multi modal flow analysis [18] and dynamic non 
linear analysis using Laguerre expansions of Volterra kernels or Principal Dynamic 
Modes [14-15] and a comparison between methods with regard to their ability to 
identify impaired CA.  
7. Understanding that CA is but one of the mechanisms involved in the control of 
cerebral perfusion. We need to know how it interacts with and is related to other 
mechanisms for CBF regulation, such as the arterial baroreflex.  
Finally, we emphasize that these guidelines are not intended to endorse TFA as the ‘best’ 
method for the quantification of CA. One of the key limitations of TFA is that it assumes a 
linear relationship between BP and CBFV. In general, however, CA is considered to be a 
non-linear phenomenon. Other methods, i.e. non-linear approaches, may provide more 
reliable or sensitive estimates of CA, but in the continued absence of a gold standard for 
dynamic CA assessment, clear criteria and multi-centre trials on a wide range of patients 
would be required to allow robust conclusions. In the mean time, these guidelines show a 
recommended way to perform TFA, thereby providing a solid standard for comparison 
between studies, including those seeking to establish better CA analysis methods. 
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ABSTRACT 
Background 
Cerebral autoregulation (CA) is the physiological mechanism that keeps the cerebral blood 
flow (CBF) relatively constant despite changes in blood pressure (BP). Currently, transfer func-
tion analysis (TFA) is widely used to assess CA non-invasively. TFA is based on the assumption 
that CA is a linear process, however, in reality CA has shown to be a non-linear process. This 
study explores the usability of convergent cross mapping (CCM) as a non-linear analysis tech-
nique to assess CA. 
Material and Methods 
CCM determines causality between variables by investigating if historical values of a time-
series X(t) can be used to predict the states of a time-series Y(t). The Pearson correlation is 
determined between the measured Y(t) and the predicted Y(t) and increases with increasing 
time-series length to converge to a plateau value. When used for CA, normal and impaired CA 
should be distinguishable by a different plateau value. With impaired CA, BP will have a 
stronger influence on CBF, and therefore the CBF signal will contain more information on BP. 
As a result, the correlation converges to a higher plateau value compared to normal CA. The 
CCM method was validated by comparing normal CA (normocapnia: breathing 0 - 2 % CO2) 
with a model of impaired CA (hypercapnia: breathing 6 - 7 % CO2). 
Results 
CCM correlation was higher (p = 0.01) during hypercapnia (0.65 ± 0.16) compared to 
normocapnia (0.51 ± 0.18). 
Conclusion 
CCM is a promising technique for non-linear cerebral autoregulation estimation. 
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INTRODUCTION 
The high metabolic demand of the brain requires an adequate cerebral blood flow (CBF). 
However, changes in blood pressure (BP) or intracranial pressure may influence CBF. To keep 
CBF relatively constant and to return CBF to baseline after a fast change in BP, adaption of the 
cerebrovascular resistance (CVR) occurs. This process is called cerebral autoregulation (CA) 
[3]. When CA is disturbed, the brain may become excessively sensitive to fluctuations in BP, 
causing hypo- and/or hyperperfusion. Hypo- and hyperperfusion can lead to ischemia or 
haemorrhages, respectively [4]. CA failure has been associated with increased morbidity and 
mortality [5]. Therefore, the ability of accurately quantifying the quality of CA may be of great 
importance in clinical practice. 
CA can be determined as static CA or dynamic CA. With static CA, the response of the CBF to 
changes in BP is studied in a semi-steady state, i.e. a measurement of CBF is obtained first at 
a constant baseline BP and constant CBF, followed by another measurement that is taken 
after the autoregulatory response to a manipulation of BP has been completed [6]. However, 
static CA represents the overall effect of the autoregulatory action, but does not address the 
time in which this is achieved. 
The use of Transcranial Doppler (TCD) ultrasound combined with servo-controlled finger 
photoplethysmography makes it possible to measure the process of CA itself, the dynamic 
CA [4, 7]. Ideally, clinical monitoring of cerebral autoregulation should be non-invasive, 
continuous, bedside and precise. Because static cerebral autoregulation measurements only 
provide steady-state point measurements and therefore is not a continuous measurement, 
the dynamic approach is preferable. 
Despite the importance of measuring dynamic CA, there is no consensus about the best way 
to analyse dynamic CA [8]. Currently, the most frequently used method in literature is 
transfer function analysis (TFA) [8]. However, this method is based on the assumption that 
the relation between BP and CBF is linear, while physiologically CA exhibits nonlinear 
dynamics [9]. In this study, a new non-linear analysis method, convergent cross mapping 
(CCM) is applied to asses dynamic CA. Originally CCM was proposed to detect causality in 
complex ecosystems. According to its definition, CA can be quantified as the causal influence 
of BP on CBF and this causal influence can therefore be determined with CCM. Therefore the 
goal of this study is to explore the use of CCM in assessing dynamic CA. 
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METHODS 
Experimental procedure 
The CCM model was validated by comparing normocapnic data with hypercapnic data. 
Hypercapnia causes vasodilatation of the cerebral vasculature and can therefore be used as a 
model for impaired CA [10]. This study included 19 healthy adults, male and female, with an 
age of 69 ± 4 (mean ± SD). BP was measured non-invasively in the middle finger of the right 
hand using photoplethysmography (FinaPres Medical Systems, Amsterdam, the Netherlands). 
The hand and arm were supported securely and comfortably with a sling, providing a stable 
position of the hand and arm at heart level. It has been shown that BP measured indirectly 
using the FinaPres is a reliable technique to track changes in BP that correlate well with 
auscultatory BP measurements in the upper arm [11]. TCD is used to measure CBF 
velocity (CBFV) in the middle cerebral artery (MCA) by insonating the left and right MCA using 
a 2 MHz TCD probe (Multi-Dop, Compumedics DWI, Germany) [12]. It is assumed that 
changes in CBFV represent changes in CBF, because the diameter of the vessel remains 
constant [10, 13]. End tidal CO2 (etCO2) was monitored with a nasal cannula using 
capnography (Biopac Systems, Goleta, Ca, USA). BP, CBFV and etCO2 are recorded with a 
200 Hz sampling frequency. 
Subjects were asked to inhale a gas mixture mimicking room air, containing 0% CO2, 21% O2, 
and 79% N2, through a tightly fitting mouthpiece until a stable plateau of CBFV had been 
reached. Next, the percentage of CO2 was increased every 30 seconds, until a CO2% of 7% was 
obtained. The first 90 seconds with a 0 - 2 % CO2 concentration and the last 90 seconds with 
6 - 7 % CO2 were selected as normocapnia and hypercapnia, respectively. Beat-to-beat data of 
the BP and CBFV were obtained using a low pass fourth-order Butterworth filter with a cut-off 
frequency of 0.5 Hz. Thereafter, CBFV and BP were downsampled to a sampling frequency of 
10 Hz. 
Data analysis 
Mathematical background of CCM 
Sugihara et al. [1, 2] presented CCM as a new non-linear analysis method to determine 
causality between variables in a dynamical system. CCM is described in detail by 
Sugihara et al [1, 2]. In short, a dynamical system can be represented by a so called attractor 
manifold (M). Figure 1A depicts as example the manifold of the Lorentz attractor consisting of 
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Figure 1. A) Attractor Manifold (M) of the Lorenz attractor. A point of M is defined by X(t), Y(t) and Z(t). B) Sha-
dow manifold My with E=3 dimensions and τ = 1.4 seconds. Each point on the manifold is defined by Y(t),    Y(t-
τ) and Y(t-2τ). The grey area in A corresponds to the grey area in B. E = dimensions of the shadow manifold, τ = 
time-lag. Adapted from Sugihara et al. [2]. 
A. 
 
 
 
 
B. 
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Figure 2. The nearest neighbour principle. A) Nearest neighbours (triangles) of point A (dot) on Mx are also 
nearest neighbours of the in time corresponding point A’ on My. Therefore Mx can be used to estimate the 
states of Y(t), i.e. Y(t) causally influences X(t). B) Nearest neighbours (triangles) of point A (dot) on Mx are not 
nearest neighbours of point A’ on My. Therefore Mx cannot be used to estimate the states of Y(t). Mx: shadow 
manifold of M with time-lagged coordinates of X(t) (E=2). My: shadow manifold of M with time-lagged 
coordinates of Y(t) (E = 2). E = dimension of the shadow manifold. Adapted from Sugihara et al. [1].  
  
Figure 3. Principle of convergence. Solid line: Y causally influences X. Dashed line: Y does not causally influence 
X. The solid line shows convergence with increasing time-series length while the dashed line does not. Adapted 
from Sugihara et al. [1]. 
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three variables, represented by the time-series X(t), Y(t) and Z(t). Interestingly, the dynamics 
of a system can also be represented using only one of the time-series, for example Y(t). 
Lagged coordinates of this time-series, for example Y(t-τ) and Y(t-2τ) can be used to 
reconstruct a shadow manifold My (Figure 1B). Tau (τ) is defined as a number of samples. My 
reproduces the two-lobed butterfly of M, i.e. My represents the dynamics of M. Similarly, 
shadow manifolds Mx and Mz can be reconstructed using X(t) and Z(t), respectively. CCM 
consists of two main steps that use these shadow manifolds to determine causality between 
variables: cross mapping and convergence. 
 
Cross mapping 
In a dynamical system, consisting of two variables (X(t) and Y(t)), cross mapping investigates if 
it is possible to predict a point on My from Mx using the nearest neighbour principle. This 
nearest neighbour principle is depicted in Figure 2. Point A is a random point on Mx and A’ is 
the in time corresponding point of A on My. The basic principle is that if nearest neighbours 
of A on Mx can accurately predict A’ on My, it can be stated that historical values of X(t) can 
be used to estimate states of Y(t). This is only possible if X(t) contains information on Y(t), in 
other words as Y(t) causally influences X(t). Cross mapping is applied to each point on Mx 
resulting in a prediction of Y(t): YPred(t). To estimate the accuracy of the YPred(t), the correlation 
between the YPred(t) and Y(t) is determined. 
Convergence 
Convergence is based on the fact that the longer the time-series length of X(t) and Y(t), the 
smaller the distance between the trajectories on the manifold. As a results, the estimation 
error decreases. Therefore, if Y(t) causally influences X(t), the correlation should increase to a 
plateau value with increasing time-series length, which is defined as convergence. The faster 
the convergence the stronger the coupling between the two variables. Figure 3 illustrates the 
convergence principle [1]. The cases that Y(t) does, and Y(t) does not causally influence X(t) 
are represented by the solid and dashed line, respectively. 
Validation of CCM  
CCM is applied to determine the CA quality during normocapnia (0 - 2 % CO2) and 
hypercapnia (6 - 7 % CO2). As the CA quality can be quantified as the causative effect of BP on 
CBFV, the shadow manifold of CBFV was used to predict BP. Generically, the shadow manifold 
maps 1:1 to the original manifold M. If a 1:1 mapping occurs then the shadow manifold is 
defined as an embedding [14]. Optimal embedding parameters, embedding dimension E and 
lag τ, were determined with the method of Gautama et al. [15], which is based on differential 
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entropy. The determined optimal embedding parameters were E is 3 dimensions and τ is 1 
sample. In this study, the correlation corresponding to the plateau value was used instead of 
the rate of convergence. A window of 890 samples was used to calculate the plateau value. 
Shifting the window of 890 samples through the entire dataset results in 10 correlations of 
which the mean is determined. The complete algorithm of CCM is described in more detail in 
the Supplementary materials of Sugihara et al. [1]. 
STATISTICS 
Results are presented as means ± SD. Statistical significance was tested using a paired t-test. 
Significance was set at p < 0.05. 
RESULTS 
In this study, 19 healthy adults (9 males and 10 females, aged 69 ± 4 (mean ± SD)) were 
included. Mean BP and CBFV levels were higher during hypercapnia (BP: 114 ± 21 mmHg, 
CBFV: 67 ± 15 cm/s) than during normocapnia (BP: 102 ± 18 mmHg, CBFV: 44 ± 10 cm/s)
(p<<0.01). Figure 4 depicts the correlation results for normocapnia and hypercapnia. The 
CCM-correlation outcome was lower during normocapnia (0.51 ± 0.18) and 
hypercapnia (0.65 ± 0.16) (p = 0.01). 
Figure 4. Correlation between real BP and predicted BP during normocapnia and hypercapnia circumstances 
(n=19). Correlation is significantly increased during hypercapnia (breathing 6-7% CO2) compared to normocap-
nia (breathing 0-1-2% CO2). * p < 0.05. BP = arterial blood pressure. 
Effect of hypercapnia
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DISCUSSION 
Our study showed that the non-linear method CCM is able to distinguish normal dynamic CA 
from impaired dynamic CA. In clinical practice, the ability to measure CA may be of great 
importance, as impaired CA can result in hypo- or hyperperfusion of the brain. Impaired CA is 
also associated with increased morbidity and mortality [5]. Several methods have been 
developed to measure CA, however no gold standard exists. In literature, TFA is currently the 
most applied method to quantify CA. However, this technique assumes that CA is a linear 
process, while in fact CA exhibits non-linear dynamics. Zhang et al. [16] pointed out that a 
coherence < 0.5 in the low frequency range using TFA is an indicator of non-linear behaviour 
of CA. In addition, Mitsis et al. [9] showed that with the use of a non-linear 
model (Laguerre-Volterra network) a 20 % reduction of the normalized mean square error 
was seen compared to a linear model when predicting CBFV based on the input BP. 
CCM is a non-linear analysis technique, which was originally proposed by Sugihara et al. [2] to 
detect causality in complex ecosystems. They applied CCM on a classic predator-prey dynamic 
system. In a classic predator-prey dynamic system, there is bidirectional causality between 
the predator and the prey, i.e. they both causally influence each other. The correlation 
converged when predicting the state of the prey using the predator data and also when 
predicting the state of the predator using the prey data. This indicates indeed that both 
factors causally influence each other. CCM was also applied on a dynamical system of 
sardines, anchovies and sea surface temperature. CCM showed that anchovies and sardines 
do not causally influence each other, but are both causally influenced by the sea surface 
temperature. 
As CCM takes non-linear dynamics into account, this technique might also be more accurate 
for the quantification of CA. A well-functioning CA attenuates the effect of changes in BP on 
changes in CBF, i.e. BP has as only a small causal influence on CBF. During impaired CA the 
effect of changes in BP on changes in CBF are less attenuated, i.e. BP has a larger causal 
influence on CBF. Therefore the causal influence of BP on CBF is a measure of impairment of 
CA and CCM can be applied to assess the functioning of CA. 
In this study, the ability of CCM to quantify CA was explored using a hypercapnia model. 
Hypercapnia is a well-known model to simulate impaired CA [17]. Hypercapnia causes 
vasodilatation, reducing the ability of the cerebral vessels to respond to changes in BP, 
leading to impaired CA. In our study a significantly higher CCM correlation value was found 
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during hypercapnia which indicates a less efficiently functioning CA. This underlines the 
potential of CCM to quantify CA. 
However, still a large spread is seen in the outcome of CCM. The standard deviation was 0.2 
and 0.16 for norm- and hypercapnia, respectively. Therefore, optimisation of this technique is 
necessary before it can be easily applied in clinical practice. There are several explanations for 
the large spread in CCM outcomes. First, the degree of impaired CA of each subject during 
hypercapnia is unknown and might differ between subjects. As a result, the spread in CCM 
outcome is large. However, breathing 7% CO2 is the physiological limit. Therefore it is likely 
that all subjects did reach their plateau of impaired CA. Second, besides the possible 
difference in effect of the CO2 on CA in subjects during hypercapnia, also the breath-to-breath 
etCO2 fluctuations in normo- and hypercapnia circumstances between subjects might 
influence the correlation. Mitsis et al. [18] showed that etCO2 fluctuations have a 
considerable effect in the lower frequencies, i.e. below 0.04 Hz. Incorporating the breath-to-
breath etCO2 fluctuations might therefore reduce the spread in CCM outcome. 
Third, the respiratory frequency is below 0.5 Hz and because the respiratory frequency is 
below the cut-off frequency of 0.5 Hz, it is still present in the BP and CBFV signal. If the 
respiratory frequency is very constant, prediction of BP using CBFV might be easier because 
the fluctuations caused by respiration are then very predictable. This might result in a high 
CCM outcome value. On the other hand, if the respiratory frequency is less constant, 
prediction of BP using CBFV is harder, because the fluctuations caused by the respiration are 
less predictable. This results in a lower CCM outcome value. Therefore, differences in 
variability of the respiratory frequency between subjects might be responsible for the large 
spread in CCM outcome. Using a low-pass filter with a cut-off frequency 0.15 Hz might reduce 
the large spread in CCM outcome, because the breathing frequency is above 0.15 Hz. Because 
CA is most prominent in frequencies below 0.15 Hz, it can be justified to use a cut-off 
frequency of 0.15 Hz. 
Besides the large spread in CCM outcome values, it should also be noted that in this study the 
plateau value was used to quantify the causal influence of BP on CBFV instead of the rate of 
convergence as suggested by Sugihara et al. [2]. The choice for the plateau value was based 
on a pilot study in which the validity of the model was investigated using the autoregulatory 
index of Tiecks et al. [6]. In this pilot study, the plateau value could discriminate the 
autoregulatory indexes. However, a situation might be possible in which the correlation does 
not convergence, but remains horizontal (dashed line in Figure 3). In this case, using only the 
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plateau value, might give inaccurate results. If this correlation is high, the plateau value 
falsely represents a high influence of the BP on CBFV while actually there is no influence at all. 
Using the rate of convergence overcomes this problem. In our study, convergence was seen 
in all subjects during normo- and hypercapnia. Therefore, using the plateau value was seen as 
a valid choice in this study. Furthermore, calculating the rate of convergence is more 
time-consuming than calculating the plateau value. This plateau value is therefore more 
promising for bedside CA monitoring. Furthermore it should be noted that the used 
embedding parameters were E = 3 dimensions and τ = 1 sample. These embedding 
parameters were determined using the differential entropy technique [15]. A τ of 1 sample is 
a delay of 0.1 seconds, which is within one heartbeat. It is difficult to interpret this τ 
physiologically, because a τ of at least one heartbeat (± 8 - 10 samples) is expected. 
In summary, the ideal clinical monitoring device of CA should be non-invasive, continuous, 
bedside and precise. CCM is indeed a non-invasive measurement which uses spontaneous 
fluctuations of the ABP and CBFV to assess CA. The use of spontaneous fluctuations has the 
additional advantage that no interventions have to be performed, making continuously 
measuring CA possible. Furthermore, CCM can quantify CA using small datasets and the 
outcome of CCM is a single value, which is very important and practical for bedside 
monitoring. When the spread in CCM outcome can be reduced, perhaps with the 
aforementioned optimisations, CCM could be a very promising technique for future bedside 
monitoring of CA. 
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ABSTRACT 
Background  
Understanding the relationship between vascular disease and Alzheimer’s disease (AD) will 
enhance our insight into this disease and pave the way for novel therapeutic research. 
Cerebrovascular dysfunction, expressed as impaired cerebral autoregulation and cerebral 
vasomotor reactivity, has been observed in transgenic mouse models for AD. Translation to 
human AD is limited and conflicting however. 
Objective  
To investigate if impaired cerebral autoregulation and cerebral vasomotor reactivity, found in 
animal models for AD, are present in human sporadic AD. 
Methods  
In 12 patients with mild to moderate AD (age 75 ± 4 yr) and 24 controls matched for age and 
history of hypertension, all without diabetes, we measured blood pressure (FinaPres) and 
cerebral blood flow-velocity (transcranial Doppler). Cerebral autoregulation was assessed 
during changes in blood pressure induced by single and repeated sit-stand manoeuvres. 
Cerebral vasomotor reactivity was assessed during hyperventilation and inhalation of 5 % 
carbon dioxide. 
Results  
During single sit-stands, controls had a 4 % (SD 8) decrease in cerebrovascular resistance 
during a reduction in blood pressure and an 8 % (SD 11) increase during a rise in blood 
pressure, indicating normal cerebral autoregulation. These changes were not seen in 
AD (p=0.04). During repeated sit-stands, blood pressure fluctuated by 20 % of baseline. This 
led to larger fluctuations in cerebral blood flow in AD (27 (6) %) than in controls (22 (6) %, 
p < 0.05). Cerebral vasomotor reactivity to hypercapnia was reduced in AD (42.7 % increase in 
CBFV, versus 79.5 % in controls, p = 0.03). 
Conclusion  
Observations of impaired cerebrovascular function (impaired autoregulation and 
vasoreactivity) in transgenic mouse models for AD were confirmed in patients with sporadic 
AD. 
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INTRODUCTION 
Alzheimer’s disease (AD), the leading cause of dementia, is a progressive neurodegenerative 
disorder. Worldwide, AD is highly prevalent and places a huge burden on patients and 
caregivers [1, 2]. While the number of AD patients grows, there remains limited 
understanding of this disease and its underlying causes. This is reflected in the lack of an 
effective curative treatment for AD. 
A large body of recent evidence suggests a strong link between AD and vascular disorders and 
vascular risk factors [3-6]. The exact relationship however between these factors and AD 
remains poorly understood. Better understanding of how vascular factors relate to AD may 
therefore enhance our insight into this disease and pave the way for novel therapeutic 
research. 
Research into the vascular pathophysiology of AD can be categorized in two hypothesized 
‘causal directions’, one direction wherein vascular disease leads to (or promotes) Alzheimer 
pathology, and another, opposite, direction wherein Alzheimer pathology causes vascular 
disease. These two ‘directions’ are likely to interact, as is exemplified by cerebral 
autoregulation. 
Cerebral autoregulation (CA) is the mechanism that aims to maintain a stable cerebral blood 
flow in the event of a change in blood pressure (BP) [7, 8]. Evidence that AD is associated with 
severe impairment in CA was first observed by Niwa et al. (2002) [9]. In this study, mice 
carrying a human AD mutation were unable to preserve cerebral blood flow when their BP 
was lowered. This evidence was corroborated by studies showing in vitro impairment in 
cerebrovascular function and structure in models for AD [9, 10]. Although this is an example 
of the vascular hypothesis direction wherein AD leads to vascular disease, the possible 
consequences of this impairment in CA serve to illustrate the complex interaction between 
the two directions: the impairment in CA (due to vascular changes brought about by AD) 
increases the risk of cerebrovascular insufficiency (e.g. ischemia, hypoperfusion) which in turn 
may contribute to the progression of AD [11]. 
In addition to an impairment in CA, evidence also suggests that cerebral vasomotor 
reactivity (CVMR) is affected in AD. CVMR is a mechanism that reflects the uniquely strong 
response of cerebral blood vessels to changes in arterial carbon dioxide concentration [12]. 
Two different mouse models for AD demonstrated cerebral microvascular impairment in 
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vasomotor reactivity to hypercapnia [10, 13]. 
Whether these animal model findings of impaired CA and CVMR can be translated to human 
AD remains uncertain [9]. The aim of this study was to assess CA and CVMR in patients with 
AD and age-matched controls, with the hypothesis that CA and CVMR both show impaired 
vasodilatatory responses in human AD, comparable to observations in AD animal models. 
MATERIALS AND METHODS 
Study Population 
We studied 12 patients with mild to moderate AD (age 75 ± 4 yr) and 24 controls matched for 
age and – because hypertension is a common comorbidity in AD – also for history of 
hypertension. None of the AD patients or controls had diabetes, however. All subjects were 
carefully screened by a geriatrician including a medical history, physical examination, and 
electrocardiogram to exclude acute medical conditions or cardiovascular diseases other than 
hypertension. Patients with AD were diagnosed as probable AD by a multidisciplinary memory 
clinic team using the NINCDS-ADRDA criteria [14, 15] based on clinical evaluation and 
additional diagnostic tests, such as MRI-scan of the brain (which was consistent with mild 
global atrophy combined with hippocampal atrophy and no or minimal cerebrovascular 
disease), neuropsychological testing (which showed a predominant disorder in episodic 
memory) , and cerebrospinal fluid analysis (available in n = 4, showing a biomarker profile 
consistent with AD). Informed consent was obtained from patients and their proxy [16], and 
from controls, before they entered the study. The study was approved by the medical ethical 
committee. 
Data Acquisition 
BP was measured continuously and noninvasively in the middle finger of the right hand using 
FinaPres (FinaPres Medical Systems, the Netherlands). The hand and arm were supported 
securely and comfortably with a sling, providing a stable position of the hand and arm at 
heart level throughout the whole measurement. It has been shown that BP measured 
indirectly in a finger by photoplethysmography is reliable in assessing changes in BP that 
correlate well with auscultatory BP measurements in the upper arm [17]. 
Cerebral blood flow velocity (CBFV) was obtained in the middle cerebral arteries (MCA) by 
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transcranial Doppler ultrasonography. The left and right MCA were insonated by placing a 
2-MHz Doppler probe (Multi-Dop, Compumedics DWL, Germany) over the temporal window. 
The MCA were identified according to their signal depth, velocity and wave 
characteristics [18]. If only one signal was available due to one-sided temporal window 
failure, we included this available signal for analysis. The probes were locked at a constant 
angle and position during data collection with a customized headband (Spencer technologies, 
Seattle, Wa.). 
End-tidal CO2 (etCO2) was monitored with a nasal cannula using capnography (BIOPAC 
Systems, Goleta, Ca.). 
Experimental Procedure 
All experiments were performed in the morning, at least 2 h after a light breakfast and 12 h 
after the last caffeinated beverage or alcohol, in a quiet, environmentally controlled 
laboratory with an ambient temperature of 22°C. After at least 10 min of rest in sitting 
position, a baseline measurement of 5 min was recorded during spontaneous respiration. 
To assess CA, subjects were asked to perform a single sit-to-stand protocol. Subjects sat in a 
straight-backed chair and were asked to stand up. The protocol consisted of three trials of 
2-min sitting followed by standing for 1 min. After this, repeated sit-stand manoeuvres were 
performed [19]. Patients were coached into performing these manoeuvres at a frequency of 
0.05 Hz (10 s sitting, 10 s standing) for 5 min. During all manoeuvres, subjects were instructed 
to keep normal breathing and to avoid performing a Valsalva manoeuvre. Adherence to this 
was confirmed by inspecting the CO2 waveforms and etCO2 registrations. 
To estimate CVMR a previously described protocol was used [20], consisting of a 30 s period 
of coached hyperventilation, followed by 2 minutes of spontaneous breathing. Next, subjects 
were asked to inhale a gas mixture containing 7 % CO2, 21 % O2, and 72 % N2 through a tightly 
fitting mouthpiece until a stable plateau of CBFV had been reached. With this protocol a wide 
range of changes in etCO2 can be obtained. 
Data Processing 
All data were simultaneously recorded at 200 Hz. Post processing was performed using 
custom-written MATLAB scripts. Real time beat-to-beat mean values of BP and CBFV were 
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calculated as waveform integration of the BP and CBFV signal within each cardiac cycle. 
The CVMR protocol evaluated changes in CBFV, BP, and calculated cerebrovascular 
conductance index (CVCI), during the transitions from hypocapnia (induced by 
hyperventilation) to normocapnia and from normocapnia to hypercapnia (induced by 7 % CO2 
inhalation). 
Because changes in CO2 cause changes in BP, which in turn may directly affect CBFV, CVCI, 
expressed as CBFV changes divided by BP changes, was used to minimize the confounding 
effects of differences in BP response during CVMR testing between subjects on CVMR 
estimation [21]. 
For CA, to evaluate the beat-to-beat dynamics of BP and CBFV responses to acute posture 
changes in the single sit-stand protocol, we calculated the differences between the sitting 
value (averaged over a period of 20 s) and the value at the nadir of BP (average of 5 values 
surrounding the nadir) for BP and CBFV. 
The repeated sit-stand manoeuvres were evaluated by calculating the differences between 
the maximal sitting value (average of 5 values surrounding the top) and the value at the nadir 
of BP after standing (average of 5 values surrounding the nadir) for BP and CBFV for each sit-
to-stand manoeuvre. 
This way only the amplitude relationship between changes in BP and CBFV was taken into 
account, the phase shift between BP and CBFV was disregarded. In addition to these absolute 
values, we also expressed these changes as percentage of baseline. The average of the trials 
for a group was then computed. 
Finally, we determined the transfer function analysis (TFA) from the spontaneous oscillations 
in the baseline measurement as a measure for CA using the method described by Zhang et al. 
(1998) and reviewed in [8]. The time series of mean BP and CBFV were first subdivided into 
950-point segments with 50% overlap for spectral estimation. This process resulted in five 
segments of data for the segment periodogram average. Fast Fourier transforms were 
implemented with each Hanning-windowed segment and averaged to quantify the transfer 
function. For quantification of CA the positive phase shift and the gain between BP and CBFV 
were quantified as means of the following frequency bands: very low frequency 
(VLF): 0.02 - 0.07 Hz; low frequency (LF): 0.07 - 0.15 Hz. 
6 
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The TFA is based on the high-pass filter model of cerebral autoregulation, wherein BP 
oscillations at lower frequencies are buffered better than higher frequencies, leading to lower 
gain (better damping) in these lower frequencies. Also, a characteristic of this model is that 
the counteractive actions of autoregulation lead to a phase shift between CBF and BP in these 
lower frequencies [8]. 
STATISTICAL ANALYSIS 
Results are presented as the means ± standard deviations (SD) or percentages unless 
otherwise stated. Differences in variables between patients and controls were evaluated with 
the independent student t-test for continuous variables and the chi-squared (χ2) statistic for 
proportions. The results were considered to be significant for p-values < 0.05. 
RESULTS 
Subject Characteristics 
Demographic and baseline data for the 12 AD patients and the 24 controls are summarized in 
Table 1. AD and controls were well matched for age and history of hypertension, however 
there was more use of anti-hypertensive medication in AD (p = 0.01), and BP was somewhat 
higher at baseline (although only significant for diastolic BP, p = 0.03). Previous 
studies [22-24] have shown higher cerebrovascular resistance in AD. This trend was observed 
here but did not reach significance likely due to the small sample and high intra-individual 
variability. 
Cerebral Vasomotor Reactivity 
One healthy control could not perform the CVMR procedure adequately and was excluded 
from this analysis. Table 2 summarizes the haemodynamic results for CVMR. 
AD patients and controls had similar etCO2 values for baseline and for the minimum and 
maximum etCO2 levels reached during hyperventilation and CO2 breathing (p > 0.05, Table 2). 
Changes in BP were also similar in both groups during normocapnia, hyperventilation and CO2 
breathing. Changes in CBFV did not differ during baseline or hyperventilation, however 
during 7 % CO2 breathing CBFV increased less in AD (p < 0.01). This difference in the CBFV 
response over the full range from hypocapnia to hypercapnia between AD and controls is also 
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Table 1. Baseline characteristics.  
All values are mean (SD). AD= Alzheimer’s disease patients. MMSE= Mini Mental State Examination. CAMCOG = 
Cambridge cognitive examination (higher scores are better, cut-off scores are age and education-dependent 
but usually lie between 77-84). CDR: clinical dementia rating scale, 0 = normal, 0.5 = mild cognitive impairment, 
1 = mild dementia, 2 = moderate and 3 = severe dementia. BP = mean arterial blood pressure, SBP= systolic and 
DBP = diastolic blood pressure. CBFV= mean cerebral blood flow velocity, CV resistance = cerebrovascular 
resistance (CBFV/BP). †significantly different (p<0.05) from control.  
 
 
 
  
AD patients Controls 
(n = 12) (n = 24) 
Age (years) 74 (4) 76 (4) 
Sex (male/female) 9-3 18/6 
MMSE (0-30) 22 (5) † 29 (1) 
CAMCOG (0-104) 69 (13)  NA 
CDR (0-3) 0.9 (0.2) 0 
Hypertension (n(%)) 6 (50) 9 (38) 
SBP (mmHg) 140 (33) 127 (19) 
DBP (mmHg) 69 (13) † 58 (9) 
BP (mmHg) 105 (24) 100 (11) 
CBFV (cm/s) 45 (15) 50 (11) 
CV resistance (mmHg*s/cm) 2.6 (1) 2.1 (0.6) 
   
Medication use   
Beta blocker 4/12 3/24 
ACE inhibitor 2/12 0/24 
ARB 0/12 0/24 
Calcium channel blocker 1/12 0/24 
Thiazide diuretics 3/12 † 0/24 
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Table 2 .Cerebral vasomotor reactivity results. 
All values are mean (SD). See legend table 1. CVCI= cardiovascular conductance index (BP/CBFV), 
etCO2 =end-tidal CO2. † significantly different (p<0.05) from control. 
Hypocapnia (Hyperventilation) AD patients (n = 12) Controls (n = 23) 
BP (mmHg) 94 (33) 93 (15) 
CBFV (cm/s) 32(12) 32 (9) 
CVCI (cm/s/mmHg) 0.32 (0.1) 0.35 (0.1) 
etCO2 (mmHg) 19 (6) 19 (6) 
Normocapnia AD patients (n = 12) Controls (n = 23) 
BP (mmHg) 118 (25) 111 (15) 
CBFV (cm/s) 44 (16)  48 (11) 
CVCI (cm/s/mmHg) 0.38 (0.1)  0.44 (0.1) 
etCO2 (mmHg) 30 (5) 31 (5) 
Hypercapnia 
AD patients (n = 12) Controls (n = 23) (CO2 breathing) 
BP (mmHg) 139 (33) 138 (21) 
CBFV (cm/s) 62 (22) †  83 (19) 
CVCI (cm/s/mmHg) 0.46 (0.2) † 0.60 (0.1) 
etCO2 (mmHg) 48 (9) 51 (6) 
Figure 1. Cerebral vasomotor reactivity. 
Mean cerebral blood flow-velocity (CBFV) changes induced by hyperventilation (hypocapnia) and CO2 
breathing (hypercapnia) in AD patients and healthy controls. Solid line: controls. Dashed line: AD.  
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shown in Figure 1. CVMR was decreased in AD for hypercapnia (42.7 % increase in CBFV, 
versus 79.5 % in controls, p = 0.03) but not for hypocapnia (30.0 % decrease in CBFV, versus 
32.4 % in controls, p = 0.2). Over the full range of etCO2, the CVMR was also clearly reduced 
in AD (controls 111.6 %, AD 73.2 %, p < 0.01). Expressed as a ratio of CBFV changes over 
changes in etCO2, CVMR was also lower in AD compared to controls (1.09 ± 0.39 vs. 
1.44 ± 0.43 cm.s-1.mmHg-1, p = 0.02). 
Cerebral Autoregulation: Cerebral Blood Flow Responses to Single Step Changes in Blood 
Pressure 
The haemodynamic changes for the single sit-stand manoeuvres are summarized in Table 3. 
The posture change from sit to stand evoked transient reductions in BP and CBFV, but did not 
result in a difference between AD and control in either the maximum reduction in BP, the 
maximum reduction in CBFV, or the time to nadir. 
  Single Sit-to-Stand Single Stand-to-Sit 
  
AD patients  Controls  AD patients  Controls  
(n = 12) (n = 24) (n = 12) (n = 24) 
Absolute change    
  
BP (mmHg) -18 (5) -20 (6) 15 (5) 13 (6) 
CBFV (cm/s) -9 (6) -8 (2) 7 (4) †  4 (3) 
CV-Resistance (mmHg*s/cm) 0.06 (0.3) †  -0.1 (0.1) -0.02 (0.2) 0.10 (0.2) 
Percentage change      
BP (%) -18 (7) -21 (7) 21 (11) 21 (10) 
CBFV (%) -18(8) -17 (5) 24 (15) †  13 (9) 
CV-Resistance (%) 3 (7) -4 (8) -0.8 (9)†  8 (11) 
tBP nadir (s) 11 (6) 11 (3) 5 (0.8) 6 (2) 
 
Table 3. Sit-stand manoeuvre.  
All values are mean (SD). See legend table 1. tBP nadir = time from standing up to the nadir of blood pressure. 
For stand-to-sit, this was the time from sitting down to the maximum increase in blood pressure.  † = significant-
ly different (p<0.05) from control. 
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Figure 2. Sit-stand manoeuvre. 
Mean cerebral blood flow-velocity (CBFV) changes (top) and cerebrovascular resistance index (bottom) induced 
by single sit-stand and stand-sit manoeuvre in AD patients and healthy controls. Sit-stand: standing up after 2 
min sitting. Stand-sit: return to sitting after 1 min standing. Solid line: controls. Dashed line: AD.  
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However, normal CA, in an attempt to restore CBF to baseline following a reduction in BP, will 
cause a reduction in cerebrovascular resistance. Despite similar proportions of changes in BP 
and CBFV, this expected normal reduction in cerebrovascular resistance was observed in 
controls but not in AD (difference: -0.06 mmHg*s/cm, p=0.04, see Table 3). The posture 
change from standing back to sitting led to similar increases in BP. Also here, the expected 
increase in CVR when CA attempts to buffer this increase in BP was not observed in AD. As a 
result, the proportional increase in CBFV for a similar increase in BP was larger in 
AD (p = 0.02; Table 3, Fig. 2). Together, these results show impaired responses in 
cerebrovascular resistance in AD, indicating diminished CA. 
Cerebral Autoregulation: Cerebral Blood Flow Responses to Repeated Changes in Blood 
Pressure 
Average BP and CBFV over time during the repeated sit-stand procedure are shown in 
Figure 3. Three AD patients were not able to perform the repeated sit-stand procedure, due 
to reduced motion and balance control, and impaired physical fitness, and were excluded 
from this analysis. The maximum haemodynamic changes caused by the repeated sit-stands 
are reported in Table 4. The repeated sit-stand manoeuvres caused similarly large 
perturbations in absolute and relative (percentage) changes in BP (p > 0.3) in AD and controls. 
However, the relative changes in CBFV were higher in AD (27 ± 6 %) than in 
controls (22 ± 6 %) (p = 0.03), suggesting less effective damping by cerebral autoregulation. 
 
Table 4. Maximal changes caused by repeated sit-stand procedure. 
All values are mean (SD). See legend table 1. †significantly different (p<0.05) from the control group. 
  AD patients (n = 9) Controls (n = 24) 
Absolute change   
BP (mmHg) 20 (4) 21 (6) 
CBFV (cm/s) 11 (4) 11 (5) 
Percentage change   
BP (%) 20 (4) 21 (4) 
CBFV (%) 27 (6) † 22 (6) 
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Figure 3. Repeated sit-stand manoeuvre. 
Average percent changes in mean arterial blood pressure (BP, black lines) and cerebral blood flow -
velocity (CBFV, grey dashed lines) for the repeated sit- stand procedure for controls (A) and AD (B). 
8 consecutive repetitions of 10 s standing followed by 10 s sitting are shown. X -axis represents the number of 
sit-stands. Note that this graphical representation only shows differences in amplitude, the temporal 
relationship between BP and CBFV, including any phase shift cannot be determined in this way.  
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Cerebral Autoregulation: Transfer Function Analysis 
A comparison between AD and controls based on the parameters derived from TFA (phase 
and gain in the very low, and low frequency ranges of spontaneous oscillations in BP and 
CBFV) revealed no differences. VLF: phase AD 0.88 ± 0.3 rad, phase controls 0.76 ± 0.3 rad, 
p > 0.05; gain AD 0.39 ± 0.2 cm/s/mmHg, gain controls 0.47 ± 0.1 cm/s/mmHg p > 0.05. 
LF: phase AD 0.76 ± 0.3 rad, controls 0.73 ± 0.3 rad, p > 0.05; gain AD 0.64 ± 0.4 cm/s/mmHg, 
controls 0.63 ± 0.2 cm/s/mmHg, p > 0.05. 
DISCUSSION 
The main finding of this study is that patients with AD demonstrated impairments in CA and 
CVMR that were similar to observations of cerebrovascular dysfunction in transgenic mouse 
models for AD. AD patients had a blunted vasodilatatory response to hypercapnia (impaired 
CVMR) as well as insufficient vasodilatatory and vasoconstrictor responses to decreases and 
increases in BP (impaired CA). 
Preclinical research suggests that Alzheimer pathology affects vascular function [9-11, 13, 25]. 
This research involved mouse models for AD and in vitro observation of animal and human 
vascular cells, such as endothelial cells. Post-mortem studies confirm that there are 
cerebrovascular changes, related to amyloid pathology, in human AD, including degenerated 
string capillaries and reduced markers linked to vasoconstriction and vasodilatation [26]. 
Together, this work implies that adaptive cerebrovascular responses may be impaired in AD, 
such as the cerebral vasodilatatory response to hypotension (cerebral autoregulation), or to 
increased neuronal demand for oxygen (neurovascular coupling), see [11, 25]for review. Such 
impaired responses would represent an increased risk of insufficient blood supply to the brain 
in a patient with AD and could accelerate cognitive decline. It is therefore essential to 
understand if these impaired cerebrovascular responses are observed not only in animal or in 
vitro human models, but also in humans known to have AD. 
Such translational evidence was limited thus far, however. To date, five studies had 
investigated CA in human AD [23, 24, 27-29], for review see [11], but found no evidence for 
impairment of CA. Four of these studies investigated dynamic CA (the CBF response to 
fluctuating changes in BP), using transcranial Doppler to measure CBF [23, 24, 27, 28]. All 
three used transfer function analysis (TFA) to assess CA [7, 8]. This method may be less 
sensitive to detect more subtle impairment in CA in small samples. This is supported by the 
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fact that also in the present study TFA did not reveal a difference in autoregulation between 
AD patients and healthy controls. TFA combines responses to BP increases and decreases, and 
does not consider each direction separately. The suggestion that TFA may be less sensitive is 
further supported by the fact that two of the studies that used TFA also investigated changes 
in cortical oxygenation and found that frontal cortical oxygenation changes in response to BP 
changes were stronger in AD, suggesting microvascular impairment, despite normal findings 
on TFA [27, 28]. 
The fifth study investigated static CA (the CBF response to a steady-state reduction in BP, 
comparable to the experiment Niwa et al. performed in mice) using PET to measure CBF [29]. 
No differences were observed between AD and controls, however, the response to increases 
in BP was not tested and a calcium-channel blocker was used to lower BP, and this may have 
supported CA by promoting cerebral vasodilatation [9]. 
Regarding CVMR, two previous studies have investigated CVMR in AD, and confirmed our 
observation of impaired CVMR [22, 30]. 
Our study adds to these seven earlier studies by combining CA and CVMR assessment in the 
same patients. In addition, the method we used to measure CA was more straightforward and 
therefore perhaps more sensitive to changes than transfer function analysis. CA operates by 
adapting cerebrovascular resistance to changes in BP [8]. We investigated these changes in 
cerebrovascular resistance during reductions and increases in BP induced by changes in 
posture, thus avoiding pharmacological interventions to change BP. We show that these 
changes in cerebrovascular resistance were reduced in AD, suggesting impaired ability to 
dilate and constrict. In addition, we challenged CA by inducing repeated increases and 
decreases in BP, and this led to larger fluctuations in CBF in AD. Again, this suggests that CA is 
less able to dampen these changes because vasodilatation and constriction are impaired. 
While CA assesses vasodilatation and constriction in response to changes in BP, CVMR 
assesses these responses to changes in CO2. AD patients had reduced vasodilatation to 
hypercapnia, but vasoconstriction to hypocapnia was not affected. In summary, AD patients 
had impaired vasodilatation and constriction responses to changes in BP, and impaired 
vasodilatation responses to hypercapnia. 
This is an important translational finding [9, 10, 13]. Criticism of transgenic animal models for 
AD is that they are not representative for the majority of AD patients who have sporadic AD 
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(i.e. who do not have genetic mutations leading to AD). Our observation of similar 
cerebrovascular dysfunction in human sporadic AD and transgenic mouse models leads to the 
following considerations. First, it can be argued that the observations of impaired CA and 
CVMR in our patients are caused not by AD but by comorbid vascular disorders that may be 
more prevalent in AD. Indeed, even though we tried to match for hypertension, as in many 
other studies AD patients had higher BP. However, the animal models find similar 
cerebrovascular dysfunction, in the absence of confounding human vascular comorbidity. This 
comparison supports the interpretation that the observed changes in CA and CVMR are 
related to AD. Second, the animal models link impaired CA and CVMR to cerebral amyloid 
angiopathy, reflecting vascular deposition of amyloid-beta [9, 13]. The impairment in CVMR in 
AD was similar to that observed in patients with cerebral amyloid angiopathy [30] and 
compares to the impairment of CVMR in the transgenic models. Third, the impairments in CA 
and CVMR are in line with post-mortem observations in AD that found cerebrovascular 
changes that were suggested to cause impairments in dilatation and constriction [26]. Taken 
together, this evidence suggests that the cerebrovascular impairments observed in animal 
models for AD are also observed in sporadic AD, and may both be explained by vascular 
effects of amyloid-beta. 
Limitations of this study are the small sample size. However, despite this small sample, the 
differences in CA and CVMR were already obvious. Second, the diagnosis of AD remains a 
clinical one. No pathological confirmation of the underlying disease was available. Still, 
previous studies have shown that a clinical diagnosis is only inaccurate in about 11 % of mild 
cases when compared to pathological diagnosis [31]. AD was diagnosed by a multidisciplinary 
memory clinic team consisting of several geriatricians, neuropsychologists, occupational 
therapists and speech therapists. Lewy body dementia and vascular dementia were excluded 
based on diagnostic criteria for these conditions, using information obtained by means of 
history, clinical examination, laboratory tests and MRI. 
Finally, the clinical implications of the observed impairments in CA and CVMR are unclear. The 
impairment in CA is clear but subtle, and did not lead to severe hypoperfusion, and may not 
lead to cerebral ischemia. Indeed, we recently found no increased susceptibility to white 
matter lesions in AD [32]. It is not unthinkable however that chronic mild hypoperfusion 
contributes to brain atrophy in AD. Impaired CVMR may affect neurovascular coupling, which 
may contribute to cognitive dysfunction [25]. 
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CONCLUSION 
AD patients have impaired cerebral autoregulation, leading to reduced ability to stabilize CBF 
during changes in BP, as well as impaired CVMR, which leads to much smaller increases in 
CBF with hypercapnia. These findings are similar to observations in transgenic animal models 
for AD, where impaired CA and CVMR are thought to be induced by amyloid pathology, 
especially perivascular amyloid depositions. These translational findings support the vascular 
hypothesis for AD, specifically the direction where AD causes vascular dysfunction. 
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ABSTRACT 
The baroreflex (BR) reflects autonomic blood pressure control. Alzheimer’s disease (AD) 
affects the autonomic system. Detailed properties of BR in AD are unknown. We hypothesized 
that BR is reduced in AD, and is influenced by autonomic effects of cholinesterase 
inhibitors (ChEI). BR was determined in 18 AD patients, 11 patients with mild cognitive 
impairment (MCI) and 19 healthy control subjects. In AD, BR was measured again after ChEI 
treatment. Receiver operating characteristic analysis was used to define a BR cut-off value, 
which was then tested in an independent validation sample of 16 AD, 18 MCI, and 18 control 
subjects. BR was lower in AD compared with MCI (p < 0.05) and in MCI compared with 
healthy control subjects (p < 0.01). Receiver operating characteristic analysis between AD and 
healthy control subjects yielded a sensitivity of 89 % and a specificity of 94 %. ChEI treatment 
increased BR with 66 % (p < 0.01). BR was reduced in AD and increased after treatment with 
ChEI. BR might be a good biomarker to further explore the link between cardiovascular 
disease and AD. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the leading cause 
of dementia. Worldwide, AD is among the top 5 of most costly diseases and places a huge 
burden on individual caregivers [2]. There is still a limited understanding of this disease and 
its underlying cause, which is reflected in the lack of an effective curative treatment for AD. 
Many of the currently developed and tested therapies are based on the amyloid cascade 
hypothesis. This hypothesis, supported by convincing genetic data, proposes that the 
extensive neuronal damage in AD is caused by increased concentration and aggregation of 
β-amyloid [3]. However, this theory does not offer an explanation for how this process is 
initiated in sporadic forms of AD, nor for the observation that the earliest changes in AD do 
not include amyloid deposition [4]. Criticism regarding the amyloid hypothesis has fuelled the 
popularity of the vascular hypothesis for AD, which states that cardiovascular disease is an 
important causal or contributing factor in sporadic AD [5-8]. 
Although cardiovascular factors are now commonly accepted as risk factors for AD, the exact 
relationship between these factors and AD remains poorly understood. For example, midlife 
hypertension increases AD risk and antihypertensive treatment potentially reduces this 
risk [9, 10], suggesting an unidirectional, possibly causal relationship between hypertension 
and AD. However, subjects with a parental history of sporadic AD are more likely to have 
hypertension than control subjects [11], suggesting either a causal relationship between AD 
and hypertension or a shared causative factor. Moreover, blood pressure (BP) levels decline 
from hypertension to normotension or even to hypotension during the course of AD [12]. 
These data imply a relationship wherein AD might influence BP or BP might influence AD. 
Better understanding of the relationship between BP control and AD might therefore provide 
important new clues toward our understanding, and ultimately, treatment, of AD. 
A possible link between AD and BP is the baroreflex (BR). The BR is a reflex loop with cardiac, 
vascular, and cerebral components involved in short-term BP regulation [13]. The BR operates 
via the autonomic nervous system to restore sudden changes in BP by changing heart rate 
(HR) or vascular tone. A clinical example is the drop in BP on standing, which the BR corrects 
by a rapid increase in HR (parasympathetic inhibition) followed by peripheral arterial 
vasoconstriction (sympathetic activation). The cholinergic system is an important component 
of cardiovascular and autonomic control, including the BR. This cholinergic system is 
prominently affected early in AD [14, 15]. Therefore, we hypothesized that BR function is 
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reduced early in patients with AD [16]. In this study, we further explored this hypothesis in 
3 steps. First, we compared BR function between patients with AD, patients with mild 
cognitive impairment (MCI), and healthy elderly subjects. Patients with MCI are thought to 
represent patients with very early-stage AD. The second step was to validate our findings in 
an independent sample of AD patients, MCI patients, and elderly control subjects. The third 
and final step was to explore the role of the cholinergic deficit on BR function in AD, by 
testing the influence of cholinesterase inhibitors on BR function in a subgroup of patients 
with AD. 
METHODS 
Study population 
Overall, this study included 34 patients with mild to moderate AD, 29 patients with MCI and 
37 healthy control subjects in 2 distinct samples: (1) a derivation sample: 18 patients with AD 
(72 ± 6 years), 11 patients with MCI (71 ± 9 years), and 19 healthy control subjects (75 ± 3 
years), recruited at Radboud University Nijmegen Medical Centre (RUNMC), and (2) a 
validation sample: 16 AD patients (71 ± 8 years), 18 patients with MCI (70 ± 7 years), and 18 
healthy control subjects (70 ± 6 years) recruited at Maastricht University Medical Center 
(MUMC). Data on cerebral hemodynamics from the RUNMC AD patients and control subjects 
and from the MUMC AD and MCI patients and control subjects have been published 
recently [17, 18]. 
In both samples, recordings of electrocardiograms (ECG) and beat-to-beat photo-
plethysmographic BP were obtained. There was a difference in body position during 
measurements between the 2 samples. Subjects at RUNMC were seated while ECG and BP 
were recorded, whereas the subjects at MUMC were supine. 
All subjects from both centres were examined by a geriatrician, and carefully screened to 
exclude acute medical conditions. A subset of subjects (15 control subjects; 15 MCI patients; 
29 AD patients) had a magnetic resonance imaging scan of the brain to investigate medial 
temporal lobe atrophy. Informed consent was obtained from all patients and healthy control 
subjects before they entered the study. Both studies were approved by the medical ethical 
committees of the corresponding centres. 
Patients with MCI and AD were diagnosed by a multidisciplinary memory clinic team using the 
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National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's 
Disease and Related Disorders Association criteria [19, 20] and MCI consensus criteria [21] 
based on clinical evaluation and additional diagnostic tests if indicated, such as magnetic 
resonance imaging scan of the brain, neuropsychological testing, and cerebrospinal fluid 
analysis. In the derivation sample from RUNMC, BR in AD patients was measured before and 
after 8 weeks of treatment with a cholinesterase inhibitor (galantamine, 4 weeks of 8 mg 
followed by 4 weeks of 16 mg). In the validation sample from MUMC, 10 of the 16 AD 
patients were already treated with cholinesterase inhibitors when BR was measured. 
Data acquisition and pre-processing 
The ECG was recorded using a 3-lead system and beat-to-beat HR was obtained from each R-
R interval identified from the QRS complexes. Arterial BP was measured noninvasively at the 
middle finger of the right hand using FinaPres (FinaPres Medical Systems) at RUNMC and the 
Task Force Monitor (CN Systems) at MUMC. It has been shown that BP measured on the 
finger by photoplethysmography is similar to conventional auscultatory measurements on the 
upper arm [22]. For both systems, the finger pressure cuff was positioned carefully at heart 
level with the hand being held in the left midaxillary line. The hand and arm were supported 
securely and comfortably with a sling. The subjects underwent several minutes of 
customization and the servo-adjust mechanism was turned off before recording. Periods of 
100 seconds of artefact- and calibration-free data were selected by visual inspection of the 
time series of the tachogram and systogram and used for subsequent analysis. The time 
series were linearly interpolated at 1 Hz to obtain equidistant time intervals. The time series 
were detrended and filtered with an eighth-order high-pass Butterworth filter (0.02 Hz), to 
ascertain signal stationarity. 
Causal model BR estimation 
BR sensitivity is often evaluated noninvasively by assessing heart rate variability (HRV) and 
systolic blood pressure (SBP) variability. However, studies using HRV and SBP variability often 
report contradictory results [23-25].  A possible explanation for this inconsistency is that the 
estimation of the BR by means of HRV assumes but does not test that the whole R-R interval 
(RRi) variability is generated by SBP changes. Therefore the causal dependencies are not 
taken into account. In this study, a bivariate causal model (ARXAR model), which was first 
introduced by Nollo et al. [1], was used to quantify the BR. With this model it is possible to 
describe the causal relationship from SBP to R-R interval (the BR pathway) and to separate it 
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from the mechanical pathway (from RRi to SBP). Details of this method are described 
elsewhere [1]. 
In short, the interactions between RRi and systolic blood pressure (SBP) are modelled as 
follows: 
 
 
According to the ARXAR model, the RRi is affected by p samples of its own past (by ak 
coefficients) and by p samples of the SBP sequence (by bk coefficients). The effects of other 
sources independent from SBP on RRi variability, considered as noise in this context, are 
accounted for in the model by means of the u(n). As outlined in Figure 1, the SBP and u 
signals are described as autoregressive processes with wsbp and wrri zero-mean input white 
noises.  
The blocks C and D are formed by the autoregressive parameters of SBP and u, respectively. 
In the open loop ARXAR model the variability of SBP around its mean value is considered as 
an exogenous input, i.e. it may affect the RRi variability without itself being affected by the 
RRi variability. The coefficient estimation follows an iterative identification task based on the 
 
Figure 1. Bivariate autoregressive model with exogenous input (ARXAR model) for the description of the causal 
effects of systolic blood pressure (SBP) on R-R interval (RRi). In the open loop scheme, RRi values are separately 
determined by the exogenous input SBP and by SBP-unrelated variations described by the series u [1]. 
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generalized least squares method. The model order p was chosen minimizing the Akaike 
figure of merit for the bivariate joint process |RRi SBP| [1]. The gain of the RRi – SBP transfer 
function (G(f)) was estimated directly from the coefficients of the A and B blocks. The value of 
the gain in the low frequency (LF) band (0.04 – 0.15 Hz) was considered by sampling G(f) on 
the LF peak of the spectrum of the driving SBP series [26]. It has been shown that there is a 
good agreement of the causal model with the traditional phenylephrine test to determine 
baroreceptor responsiveness [1]. 
STATISTICS 
Results are presented as the mean ± SD or percentage, unless stated otherwise. Differences in 
baseline variables and BR between control subjects and patients were evaluated with the 
Mann-Whitney test for continuous variables and χ2 statistics for proportions. Sensitivity and 
specificity pairs for different BR values distinguishing the groups were determined. These 
sensitivity and specificity values were used to construct a receiver operating characteristic 
(ROC) curve, in which the optimal sensitivity and specificity combination is visualized. A p 
value < 0.05 was considered statistically significant. 
RESULTS 
Derivation sample 
Sample description 
Eighteen AD patients (11 women), 19 age-matched healthy control subjects (5 women) and 
11 MCI patients (6 women) from RUNMC participated in this study and had the BR measured 
successfully. Table 1 summarizes the sample characteristics. AD and control subjects did not 
differ with respect to SBP. However, SBP in MCI patients was higher than in the healthy 
control subjects (p < 0.01). 
BR function 
BR function was calculated in correspondence with the peak in the power spectra of the SBP 
between 0.04 and 0.15 Hz (dashed line), the frequency range in which BR modulation of HR 
occurs. Mean values of the BR gain obtained by the ARXAR model are shown in Figure 2. BR 
was lower in AD (1.4 ± 0.8 ms/mmHg) compared with control subjects (6.4 ± 2.7 ms/mmHg) 
(p < 0.01). BR in MCI (2.9 ± 0.7 ms/mmHg) differed from both AD (p < 0.01) and control 
subjects (p<0.01) and was in between the values for AD and control subjects. The area under 
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  Derivation sample Validation sample 
  Controls MCI AD Controls MCI AD 
  (n = 19) (n = 11) (n = 18) (n = 18) (n = 18) (n = 16) 
Age (years) [mean ± SD] 75 ± 3 74 ± 9 72 ± 6 70 ± 6 70 ± 7 71 ± 8 
Sex (male/female) 14 / 5 5 / 6 7 / 11 9 / 9 8 / 10 7 / 9 
MMSE (0-30) [mean± SD] 29 ± 5 25 ± 3* 22 ± 5* 29 ± 1 28 ± 1† 21 ± 4* 
MTA [ mean] 0.6  2*      
            
Hypertension (n(%)) 4 (27) 7 (64)* 6 (33) 9 (50) † 6 (55) 7 (44) 
            
HR (bpm) [mean± SD] 62 ± 8 60 ± 12 71 ± 12 58 ± 6† 60 ± 8 62 ± 7 
SBP(mmHg) [mean ± SD] 125 ± 20 152 ± 25* 133 ± 31 136 ± 16 133 ± 17† 133 ± 15 
            
Medication use           
- Beta blocker 2 / 19 4 / 11 5 / 18 0 / 18 3 / 18 0 / 18 
- ACE inhibitor 0 / 19 0 / 11 3 / 18 0 / 18 0 / 18 0 / 16 
- ARB 0 / 19 0 / 11 1 / 18 0 / 18 0 / 18 0 / 16 
- Calcium channel blocker 0 / 19 1 / 11 2 / 18 0 / 18 0 / 18 0 / 16 
- Thiazide diuretics  3 / 19 0 / 11 4 / 18 0 / 18 1 / 18 0 / 16 
- Vasodilator 0 / 19 1 / 11 1 / 18 0 / 18 0 / 18 0 / 16 
Table 1. Characteristics of derivation and validation sample.  
The results are reported as mean ± standard deviation, absolute number or frequencies. MMSE, Mini Mental 
State Examination; MTA, medial temporal lobe atrophy; HR, heart rate; SBP, systolic blood pressure; ACE 
inhibitor, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker. * significantly different 
(p<0.05) from the control group of the same sample. † significantly different from the matching group of the 
derivation sample. 
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Figure 2. BR function. 
BR values in mean ± standard deviation for the three groups (MCI patients, patients with AD and healthy 
age-matched controls; left graph). The solid lines represent the derivation sample and the dashed lines represent 
the validation sample. Significant differences are indicated by the connecting lines (dashed for data of the 
derivation sample,and solid for data of the validation sample).  
Figure 3. ROC curve. 
ROC curve analysis of the predictive value of BR in distinguishing AD patients from healthy controls. The area 
under the curve equals 0.92; 95 % confidence interval is 0.84 -1.00; p-value < 0.01. The square shows the optimal 
BR cut-off point at 3.2 ms/mmHg resulting in a sensitivity of 89 % and a specificity of 94 % is reached.  
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the ROC curve for the relationship between AD and healthy elderly was 0.92 (Figure 3). With 
a threshold (cut-off point) of 3.2 ms/mmHg for AD, sensitivity was 89 % and specificity 
was  94 %. 
Validation sample 
Sample description 
SBP and RRi data were obtained from 16 AD patients (9 women), 18 age-matched healthy 
control subjects (9 women), and 18 MCI patients (10 women) from MUMC. Table 1 
summarizes their characteristics. In the derivation sample (RUNMC), MCI patients had higher 
SBP than healthy control subjects. This was not the case in the validation sample from 
MUMC. There were additional differences between the derivation and validation sample: the 
MUMC MCI group had lower SBP (133 mmHg) than the RUNMC MCI group (152 mmHg)
(p = 0.02) and the MUMC control group had a lower HR (58 bpm) compared with the RUNMC 
control group (62 bpm) (p = 0.04). 
BR function 
BR function was calculated in the same way as for the derivation sample. Mean values for BR 
gain obtained by the ARXAR model are shown in Figure 2 (dashed lines). Also, BR was lower in 
AD (1.6 ± 1.3 ms/mmHg) compared with healthy control subjects (3.6 ± 0.8 ms/mmHg) 
(p < 0.01). BR gain in the MCI group (2.3 ± 1.4 ms/mmHg) also was lower than in healthy 
control subjects (p < 0.01) and higher than AD (p = 0.03). Application of the BR cut-off value of 
3.2 ms/mmHg, as it had been obtained in the derivation sample, yielded a sensitivity of 93% 
and a specificity of 78% for differentiating AD from healthy control subjects in this validation 
dataset (Table 2). 
 
Table 2. Performance of the proposed baroreflex cut-off score. 
Performance of the proposed baroreflex cut-off score to distinguish between AD and healthy controls, in the 
validation sample. 
  n of patients          
Baroreflex value (% of total) AD Controls sensitivity specificity 
≤ 3,2 ms/mmHg 18 (51 %) 14 4 93% 78% 
> 3,2 ms/mmHg 17 (49 %) 1 14     
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Cholinesterase inhibitors 
In 18 AD patients (11 women) in the derivation sample, SBP and RRi data were obtained 
before and after treatment with cholinesterase inhibitors. After treatment with 
cholinesterase inhibitors, BR increased from 1.4 ± 0.8 ms/mmHg to 2.4 ± 0.9 ms/mmHg 
(p < 0.01). In the validation sample, no before and after cholinesterase inhibitor treatment 
comparisons were available, however in this sample, BR was higher in the 10 patients who 
were treated with cholinesterase inhibitors (2.0 ± 1.5 ms/mmHg) compared with the 
6 patients who were not treated (0.89 ± 0.4 ms/mmHg) (p = 0.02). Cholinesterase 
inhibitor-treated patients in the derivation sample had a slightly higher BR than those in the 
validation sample (p = 0.03). 
DISCUSSION 
The main finding of our study is that the BR function is lowered in patients with AD compared 
with age-matched control subjects. Our results are in agreement with the depressed BR 
sensitivity observed in 24 patients with AD [27]. Our study adds to these observations by the 
addition of a group of patients with MCI, reflecting early-stage AD, by reproducing our 
findings in an independent sample and by investigating the effect of cholinesterase inhibitors 
on BR. Furthermore, a more precise BR quantification method was used. The traditional 
sequence analysis used in the study of Szili-Törok et al. [27] assumes, but not tests, that the 
whole RRi variability is generated by SBP changes. The method used in our study takes this 
causal dependency into account by dividing the RRi variability in SBP-related and SBP-
unrelated parts. 
The difference in BR function was so prominent that it was possible to distinguish patients 
with AD from control subjects by their BR function. The discriminatory value of BR was so 
strong that it achieved a performance that compares with or even exceeds that of current 
diagnostic biomarkers, such as cerebrospinal fluid analysis of amyloid β42. Indeed, a cut-off 
value for BR gain of 3.2 ms/mmHg reached a sensitivity of 89 % and a specificity of 94 % to 
discriminate AD from control subjects in the derivation sample. For comparison, 
cerebrospinal fluid analysis of amyloid β42 has an ROC of 0.9, with a sensitivity of 93 % and a 
specificity of 87 % to discriminate AD from control subjects [28]. This discriminatory cut-off 
value for BR performed equally well in the independent validation sample with a sensitivity of 
93 % and a specificity of 78 % for differentiating AD from healthy control subjects. 
Additionally, MCI patients had a BR value that was intermediate between control subjects 
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and AD. A strength of our study is that these results were also confirmed in the independent 
validation sample. 
These findings underscore the importance of exploring the underlying mechanism that 
explains this association between impaired BR functioning and AD. They raise the question 
whether AD pathology results in impaired BR functioning or whether impaired BR functioning 
contributes to (acceleration of) AD pathology. 
Possible mechanism and consequence of the decreased BR in AD 
The BR is the major feedback control system for BP. Primary afferent fibres from arterial 
baroreceptors —in the carotid sinus and aortic arch—send information to the nucleus tractus 
solitarius in the medulla oblongata [29]. From here, information is sent via interneurons to 
the hypothalamus or to higher regions in the brainstem and forebrain [30], including the 
insular cortex [31]. The insular cortex is a recognized site of autonomic cardiovascular control 
and BR-mediated autonomic cardiovascular function [32]. In 1998, Braak and Braak [33] 
demonstrated a hierarchical progression of AD pathology that includes the insular cortex in 
an early stage. This insular involvement might lead to changes in cardiovascular and 
autonomic control, and might consequently affect the BR [32, 34]. 
Further circumstantial evidence is found in the effects of exercise. Exercise improves 
cardiovascular function and BR [35]. Exercise has also been shown to lower the risk of 
AD [36]. Although direct associations between exercise, BR and AD risk have not been 
investigated, and BR could be no more than a marker of exercise, it can be hypothesized that 
BR function is part of the causal pathway that links exercise to reduced AD risk, or that 
augmented BR is a marker of beneficial effects of exercise on autonomic brain centres. 
Here, we have also shown that treatment with cholinesterase inhibitors augmented BR 
function in AD. This is in line with recent findings that atropine, in a dose which augments 
vagal tone, increases cardiovagal BR gain in older subjects [37]. Our findings cannot be 
explained by age-related effects only [38] because we compared AD and MCI patients with 
age-matched healthy control subjects. Cholinesterase inhibitors partly compensate for the 
cholinergic deficit in AD. The cholinergic system has a pivotal role in learning and 
memory [39]. However, the augmented BR function suggests that cholinesterase inhibitors 
might slow clinical disease progression not only through direct cognitive effects but also 
through their influence on cardiovascular factors such as BP regulation. 
7 
169  
B
aro
refl
ex fu
n
cti
o
n
 is red
u
ced
 in
 A
lzh
eim
er’s d
isease: a can
d
id
ate b
io
m
arker? 
Our findings might extend to preclinical and early clinical AD, for example, patients with MCI. 
Patients with MCI have a high risk of progression to dementia, particularly of the Alzheimer 
type [21, 40]. There is a greater orthostatic fall in SBP in MCI and Alzheimer patients than in 
control subjects [23, 24] and the prevalence of orthostatic hypotension in MCI patients lies 
between control subjects and AD patients [41]. This observation parallels the BR values in 
control subjects, MCI, and AD found in our study and is in line with an earlier study which 
showed an association between blunted BR functioning and increased risk of orthostatic 
hypotension [42]. 
Despite the fact that several studies have shown an association between AD and autonomic 
instability, such as increased pupillary dilatation [43], diminished HR variability [44] and 
orthostasis, the significance of the abnormalities in BR among AD patients is not yet fully 
known. However, impaired BR in other common dementia subtypes, such as Parkinson 
disease and Lewy body disease, is held partly responsible for the higher prevalence of 
orthostatic hypotension [24] and increased cardiovascular mortality. These patients also 
exhibit a significant loss of cholinergic forebrain neurons [45]. 
BR functioning as a diagnostic tool 
In the perspective of new therapeutic options to slow the progression of dementia, an early 
diagnosis of AD is of utmost importance because all treatment strategies are more effective in 
the earlier phases of the disease [46]. In this study, a rapid, non-invasive and inexpensive 
procedure without need for active patient cooperation was used to estimate BR function 
from ECG and BP recordings, obtained when the patient quietly sits or lies down. Our results 
show that in patients with AD, a lowered BR could be a sensitive and specific marker of the 
disease. A strength of the study is the consistent decrease in BR found over the different 
groups (from healthy subjects to MCI patients to AD patients). This result points toward a 
disease-specific involvement of the BR. However, although we have shown that BR 
discriminates between AD and control subjects, further evidence must be obtained for its 
discriminatory value against important differential diagnoses in memory clinics (i.e., other 
causes of dementia and depression). 
Limitations 
Some methodological issues need to be considered. First of all, the diagnosis of AD and MCI 
in our study remains a clinical one. There was no pathologic confirmation of the underlying 
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disease. However, previous studies have shown that a clinical diagnosis is only inaccurate, 
compared with pathologic diagnosis, in approximately 11 % of mild cases [47]. The patients 
with MCI and AD were diagnosed by a multidisciplinary memory clinic team consisting of 
several geriatricians, neuropsychologists, occupational therapists, and speech therapists. 
Lewy body dementia and vascular dementia were excluded based on diagnostic criteria for 
these conditions, using information obtained by means of history, clinical examination, 
laboratory tests, and additional, mostly radiologic, investigations. In a population referred to 
a memory clinic (as in this study), depending on criteria, a high percentage of MCI patients 
will develop AD [48, 49]. Still, in some patients MCI remains stable and never progresses to 
AD. Therefore the assumption that abnormal BR function serves as early detection of the 
Alzheimer disease process remains hypothetical. To overcome this limitation, larger scale 
studies with follow-up of MCI and AD patients are needed, with observations of BR during the 
different stages of progression of AD. Maybe a combination with other easy to determine 
parameters, in particular the cerebrovascular resistance index [18],  could enhance 
discrimination of patients at risk for developing AD. 
Second, it might be argued that results should have been corrected for differences in use of 
medication, because we included patients with comorbidities and medication. There is some 
information about whether commonly used antihypertensive agents, such as metoprolol and 
enalapril, can augment the cardiac autonomic function in hypertensive patients. Keeley et al. 
showed that β-blockers can directly improve cardiovascular autonomic regulation in 
normotensive and hypertensive patients [50]. Further, Mancia et al. showed an increase in BR 
function when the circulating levels of angiotensin II and aldosterone were reduced by 
angiotensin-converting enzyme inhibitors [51]. Because antihypertensive drugs mostly show 
an increase of the BR function, we argue that the difference in BR function between AD 
patients and healthy elderly would have been even greater when the AD patients had used no 
antihypertensive agents. 
Third, some differences exist in population and protocol characteristics between the 
derivation and validation sample. In the validation sample the control subjects had a higher 
SBP (136 mmHg compared with 125 mmHg) than in the derivation sample. Furthermore, in 
the derivation sample BP and HR were obtained in the sitting position, in the validation 
sample BP and HR were obtained supine. These differences might explain the difference in BR 
between the 2 control groups (6.4 ms/mmHg in the derivation sample versus 3.6 ms/mmHg 
in the validation sample). Bristow et al. showed an inverse relationship between resting mean 
BP and BR, with reduced BR sensitivity in hypertension [52]. This might explain the observed 
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lower BR in the derivation sample where the SBP was higher. However, literature yields 
discordant results about the influence of posture on the BR results [53, 54]. 
Finally, a limitation of the study is the cross-sectional design. This design allows us to establish 
the relationship between BR and AD, but we are unable to establish whether the impaired 
functioning of the BR is the effect or the cause of neurodegeneration. 
CONCLUSIONS 
This study shows a strong association between AD and diminished BR function. A possible link 
is the cholinergic system which is involved in both BR and AD. Cholinesterase inhibitors 
increase BR function in AD. Furthermore, MCI patients have an intermediate BR function 
between the normal and the AD subjects. Considering this, it is possible that early in AD 
besides cognition also BP regulation is affected. Further research on the relationship between 
BR and AD might provide valuable insights into the pathophysiology and for the diagnosis and 
treatment of AD. 
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ABSTRACT 
Spontaneous slow oscillations occur in cerebral haemodynamics and blood pressure (BP), and 
may reflect neurogenic, metabolic or myogenic control of the cerebral vasculature. Aging is 
accompanied by a degeneration of the vascular system, which may have consequences for 
regional cerebral blood flow and cognitive performance. This degeneration may be reflected 
in a reduction of spontaneous slow oscillations of cerebral haemodynamics and BP. 
Therefore, we aimed to establish the dependency of slow oscillations of cerebral 
haemodynamics and BP on the factors age and cognitive load, by using functional Near-
Infrared Spectroscopy (fNIRS). Fourteen healthy young (23 - 32 years) and 14 healthy older 
adults (64 - 78 years) performed a verbal n-back working-memory task. Oxygenated and 
deoxygenated haemoglobin concentration changes were registered by two fNIRS channels 
located over left and right prefrontal cortex. BP was measured in the finger by 
photoplethysmography. We found that very-low-frequency oscillations (0.02 - 0.07 Hz) and 
low-frequency oscillations (0.07 - 0.2 Hz) of cerebral haemodynamics and BP were reduced in 
the older adults compared to the young during task performance. In young adults, very-low-
frequency oscillations of cerebral haemodynamics and BP reduced with increased cognitive 
load. Cognitive load did not affect low-frequency oscillations of the cerebral haemodynamics 
and BP. Transfer function analysis indicated that the relationship between BP and cerebral 
haemodynamic oscillations does not change under influence of age and cognitive load. Our 
results suggest aging-related changes in the microvasculature such as declined spontaneous 
activity in microvascular smooth muscle cells and vessel stiffness. Moreover, our results 
indicate that in addition to local vasoregulatory processes, systemic processes also influence 
cerebral haemodynamic signals. It is therefore crucial to take the factors age and BP into 
consideration for the analysis and interpretation of haemodynamic neuroimaging data. 
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INTRODUCTION 
Neuroimaging with functional Near-Infrared Spectroscopy (fNIRS) and fMRI has registered the 
occurrence of spontaneous slow oscillations of cerebral haemodynamics [1]. The driving force 
for these oscillations may vary between neurogenic, metabolic and myogenic control of the 
cerebral vasculature [2-5]. Different physiological origins for slow oscillations of cerebral 
haemodynamics are suggested in the literature and may be summarized as follows: 1) 
spontaneous slow changes in cerebrovascular tone (vasomotion), 2) changes in systemic 
haemodynamics (blood pressure (BP)) reflected in cerebral haemodynamics and 3) slow 
oscillations in neuronal activation, related to functional network connectivity. Slow 
oscillations are further characterized by their frequencies. Very-low-frequency oscillations 
(VLFOs) occur at approximately 0.04 Hz and low-frequency oscillations (LFOs) are centred 
around 0.1 Hz [6]. These slow oscillations can thus be differentiated from high-frequency 
oscillations (HFOs) that are known to be of respiratory origin, around 0.2 - 0.3 Hz, and the 
heartbeat cycles that occur at approximately 1 Hz [7]. 
Slow oscillations of cerebral haemodynamics are modulated by functional stimulation. Obrig 
et al. (2000) established using fNIRS that functional activation affects slow oscillations of 
cerebral haemodynamics in the visual cortex in young adults [6]. In comparison to rest, visual 
checkerboard stimulation reduced VLFOs of oxygenated haemoglobin ([O2Hb]), centred 
around 0.04 Hz. No significant effects of functional activation were found for VLFOs of 
deoxygenated haemoglobin ([HHb]) or for LFOs centred around 0.10 Hz. For functional 
activation research it is relevant to know how slow oscillations are affected not only by 
functional stimulation versus rest, but also by cognitive load. To date, however, it is unclear if 
and how cognitive load influences these oscillations. Furthermore, because systemic BP 
oscillations have been investigated together with cerebral haemodynamics only in a relatively 
small number of studies, it remains insufficiently known to what extent the effects of 
cognitive load on cerebral oscillations may be mediated by effects on these systemic 
oscillations. 
In addition to functional activation, slow oscillations may be affected by aging. Schroeter et al. 
showed with fNIRS that LFOs (0.07 - 0.11 Hz) of [O2Hb] and [HHb] in the cerebral 
microvasculature strongly declined with aging during both rest and visual checkerboard 
stimulation [8]. VLFOs (0.01 - 0.05 Hz) were not affected by age, but functional stimulation 
increased VLFOs of [O2Hb] and [HHb] in young adults and increased VLFOs of [HHb] in older 
adults. These results might indicate a decline in spontaneous activity in microvascular smooth 
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muscle cells in conjunction with an increase in vessel stiffness in the elderly. Aging is further 
accompanied by a degradation of the cerebrovascular system encompassing changes in 
resting cerebral blood flow, vascular reactivity and vascular ultrastructure [9]. For example, 
changes in the ultrastructural integrity of the cerebral vasculature result in a decrease in the 
elasticity and compliancy of affected vessels, including capillaries, larger arterioles and 
cerebral arteries [10]. Accordingly, the diversity of aging-related vascular pathological 
changes may have a large influence on the cerebral haemodynamic oscillations, and hence on 
the interpretation of haemodynamic neuroimaging data [11]. 
Recently, spontaneous slow oscillations of the fMRI BOLD-signal have gained much interest. 
Specifically, it has been suggested that these oscillations reflect spontaneous neuronal 
activity and that they may play a role in functional connectivity between different brain 
regions. Accordingly, several studies have focused on inter-regional correlations in slow BOLD 
oscillations during resting-state and task performance [12]. Sambataro et al. investigated slow 
oscillations (0.03 - 0.08 Hz) of the fMRI BOLD-signal during performance of the n-back 
working-memory task [13]. In older adults oscillations were reduced in power in posterior 
regions of the default mode network in comparison to young adults. With increasing cognitive 
load (1-back and 2-back versus 0-back), power decreased in both groups, but the power 
attenuation was smaller in older adults. The authors concluded that older adults show 
decreased functional connectivity and a decreased ability to suppress slow oscillations of the 
default mode network. Systemic oscillations were not measured in that study however. 
It is relevant to know how the amplitude of the haemodynamic oscillations is affected by 
different cognitive loads, since aging-related changes in these oscillations are likely to reflect 
aging-related changes in neurogenic, metabolic or myogenic regulation of microvascular 
blood flow. This knowledge will contribute to improved analysis and interpretation of 
haemodynamic neuroimaging data. Therefore, the first aim of this study was to examine 
interaction effects of age and cognitive load on oscillations of cerebral haemodynamics by 
using functional fNIRS, a non-invasive neuroimaging technique which is particularly sensitive 
to the microvasculature. 
When analysing task-related changes in the regional cerebrovascular response, the systemic 
response is often neglected or assumed to be unchanged. However, Tachtsidis et al. found 
significant task-related changes in both regional cerebral haemodynamic and systemic signals 
during functional activation of the frontal cortex. In some participants, these changes were 
highly correlated [14]. These results suggest a centrally mediated mechanism influencing both 
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the cerebrovascular and cardiovascular systems. Therefore, the second aim of our study was 
to examine the impact of age and cognitive activation on BP oscillations. We performed 
transfer function analysis to gain more insight into the relationship between the task-induced 
BP oscillations and cerebral haemodynamic oscillations. 
Taken together, we hypothesized that not only aging, but also cognitive load may affect slow 
oscillations of cerebral haemodynamics. To enhance our understanding of the origins of these 
oscillations, we recorded both cerebral and systemic BP oscillations and investigated their 
possible relationship using transfer function analysis. 
MATERIALS AND METHODS 
Participants 
Fourteen healthy young adults (8 female, mean age = 26.4 ± 3.0 years, range 23 - 32) and 14 
healthy older adults (10 female, mean age = 70.3 ± 4.7 years, range 64 - 78) participated in 
this study. Educational level slightly differed between the young (M = 16.7 ± 2.8 years, 
range 10.5 - 18.0) and older adults (M = 12.6 ± 3.2 years, range 9.0 - 18.0) (Mann-
Whitney U = 33.00, p = .002). All participants completed secondary school or higher. None of 
the older adults experienced subjective memory problems, all were living independently and 
all had unimpaired overall cognitive function as assessed with the Mini Mental State 
Examination ([15]; mean score = 29.1 ± 0.9, range 27 - 30). All participants were right-handed 
and had normal or corrected-to-normal vision. None of the participants had a history of 
neurological or psychiatric disease, or used psychopharmacological drugs. Four older adults 
used antihypertensive medication. All participants refrained from alcohol, caffeine and 
nicotine from at least 3 h before the experimental session. The study was approved by the 
local medical ethics committee and all participants gave written informed consent. 
Experimental procedure 
The experimental procedure utilized in the present study and the accompanying behavioural 
results have previously been described in detail [16]. Participants performed two versions of a 
verbal n-back task; after the 0-back task (control condition) the 2-back task (high 
working-memory load condition) was realized. This paradigm has reliably and validly been 
employed in establishing cerebral activity patterns in the prefrontal cortex in relation to 
increasing working-memory load in fMRI research [17, 18]. The 2-back task places a large 
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demand on a number of key processes within working memory. The 0-back task has regularly 
been used as control condition to measure attention and alertness without working-memory 
load. Since the aim of our study was to specifically investigate the effects of working-memory 
load, and cognitive processes are uncontrolled during resting periods, we decided to use 0-
back as control situation instead of rest. 
Prior to both conditions, participants practiced the task for 1 min and received feedback 
about their performance. Both conditions were preceded by a baseline period of 1 min, 
during which a black fixation cross was displayed at the centre of the 15 inch screen. Both 
conditions consisted of 60 trials, 17 of which were target trials. In each trial, a letter that was 
randomly selected from a set of 20 consonants was presented in black on a light gray 
background with a presentation time of 500 ms. Interstimulus interval was 3000 ms. During 
each trial, participants indicated whether the stimulus was a target by pressing the button 
under the right index finger, or a non-target by pressing the button under the right middle 
finger (PST Serial Response Box, Psychology Software Tools Inc., PA, USA). In the 0-back 
condition, the letter “X” was defined as target. In the 2-back condition, the target was any 
letter that was identical to the letter presented two trials before, while the letter “X” was no 
longer shown. 
Data acquisition 
We used a continuous-wave NIRS device (Oxymon Mk III, Artinis Medical System, The 
Netherlands), using light of three wavelengths (765, 857, 859 nm), to monitor concentration 
changes in cortical oxygenated haemoglobin ([O2Hb]) and deoxygenated haemoglobin ([HHb]) 
with high temporal resolution. The principle behind fNIRS is that near-infrared light 
penetrates the skull and brain and is absorbed by the chromophores O2Hb and HHb, which 
have different absorption spectra. Assuming constant scattering [19] and by using the 
modified Lambert-Beer Law, it is possible to calculate the concentration changes of these 
chromophores in the penetrated brain tissue based on changes in the detected light intensity. 
Both increases in [O2Hb] and decreases in [HHb] are indicators of cortical activation. 
Concentration changes in total haemoglobin ([tHb]), defined as the sum of changes in [O2Hb] 
and [HHb], represent an indicator of alterations in total blood volume. 
In the present study, two pairs of optodes were bilaterally attached to the forehead and were 
tightly fixed in a customized headband (Spencer technologies, Seattle, WA). The detection 
optodes were placed 25 - 30 mm above the midpoint of the eyebrow, at approximately FP1 
8 
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and FP2 according to the international 10 - 20 electrode system. The emission optodes were 
laterally placed at approximately F7 and F8. The emitter-detector spacing was 50 mm to 
minimize contamination from the extra-cerebral circulation and maximize signal 
intensity [20,21]. The differential pathlength factor (DPF), which accounts for the increased 
distance travelled by light due to scattering, is age-dependent [22]. For the young adults, DPF 
was calculated by the formula 4.99 + 0.067 × Age0.814. At present however, no data are 
available on the actual variation of DPF in adults aged above 50 years. Therefore, the DPF was 
set to 6.61, corresponding to age 50, in the older adults [22, 23]. 
BP was measured simultaneously using a photoplethysmography cuff on the index or middle 
finger of the left hand of the participant (Finometer, FinaPres Medical Systems, the 
Netherlands). A three-lead ECG was recorded for measurement of the R-R interval. 
Data processing 
BP, ECG, [O2Hb], [HHb] and [tHb] were simultaneously recorded with a sample frequency of 
125 Hz. Analyses were performed with MATLAB (MathWorks, MA, USA). Samples obtained 
from the left and right fNIRS channels were averaged for each time point. From the BP 
recordings, mean beat-to-beat blood pressures were extracted. 
Mean baseline values of [O2Hb] and BP were calculated over the last 20 s of the pre-task 
baseline period. To establish the haemodynamic and systemic responses to cognitive 
performance, mean values of [O2Hb] and BP were calculated over 180 s of the 0-back and 
2-back task period, respectively. The first three trials (all non-targets) of both conditions were 
excluded from data analyses. 
Beat-to-beat changes in mean BP, [O2Hb], [HHb] and [tHb] were aligned with the time of the 
R wave peak of the ECG. The time series were cubically interpolated at 1 Hz to obtain 
uniformly spaced time series for spectral and transfer function analysis. The signals were 
linearly detrended and were filtered using a Butterworth high-pass filter with a cut-off 
frequency of 0.02 Hz. Spectral analysis was performed on 180-second data segments of BP, 
[O2Hb], [HHb] and [tHb] of both the 0-back and 2-back task. Spectral estimation was based on 
the Welch algorithm [24]. Spectral estimates were determined as the average of 50-second 
windows, overlapping by half. In this way, each data segment contains at least one full period 
of oscillations at the lowest frequency (0.02 Hz). The following frequency ranges were chosen 
for spectral analysis: very-low-frequency (VLF; 0.02 - 0.07 Hz), low-frequency (LF; 0.07 - 0.2 
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Hz) and high-frequency (HF; 0.2 - 0.35 Hz). 
The relationship between oscillations of BP and [O2Hb] was studied by means of transfer 
function analysis. The parameters gain, phase and coherence were estimated using the 
cross-spectral method which has been described in detail previously [25-27]. Fast Fourier 
transforms were implemented with each Hamming-windowed segment and averaged to 
quantify the transfer function. 
It should be noted that the downstream [O2Hb] oscillations are related to BP oscillations, and 
are also influenced by the relationship between oscillations of BP and upstream cerebral 
blood flow in conduit and resistance vessels, which is subject to continuous cerebral 
autoregulatory action. Thus, in short, the parameter gain quantifies how the amplitudes of 
the oscillations in BP are transmitted to the oscillations of [O2Hb]; a lower gain implies that 
these oscillations are reduced by efficient dynamic cerebral autoregulation, or might reflect 
enhanced metabolic reserve or enhanced diffusion of oxygen [20]. The phase shift describes 
the time relationship between oscillations of BP and [O2Hb] and may reflect cerebral 
autoregulatory action and circulatory transit times [28]. Coherence indicates the linearity of 
the relation between BP and [O2Hb] oscillations. Coherence approaching unity suggest a 
linear relationship, while coherence approaching zero suggest no relationship between the 
signals, severe extraneous noise, or a non-linear relationship. Data with coherence ≤ 0.1 for 
VLF were excluded from analysis; data with coherence > 0.1 < 0.4 in VLF were not rejected if 
corresponding coherence in LF was > 0.4. This threshold of 0.1 was chosen because a higher 
threshold for VLF would lead to a biased rejection of estimates of gain and phase. With active 
and intact cerebral autoregulation coherence values will be by definition low in the VLF range 
where cerebral autoregulation is most active [29]. 
Accordingly, data from 12 young and 13 older adults were included for transfer function 
analysis in the VLF range, and data from 14 young and 12 older adults for analysis in the LF 
range. Because the coherence between BP and [O2Hb] oscillations in the HF range 
approached zero in almost half of the participants, no analyses were performed in this 
frequency range. Transfer function analysis was not applied to the relationship between BP 
and [HHb], since oscillations of [HHb] are too weak for a reliable calculation of transfer 
function estimates. 
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Figure 1. Beat-to-beat time series.  
Mean blood pressure (BP) and oxygenated haemoglobin  [O2Hb] from a representative young participant 
(upper panel) and an older participant (lower panel) during baseline and 0 -back performance. The dashed line 
marks the start of the task. Note that in the lower panel high-frequency oscillations of blood pressure are 
clearly visible. 
 
Table 1. Spectral power peaks. 
Averages (mean ± standard deviation) of spectral power peaks in the different frequency bands in young and 
older adults during 0-back and 2-back performances. Note that subjects were left out of the calculation of the 
average spectral power peak if they did not show a clear peak in that particular frequency band. No clear peaks 
were found for HFOs of [O2Hb]. BP = blood pressure; [O2Hb] = concentration changes in oxygenated 
haemoglobin; VLF = very-low-frequency range (0.02 - 0.07 Hz); LF = low-frequency range (0.07 - 0.2 Hz); HF = 
high-frequency range (0.2 - 0.35 Hz). 
 0-back           2-back           
 
Fre-
quency 
(Hz)      
Frequen-
cy (Hz)      
  Young adults 
Young 
adults     
Older 
adults     Older adults 
BP VLF 0.044 ± 0.009 0.045 ± 0.016 0.039 ± 0.011 0.045 ± 0.012 
BP LF  0.097 ± 0.021 0.102 ± 0.023 0.101 ± 0.026 0.099 ± 0.014 
BP HF  0.282 ± 0.008 0.278 ± 0.01 0.278 ± 0.031 0.27 ± 0.03 
[O2Hb] VLF  0.041 ± 0.011 0.044 ± 0.017 0.04 ± 0.011 0.039 ± 0.014 
[O2Hb] LF 0.096 ± 0.012 0.088 ± 0.011 0.094 ± 0.015 0.097 ± 0.023 
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STATISTICAL ANALYSIS 
Statistical analysis was performed using PASW Statistics software version 18.0 (SPSS Inc., 
Chicago, IL, USA). Statistical significance was set at an alpha of .05. Data are presented as 
mean ± SD. Shapiro-Wilk tests indicated that the power spectral data were not normally 
distributed. Accordingly, the power spectral data were log transformed before statistical 
testing. For the transfer function estimates, the assumption of normality was 
met (Shapiro-Wilk). Comparisons between the young and older adult groups, and between 
the high working-memory load condition and control condition were made using 
repeated-measures ANOVA. Significant main and interaction effects were further analysed by 
means of planned contrasts. 
RESULTS 
Representative oscillations of BP and [O2Hb] during task performance are presented in 
Figure 1. Table 1 shows the averaged spectral power peaks in the VLF, LF and HF range in 
young and older adults during 0-back and 2-back performances. 
Cerebral haemodynamic measurements 
During 0-back performance, mean [O2Hb] increased in comparison to baseline 
0.32 ± 0.25 µmol/L in older adults (F(1,13) = 23.13, p < .001). No significant change of [O2Hb] 
was detected during 0-back performance in young adults (0.19 ± 0.46 µmol/L; (F(1,13) = 2.32, 
p = .151). Mean [O2Hb] changes from baseline did not differ between groups (F(1,26) = 0.94, 
p  = .341). 
During 2-back performance, mean [O2Hb] increased in comparison to baseline 0.34 ± 0.43 
µmol/L in young adults (F(1,13) = 8.75, p = .011)) and 0.61 ± 0.23 µmol/L in older 
adults (F (1,13) = 99.61, p < .001). Mean [O2Hb] changes from baseline marginally differed 
between groups (F(1,26) = 4.19, trend: p = .051). 
Spectral analysis of cerebral oscillations 
Figure 2 demonstrates that the magnitude of VLFOs in [O2Hb] and [tHb] is influenced by both 
age and working-memory load. VLFOs of [O2Hb] (F(1,26) = 9.70, p = .004) 
and [tHb] ((1,26) = 13.18, p = .001) were stronger in young adults compared to older adults  
8 
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Figure 2. Spectral power. 
Spectral power of very-low-frequency oscillations in blood pressure (BP) and cortical haemoglobin in young and 
older adults during 0-back and 2-back performances. Bar graphs show the untransformed power spectral density 
values (mean ± standard deviation) for oscillations in BP, oxygenated, deoxygenated and total 
haemoglobin ([O2Hb]; [HHb]; [tHb]) in the very-low-frequency range (VLF = 0.02 - 0.07 Hz). Note however, that 
statistical analysis has been performed on log transformed data. *p < .05, **p < .005. 
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during the control condition. Power of VLFOs of [O2Hb] was reduced by 23.4% with increased 
working-memory load in young adults (F(1,13) = 8.07, p = .014) and became similar to the 
magnitude of VLFOs in older adults (F(1,26) = 4.09, p = .053). Power of VLFOs of [tHb] 
declined 22.5 % with increased working-memory load in young adults (F(1,13) = 5.30, 
p = .039) and became similar to the magnitude in older adults (F(1,26) = 1.67, p = .208). VLFOs 
of [HHb] were not influenced by cognitive load or age. 
The spectral power of LFOs and HFOs of [O2Hb], [HHb] and [tHb] was not influenced by 
differences in cognitive load, but overall declined with age (Table 2). 
Systemic measurements 
Mean BP was higher in older adults than in young adults in all conditions. In comparison to 
baseline measurements, BP rose slightly under high working-memory load in young (4.3 ± 4.4 
mmHg, F(1,13) = 13.39, p = .003) and older adults (5.9 ± 5.0 mmHg, F(1,13) = 19.51, p = .001), 
but the increase did not differ between groups (F(1,26) = 0.83, p = .371). 
Table 2. Untransformed power spectral density values of low- and high-frequency oscillations of blood pressure 
and cortical haemoglobin in young and older adults during 0 -back and 2-back performances. BP = blood 
pressure; [O2Hb], [HHb], [tHb] = concentration changes in oxygenated, deoxygenated and total haemoglobin, 
respectively; LF = low-frequency range (0.07 - 0.2 Hz); HF = high-frequency range (0.2 - 0.35 Hz). *p < .05, 
**p < .005. 
  0-back           2-back           
  Young adults Older adults Young adults Older adults 
BP LF (mmHg2) 4.484 ± 2.9861 1.6832 ± 1.4272** 4.5353 ± 3.3221 1.6222 ± 1.0363** 
BP HF (mmHg2) 0.44 ± 0.3086 0.6318 ± 0.61 0.4464 ± 0.3384 0.5888 ± 0.6532 
[O2Hb] LF ((µmol/L)
2) 0.0175 ± 0.0135 0.0037 ± 0.0038** 0.0155 ± 0.011 0.0036 ± 0.0022** 
[O2Hb] HF ((µmol/L)
2) 0.0007 ± 0.0003 0.0002 ± 0.0002** 0.0007 ± 0.0006 0.0003 ± 0.0004* 
[HHb] LF ((µmol/L)2) 0.0038 ± 0.0048 0.0007 ± 0.0007** 0.0026 ± 0.0027 0.0006 ± 0.0005** 
[HHb] HF ((µmol/L)2) 0.0002 ± 0.0001 0.0001 ± 0.0000** 0.0002 ± 0.0002 0.0001 ± 0.0001* 
[tHb] LF ((µmol/L)2) 0.0084 ± 0.0058 0.0019 ± 0.0016** 0.0081 ± 0.0066 0.0025 ± 0.0018** 
[tHb] HF ((µmol/L)2) 0.0007 ± 0.0005 0.0002 ± 0.0002* 0.0007 ± 0.0006 0.0004 ± 0.0008 
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Figure 3. Transfer function analysis of oscillations in blood pressure and oxygenated hemoglobin in young and 
older adults during 0-back and 2-back performances. Bar graphs show the values (mean ± standard deviation) 
of phase (top panels), gain (middle panels), coherence (bottom panels) for oscillations in the very -low-
frequency range (VLF = 0.02 - 0.07 Hz)and low-frequency range (LF = 0.07 - 0.2 Hz). *p < .05. 
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Spectral analysis of systemic oscillations 
In the control condition, VLFOs of BP were equal in power for young and older adults. 
However, high working-memory load resulted in a power decline of 24.0 % in young adults (F
(1,13) = 13.78, p = .003), while in older adults the VLFOs did not change (F(1,13) = 2.26, 
p = .156). The spectral power of LFOs of BP was not influenced by cognitive load, but declined 
with age. HFOs of BP were not affected by either working-memory load or age (Table 2). 
Relationship between cerebral and systemic oscillations 
Figure 3 gives an overview of the transfer function parameters phase, gain and coherence for 
oscillations of BP and [O2Hb] in the VLF (left panel) and LF range (right panel) during 0-back 
and 2-back performances. No within- or between-group differences were found for transfer 
function parameters phase and coherence. In the VLF range, phase shift was on average 
slightly negative, but varied largely across participants; BP oscillations followed [O2Hb] 
oscillations in some participants, while they led [O2Hb] oscillations in others. In the LF range, 
BP oscillations led [O2Hb] oscillations in all participants. Coherence values between BP and 
[O2Hb] oscillations were as follows: in young adults 0.46 ± 0.22 (0-back) and 
0.51 ± 0.20 (2-back) in the VLF range, and 0.62 ± 0.16 (0-back) and 0.65 ± 0.14 (2-back) in the 
LF range; in older adults 0.59 ± 0.18 (0-back) and 0.58 ± 0.16 (2-back) in the VLF range, and 
0.61 ± 0.18 (0-back) and 0.64 ± 0.15 (2-back) in the LF range (Figure 3). 
For the parameter gain, we found an age effect in the VLF range (F(1,23) = 5.35, p = .030) and 
LF range (F(1,24) = 7.24, p = .013). Further testing revealed this effect was only present for the 
2-back task (VLF range ( F(1,23) = 5.15, p = .033); LF range (F(1,24) = 8.75, p = .007)). However, 
no significant effects of working-memory load or interaction effects between working-
memory load and age were present, which indicates that possible age effects on gain did not 
significantly differ between the different levels of working-memory load. Therefore, we 
conclude that there is no clear effect of age on gain. 
Taken together, the results of transfer function analysis show a clear relationship between 
systemic and cerebral oscillations. This relationship displays the known properties of cerebral 
autoregulation. We found no overall effects of age and working-memory load on the 
relationship between BP and [O2Hb] oscillations. 
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DISCUSSION 
The aim of our fNIRS study was to examine interaction effects of age and cognitive load on 
VLFOs (0.02 - 0.07 Hz), LFOs (0.07 - 0.2 Hz) and HFOs (0.2 - 0.35 Hz) of cerebral 
haemodynamics and BP. In young adults, increased working-memory load resulted in a 
reduction of VLFOs of cerebral haemodynamics and BP. Moreover, our study shows that 
VLFOs, LFOs and HFOs of cerebral haemodynamics declined with aging. BP oscillations in the 
LF range also declined with aging. Transfer function analysis identified a relationship between 
BP and [O2Hb] oscillations. Furthermore, it demonstrated that this relationship did not 
change under influence of age or cognitive load. 
The present study is the first to utilize fNIRS to investigate the effects of cognitive load on 
slow oscillations in cerebral haemodynamics in both young and older adults. Our results are 
in agreement with the studies of Obrig et al. [6] and Schroeter et al. [8]. From these studies 
and the current study, it can be concluded that VLFOs are affected by functional stimulation 
and that LFOs decrease in amplitude with age. Schroeter et al. reported that the power 
spectral density peak in the VLF range in their study corresponded to the duration of the 
functional stimulation cycle [8]. In our study, task duration was 180 s. Hence, our results on 
VLFOs cannot be attributed to the frequency or duration of stimulus presentation. 
The second aim of our study was to examine the effects of age and cognitive load on BP 
oscillations. Our results showed that increased cognitive load resulted in systemic changes; 
BP increased slightly in both young and older adults, and VLFOs of BP reduced in amplitude in 
young adults. We performed transfer function analysis to investigate the relationship 
between BP and [O2Hb] oscillations in the VLF and LF range. In accordance with the literature, 
the coherence between BP and [O2Hb] oscillations was found to be large [6, 30]. Phase shifts 
in the VLF range approached zero, but, consistent with other studies, the standard deviations 
were very large in both groups. The study of Pfurtscheller et al. [30] showed that phase shifts 
between cardiovascular oscillations and cerebral haemodynamic oscillations vary largely 
across individuals, but are relatively stable within one individual. In general, phase 
relationships have been more widely studied between BP and cerebral blood flow 
velocity (CBFV), with fewer studies also including [O2Hb] (e.g. [20]). Due to effects of cerebral 
autoregulation, CBFV oscillations lead BP oscillations in the VLF range and, to a lesser extent, 
in the LF range, and they are in phase in the HF range. Because of the time delay between 
changes in CBFV and changes in [O2Hb], this pattern differs for phase shifts between BP and 
[O2Hb]; in the VLF range, where CBFV leads BP, oscillations in [O2Hb] become more or less in 
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phase with BP due to the delay in [O2Hb]. This may result in the large variation around zero 
we found in our study. In the LF range, our results showed that BP oscillations lead [O2Hb] 
oscillations, which is in agreement with previous studies [6, 20, 28]. In accordance with the 
results of Phillip et al. we did not find a clear effect of age on gain between BP and [O2Hb] 
oscillations [31]. Taken together, we conclude that the relationship between BP and [O2Hb] 
oscillations (cerebral autoregulation) was not affected by cognitive load and age. 
We observed that both VLFOs of cerebral haemodynamics and BP declined by a similar 
magnitude with cognitive load in young adults. In view of the established relationship 
between BP and cerebral oscillations using transfer function analysis, this observation 
suggests – but does not prove – that this decrease in VLFOs is explained by the decrease in 
VLFOs of BP. In turn, this speculatively implies a systemic effect of cognitive load, possibly due 
to activation of the autonomic nervous system. However, in the older subjects, alterations in 
cerebral haemodynamic oscillations appeared less clearly dependent on BP oscillations. The 
origins of the slow haemodynamic oscillations are under debate and to date largely unclear 
(see, e.g., [32]). They may reflect either vasomotion or Mayer waves, which represent distinct 
but related phenomena. Vasomotion refers to tone oscillations in microvascular smooth 
muscle cells, resulting in spontaneous variation of the vascular diameter [33]. Mayer waves 
are defined as spontaneous oscillations in arterial BP, representing feedback oscillations of 
the baroreflex loop modulated by the sympathetic nervous system [34]. Previous studies have 
made a distinction between VLFOs and LFOs of cerebral haemodynamics, although no 
agreement exists on the frequency ranges. Therefore, it is unclear how power changes in the 
different frequency bands are linked to specific underlying physiological mechanisms. It has 
been proposed, however, that slow wave vasomotion (VLFOs) originates from the large 
arterioles (50 - 100 µm), whereas fast wave vasomotion (LFOs and HFOs) arises from terminal 
arterioles [35]. Neurogenic innervation occurs in the large arterioles, while the terminal 
arterioles lack such a neural supply [9]. Aging is accompanied by a degeneration of structure 
and function of the cerebral vasculature [10]. Schroeter et al. therefore hypothesized that a 
reduction of LFOs with aging suggests a decline in the activity of the microvascular smooth 
muscle cells together with increased vessel stiffness [8]. Our data are in line with this 
interpretation, since we found an aging-related reduction of VLFOs, LFOs and HFOs of 
cerebral haemodynamics. Furthermore, our results showed that VLFOs varied in power with 
cognitive load in young adults, but not in older adults. Since VLFOs may originate from large 
arterioles for which neurogenic innervation was shown, we speculate that the contribution of 
neurogenic activity to the regulation of regional cerebral blood flow is relatively lower in 
elderly, presumably due to vessel stiffness. 
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For the HF range we observed an aging-related decline of cerebral haemodynamic 
oscillations. Furthermore, it can be noticed that the spectral power peaks of BP in the HF 
range coincide with the frequency of stimulus presentation, which was approximately 0.28 
Hz. No clear peaks in the HF range could be detected for [O2Hb] oscillations, which is likely 
related to the inherently lower power of this signal. Respiratory cycles are a main contributor 
to HFOs of BP and cerebral haemodynamics. Additionally, the motor response may influence 
the HFOs via two mechanisms, although with a latency of several seconds [30, 36, 37]. First, 
neocortical structures involved in movement execution initiate heart rate changes via 
brainstem cardiovascular nuclei [38]. Second, the reafferent input from the kinaesthetic 
receptors evoked by the button press elicits a BP response [39]. Taken together, when the 
influence of respiration and motor execution is taken into account, it is plausible that 
participants were breathing in synchrony with stimulus presentation or button pressing. This 
may have influenced the results on HFOs of BP and cerebral haemodynamics. 
Task-evoked systemic changes may confound the fNIRS signal [40]. A major challenge for 
signal analysis is to separate these systemic changes from the haemodynamic changes that 
are related to neural activity. Katura et al. quantified the contribution of systemic signals to 
LFOs (0.04 - 0.15 Hz) in cerebral haemodynamics under rest [4]. Using transfer entropy for 
analysis, they found that the contribution of systemic signals to LFOs of [O2Hb] was 35 %; 
20 % could be attributed to heart rate, 5 % to BP, while their common contribution was 10 %. 
For LFOs of [HHb] this was 7 %; 5 % could be attributed to heart rate, 1 % to BP, while their 
common contribution was 1 %. Katura et al. concluded that the origin of LFOs in cerebral 
haemodynamics may lie in the regulation of regional cerebral blood flow and energetic 
metabolism rather than due to the systemic regulation of the cardiovascular system. Task-
evoked systemic fluctuations may however be substantial and may mask cerebral 
haemodynamic changes or lead to false positive findings [14, 41-43]. 
Several methods have been proposed to separate systemic contributions to the fNIRS signal 
from local cerebral haemodynamic contributions and these have been summarized in the 
paper of Kirilina et al. [42]. Methods include for example short-separation measurement to 
estimate extracranial contribution [44], statistical parametric mapping with the inclusion of 
systemic variables as regressors [45], or independent component analysis [46, 47]. Our 
current study not only stresses the importance of taking systemic variables into account in 
fNIRS signal analysis, but also indicates that the factors cognitive load and aging influence 
both systemic and cerebral haemodynamic contributions. 
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We recognize some limitations of our study. First, respiration was not recorded in this study. 
The observed HF spectral power peaks suggest that participants were breathing in synchrony 
with stimulus presentation or button pressing. For future research it is recommended to 
monitor respiration, or end tidal CO2, to control for task induced changes in respiration, or 
hyperventilation. Second, the exact moment of a button press was not marked in the 
recorded signals. Therefore, we were not able to calculate the movement-triggered BP and 
heart rate fluctuations. However, the design of our study may not have allowed such a 
calculation due to the latency of the BP response. Third, we cannot quantify the exact 
contribution of systemic noise to the fNIRS signals. Transfer function analysis showed a 
relationship between BP and [O2HB] oscillations, but the extent of the contribution remains 
unclear. Methods that are being used to separate systemic contributions to the fNIRS signal 
from local cerebral haemodynamic contributions have been mentioned above. For future 
research it is recommended to gain more insight in the sources of noise by for example co-
registering skin blood flow. 
The application of spectral analysis to study spontaneous oscillations in elderly may be useful 
for clinical practice. Previous studies demonstrated reduced spontaneous oscillations in 
patients with cerebral infarction [48], people at risk for atherosclerotic stroke [49] and people 
with cerebral microangiopathy [50], indicating vascular alterations such as vessel stiffness. 
Moreover, Schroeter et al. found that changes in the amplitude of the oscillations were 
tightly related to arterial hypertension and neuropsychological deficits [50]. Hence, spectral 
analysis, next to time course analysis, of the cerebral haemodynamic signal may be useful for 
early detection of vascular dementia or stroke. 
To summarize, our fNIRS study showed that slow oscillations of cerebral haemodynamics and 
BP decline with aging. VLFOs are influenced by cognitive load in young adults, but not in older 
adults. These findings are presumably due to aging-related changes in the microvasculature 
such as vessel stiffness. Moreover, our results indicate that not only local vasoregulatory 
processes, but also systemic processes influence the cerebral haemodynamic signals. To 
conclude, the effects of age and BP should be taken into account in the analysis and 
interpretation of neuroimaging data that rely on blood oxygen levels. 
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Chapter 9. 
Cerebral perfusion in hypertensive elderly  
before and after antihypertensive treatment. 
           Aisha SS Meel-van den Abeelen 
Jurgen AHR Claassen  
 
202  
ABSTRACT 
Hypertension affects 20 % to 30 % of the world population and is the most prevalent 
modifiable risk factor for stroke. Several studies have demonstrated that antihypertensive 
drug therapy reduces the development of new coronary events, stroke and congestive heart 
failure in elderly persons. However, at short term antihypertensive drug therapy may also 
have disadvantages. Indications exist that hypertension impairs the mechanism of cerebral 
autoregulation itself. Furthermore, orthostatic hypotension is a common problem among 
elderly patients and could be attenuated by antihypertensive drug therapy. Hence, a higher 
risk for hypoperfusion occurs. 
Herein, we report haemodynamic changes after antihypertensive treatment in three elderly 
patients with hypertension. In the three elderly patients, over the age of 70 years, with 
hypertension described in this case report it was shown that BP lowering did not result in a 
lowering of the CBFV. Also the cerebral autoregulatory functioning was preserved after 
3 months of antihypertensive treatment. One patient did show increased orthostatic 
hypotension after antihypertensive treatment, but the ratio between BP and cerebral blood 
flow remained the same. 
Overall, the findings of this case report suggest that it is save to apply antihypertensive 
treatment in elderly regarding brain perfusion. 
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INTRODUCTION 
Hypertension affects 20 % to 30 % of the world population and is the most prevalent 
modifiable risk factor for stroke [1]. Long-standing hypertension may result in structural 
changes of the cerebral vessels, such as thickening of the vessel walls with narrowing of the 
lumen and hyalinosis of the media resulting in stiffness. The seventh report of the Joint 
National Committee on prevention, detection, evaluation and treatment of high blood 
pressure (BP) considered that vascular risk begins with BP values of 115/75 mmHg, and that 
the risk doubles with each increase of 20/10 mmHg [2]. The relationship between BP and 
stroke risk has been demonstrated for all age groups studied. While the strength of the 
association becomes attenuated with increasing age, it is still strong and continuous among 
those aged 70 years or more. Several studies have demonstrated that antihypertensive drug 
therapy reduces the development of new coronary events, stroke and congestive heart 
failure in elderly persons [2]. Results from HYVET (Hypertension in the Very Elderly Trial) 
showed that, at 2-year follow-up, antihypertensive drug therapy reduced stroke by 30 %, 
all-cause mortality by 21 %, cardiovascular death by 23 % and heart failure by 64 % [3]. 
However, at short term antihypertensive drug therapy may also have disadvantages. 
Indications exist that hypertension impairs the mechanism of cerebral autoregulation itself, 
by shifting the ranges of the autoregulatory curve upwards [4]. This upwards shift may result 
in transient falls in cerebral blood flow when BP is lowered with antihypertensive drug 
treatment. Furthermore, orthostatic hypotension is a common problem among elderly 
patients [5] and could be attenuated by antihypertensive drug therapy. Hence, a higher risk 
for hypoperfusion occurs. The HYVET study did not present any indications for these 
disadvantages, however the population studied contains less comorbidities and is not 
representative for the Western population. Furthermore, systolic BP was only lowered to 150 
mmHg [3]. 
Herein, we report haemodynamic changes after antihypertensive treatment in three elderly 
patients with hypertension. 
METHOD 
Three patients (1 man and 2 women), over the age of 70 years, with hypertension (systolic 
BP >150 mmHg) participated in research in our department. They had been carefully 
screened by a geriatrician including a medical history, physical examination and 
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electrocardiogram to exclude acute medical conditions or cardiovascular diseases other than 
hypertension. To ensure true hypertension, patients were asked to record their BP twice daily 
(approximately 8 AM and 8 PM) at home using a semiautomatic device. 
At their first visit, none of the hypertensive patients had received antihypertensive therapy. 
They underwent the test protocol described below. After their visit, they received common 
antihypertensive treatment as endorsed by the Dutch CBO guidelines which has as goal to 
lower the systolic BP to below 140 mmHg. Patient came back for a follow-up measurement 
after 3 months of antihypertensive treatment. 
The test protocol took place in the morning, at least 2 h after a light breakfast and 12 h after 
the last caffeinated beverage or alcohol, in a quiet, environmentally controlled laboratory 
with an ambient temperature of 22°C. Continuous BP (FinaPres Medical Systems, the 
Netherlands), three-lead ECG, cerebral blood flow velocity (CBFV) (Multi-Dop, Compumedics 
DWL, Germany), end-tidal CO2 (capnography BIOPAC Systems, Goleta, Ca.) and oxygenation 
index (HbDiff) (near-infrared spectroscopy, Oxymon Mk III, Artinis Medical System, The 
Netherlands) were recorded. After at least 10 min of rest in sitting position, a baseline 
measurement of 5 min was recorded during spontaneous respiration. Patients were asked to 
perform a single sit-to-stand protocol. They sat in a straight-backed chair and were asked to 
stand up. The protocol consisted of three trials of 2-min sitting followed by standing for 
1 min. During all manoeuvres, patients were instructed to keep normal breathing and to 
avoid performing a Valsalva manoeuvre. Adherence to this was confirmed by inspecting the 
CO2 waveforms and etCO2 registrations. To investigate cerebral vasomotor reactivity (CVMR), 
a previously described protocol was used [6], consisting of a 30 s period of coached 
hyperventilation, followed by 2 minutes of spontaneous breathing. Next, subjects were asked 
to inhale a gas mixture containing 7 % CO2, 21 % O2 and 72 % N2 through a tightly fitting 
mouthpiece until a stable plateau of CBFV had been reached. With this protocol a wide range 
of changes in etCO2 can be obtained. 
Data processing 
All data were simultaneously recorded at 200 Hz. Post processing was performed using 
custom-written MATLAB scripts. Real time beat-to-beat mean values of BP and CBFV were 
calculated as waveform integration of the BP and CBFV signal within each cardiac cycle. To 
evaluate the beat-to-beat dynamics of BP, CBFV and HbDiff responses to acute posture 
changes in the single sit-stand protocol, we calculated the differences between the sitting 
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value (averaged over a period of 20 s) and the value at the nadir of BP (average of 5 values 
surrounding the nadir) for BP, CBFV and HbDiff. 
The CVMR protocol evaluated changes in BP, CBFV, calculated cerebrovascular conductance 
index (CVCI) and HbDiff during the transitions from hypocapnia (induced by hyperventilation) 
to normocapnia and from normocapnia to hypercapnia (induced by 7 % CO2 inhalation). 
Because changes in CO2 cause changes in BP, which in turn may directly affect CBFV, CVCI, 
expressed as CBFV changes divided by BP changes, was used to minimize the confounding 
effects of differences in BP response during CVMR testing between subjects on CVMR 
estimation [7]. 
Transfer function analysis was performed on the spontaneous oscillations in the baseline 
measurement as a measure for cerebral autoregulation using the method described by Zhang 
et al. [8] and reviewed by van Beek et al. [9]. The time series of mean BP and CBFV were first 
subdivided into 950-point segments with 50 % overlap for spectral estimation. This process 
resulted in five segments of data for the segment periodogram average. Fast Fourier 
transforms were implemented with each Hanning-windowed segment and averaged to 
quantify the transfer function. For quantification of CA the positive phase shift and the gain 
between BP and CBFV were quantified as means of the following frequency bands: very low 
frequency: 0.02 - 0.07 Hz; low frequency: 0.07 - 0.15 Hz; and high frequency: 0.15 - 0.35 Hz. 
The transfer function analysis is based on the high-pass filter model of cerebral 
autoregulation, wherein BP oscillations at lower frequencies are buffered better than higher 
frequencies, leading to lower gain (better damping) in these lower frequencies. Also, a 
characteristic of this model is that the counteractive actions of autoregulation lead to a phase 
shift between CBF and BP in these lower frequencies [9]. 
RESULTS 
Demographic baseline data and follow up data for the three patients are summarized in Table 
1. In all three patients, antihypertensive treatment lowered BP (average of -19 mmHg). Mean 
CBFV rose after antihypertensive treatment (average of 12 cm/s). 
The haemodynamic changes for the single sit-stand manoeuvres are shown in Figure 1. The 
posture change from sit to stand evoked transient reductions in BP. Patient 1 and 2 did not 
show any differences in BP. Only patient 3, whom showed a greater fall in BP after 
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Table 1. Demographic data before and after treatment. 
SBP = systolic blood pressure. DBP = diastolic blood pressure. HR = heart rate. MCBFV = mean cerebral blood 
flow velocity. 
 patient 1   patient 2   patient 3   
Age (years) 70 78 71 
Sex (male/female) male female female 
       
  
before 
treatment 
after  
treatment 
before 
treatment 
after  
treatment 
before 
treatment 
after  
treatment 
Average home  
measurements 
            
SBP morning (mmHg) 151 130 166 147 163 147 
DBP morning (mmHg) 80 69 90 81 72 69 
HR morning (bpm) 77 87 65 61 50 51 
SBP evening (mmHg) 169 141 165 152 150 144 
DBP evening (mmHg) 88 72 91 82 74 65 
HR evening (bpm) 85 84 70 68 56 54 
              
MCBFV (cm/s)  41 48 35 57 35 41 
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Figure 1. Haemodynamics during sit-to-stand manoeuvre before and after treatment. Results are shown for 
20 seconds before standing up till 30 seconds after standing up. MBP = mean blood pressure. MCBFV = mean 
cerebral blood flow velocity. HbDiff = oxygenation index.  
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Figure 2. Haemodynamics during cerebrovasomotor reactivity test. 
The cerebral vasomotor reactivity test consisted of a 30 s period of coached hyperventilation (hypocapnia), 
followed by 2 minutes of spontaneous breathing (normocapnia). Next, subjects were asked to inhale a gas 
mixture containing 7% CO2, 21% O2 and 72% N2 through a tightly fitting mouthpiece to create hypercapnia 
(hypercapnia). MBP = mean blood pressure. MCBFV = mean cerebral blood flow velocity. 
CVCI = cerebrovascular conductance index. 
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antihypertensive treatment, had a greater decrease in mean CBFV and HbDiff after 
antihypertensive treatment. The haemodynamic changes for CVMR are shown in Figure 2. 
Before antihypertensive treatment, all patients showed a lowered CBFV during hypocapnia 
and an increased CBFV during hypercapnia. After antihypertensive treatment, this 
cerebrovascular reactivity phenomenon was preserved in patient 2 and 3. Patient 1 showed 
no changes in CBFV during hypo- and hypercapnia after antihypertensive treatment. 
Transfer function analysis revealed that the high-pass filter characteristics of cerebral 
autoregulation were remained after antihypertensive treatment. 
DISCUSSION 
Although tight BP control is known to have beneficial impacts in patients with hypertension 
[10, 11], physicians are cautious with prescribing anti-hypertensive treatment in elderly due 
to the unknown effect on cerebral perfusion. In the three elderly patients with hypertension 
described in this case report it was shown that BP lowering did not result in a lowering of the 
CBFV. In contrast, even a rise in CBFV was observed. 
Hypertension affects nearly a third of the general population, which is about one billion 
people worldwide [12], and is an important risk factor for cardiovascular disease. The 
prevalence of hypertension increases dramatically with age, such that as much as 77 % of 
subjects over age 70 are hypertensive [13]. If hypertension is adequately treated it is possible 
to minimize the risk of heart attack, heart failure, stroke and kidney failure. However, in 
severe hypertension the cerebral vessels are narrowed with thickened walls and hyalinosis of 
the media results in stiffness, which may result in a need for higher perfusion pressures for 
the brain and a lower ability for cerebral autoregulatory vasodilatation [4]. Lowering the BP 
with antihypertensive treatment may thus make hypertensive patients more vulnerable to 
cerebral hypoperfusion. The concern that anti-hypertensive treatment may lead to 
hypoperfusion of the brain is reflected in the low number of elderly patients with 
hypertension who receive treatment. Only a third of hypertensive patients aged above 70 
years receives treatment and has adequate controlled BP (defined as a systolic BP ≤ 140 
mmHg); another third receives treatment but has inadequate control of hypertension, the 
final third is untreated [13]. This lack of knowledge may unnecessarily expose patients in need 
for antihypertensive treatment to a higher risk for i.e. stroke. 
Several studies have investigated the negative effects of BP lowering on morbidity, quality of 
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life and mortality in patients of middle age with moderate hypertension [14, 15]. Thus far, 
antihypertensive treatment does not seem to have a negative influence on brain blood flow. 
However, with advancing age, evidence is scarce and less clear and concern for treatment-
related harm increases. 
Although aging is associated with changes in cerebrovascular haemodynamics [16-18], recent 
research has shown that the cerebral autoregulatory functioning is unaffected in 
normotensive aging [19]. In this case report, we have shown that in these hypertensive 
elderly, aged between 70 and 80 years, also the cerebral autoregulatory functioning was 
preserved. As the primary goal of cerebral autoregulation is to maintain an adequate cerebral 
perfusion despite changes in BP, an adequate cerebral autoregulatory functioning predicts 
that cerebral blood flow would be preserved following BP lowering with antihypertensive 
treatment. After 3 months of antihypertensive treatment, the BP lowering did, indeed, not 
result in a lowering of the CBFV. In contrast, even a rise in CBFV was observed. One patient 
did show increased orthostatic hypotension after antihypertensive treatment, but the ratio 
between BP and cerebral blood flow remained the same. In another patient, after 
antihypertensive treatment, no decrease nor increase in cerebral blood flow was seen during 
hypo- and hypercapnia, respectively. This suggests a blunted cerebral vasomotor reactivity. 
We need to mention that the use of CBFV with transcranial Doppler to estimate actual blood 
flow requires that the vessel diameter remains unchanged and that the perfusion territory of 
a given artery remains constant [20]. Numerous studies have shown that middle cerebral 
artery diameter in humans remains relatively constant under a variety of haemodynamic 
conditions [21-23]. However, it is possible that the medications used to induce hypertension 
may have had a direct effect on the cerebral vessels confounding our results. During 
hypotension, hypocapnia and hypercapnia in healthy subjects and neurosurgical patients, 
diameter of the middle cerebral artery was unchanged or showed less than 4 % change [21, 
23]. Studies in hypertensive patients are lacking. Measurements of isolated middle cerebral 
artery from spontaneously hypertensive rats indicate a 10 % change in diameter with large 
changes in mean BP from 40 to 140 mmHg, suggesting that in our study, small changes in 
MCA diameter cannot be excluded. However, such changes would have led to a finding of 
reduced CBFV after treatment. The relatively narrower the lumen of the middle cerebral 
artery in hypertensive patients before treatment might increase CBFV, overestimating CBF. 
Subsequently, we doubt that, in this case report, the found rise in CBFV after treatment is 
caused by a significant effect of the medication on the cerebral vessels. 
9 
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Overall, the findings of this case report have clinical significance since they suggest that it is 
save to apply antihypertensive treatment in elderly patients with regard to the level of 
cerebral blood flow and cerebral autoregulatory functioning. Antihypertensive treatment 
would have the benefit of reducing the development of (new) coronary events, stroke and 
congestive heart failure [2]. However, as these results are only obtained in a small sample of 
three patients, a larger observational trial is needed to confirm our findings. Furthermore, as 
this case report is inconclusive on a possible causal relationship between blunted cerebral 
vasomotor reactivity and anti-hypertensive treatment further studies on this topic are 
warranted. 
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ABSTRACT 
Background 
Though highly prevalent, the pathophysiology of orthostatic hypotension (OH), postprandial 
hypotension (PPH) and carotid sinus hypersensitivity (CSH) are rarely studied together. There-
fore, we conducted such a comprehensive study focusing on the common role of the cardio-
vascular autonomic system. We hypothesized that in geriatric patients, OH, PPH and CSH are 
manifestations of cardiovascular autonomic dysfunction and investigated state-of-the-art 
cardiovascular autonomic function indices in a group of geriatric falls or syncope patients. 
Methods 
In a cross-sectional study of 203 consecutive eligible falls clinic patients, we compared heart 
rate variability (HRV), blood pressure variability (BPV) and baroreflex sensitivity (BRS) as po-
tential autonomic function determinants of the three different hypotensive syndromes. 
Results 
OH, PPH and CSH were diagnosed in 53%, 57% and 50% of the patients, respectively. In a pop-
ulation relevant for geriatric practice, we found no differences in HRV, BPV and BRS between 
patients with and without OH, with and without PPH, and with and without CSH, respectively, 
nor between patients with and without falls, dizziness, or syncope as presenting symptom, 
respectively. 
Conclusions 
In geriatric patients with hypotensive syndromes, cardiovascular autonomic function as meas-
ured by HRV, BPV and BRS is comparable to patients without such syndromes. These findings 
argue against a single or dominant etiological factor, that is, cardiac autonomic dysfunction 
and underline the structured, broad and multifactorial approach to elderly patients with falls 
and/or syncope as proposed in the current evidence-based syncope guidelines. 
10 
217  
C
ere
b
ral perfusio
n
 in
 h
yp
erten
sive eld
erly befo
re an
d
 aft
er an
ti
h
yp
erten
sive treatm
en
t 
INTRODUCTION 
Heart rate variability (HRV), blood pressure variability (BPV) and baroreceptor sensitivity 
(BRS) are established measures of cardiovascular autonomic function in research [1-3]. The 
clinical relevance of these measures has also been shown, as diminished BRS, diminished HRV 
and increased BPV have prognostic significance for mortality and cardiovascular risk [4-6]. 
Orthostatic hypotension (OH), postprandial hypotension (PPH) and carotid sinus 
hypersensitivity (CSH) are disorders of blood pressure (BP) regulation with high prevalence in 
elderly patients [7-12]. OH is predominantly seen as a disorder of autonomic failure, and PPH 
and CSH are classified as reflex or neurally mediated syncope [13]. The cardiovascular 
autonomic system plays an important role in the distribution of blood volume and the 
regulation of BP [8, 14-17], and failure of this system might play an important role in the 
aetiology and pathophysiology of these hypotensive syndromes. 
Therefore, we hypothesized that commonly available and non-invasive autonomic function 
indices of HRV, BPV and BRS are different in patients with and without OH, PPH and CSH. 
METHODS 
Study Population 
This study included 242 consecutive patients, who visited the geriatric outpatient falls and 
syncope clinic of the Radboud University Nijmegen Medical Centre because of falls, dizziness 
and/or syncope. This test protocol was part of the standard diagnostic work-up. Patients were 
excluded if they were unable to follow the instructions due to delirium, psychosis or very 
severe dementia (Clinical Dementia Rating 3), if they were unable to stand for 10 min or drink 
a test meal of 200 mL within 10 min. Furthermore, patients were excluded for CSH testing in 
case of a recent (less than 3 months) myocardial infarction, transient ischemic attack, or 
stroke, respectively, a medical history of ventricular tachyarrhythmias or the presence of a 
carotid bruit [18]. 
The protocol conformed to the Declaration of Helsinki and informed consent was asked 
verbally prior to the tests. 
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Baseline Assessment 
Preceding OH, PPH and CSH testing, patients underwent a complete medical history and 
physical examination. Baseline characteristics (age, gender, body mass index [BMI], systolic 
BP [SBP], diastolic BP [DBP] and heart rate [HR]) were measured. The presence and severity of 
comorbidity was recorded using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G), 
ranging from 0 to 56 [19]. For medical history, we used the following disease groups: 
dementia; depression or anxiety disorder; chronic obstructive pulmonary disease; diabetes 
mellitus; Parkinson’s disease or disorders with parkinsonism; cardiovascular disease (CVD) 
including myocardial infarction, angina pectoris, heart failure, peripheral vascular disease, 
aneurysm of the aorta, stroke, and transient ischemic attack; hypertension; and malignancy. 
Test Protocol 
Patients fasted overnight and medication was withheld from midnight the night before. All 
tests were performed in the morning or afternoon. During the tests, BP and HR were 
constantly measured using a beat-to-beat finometer (FinaPres [20]) and a three-lead 
electrocardiogram (ECG). BP was measured at the nondominant arm, which was held at heart 
level with a sling. 
The test protocol started with the OH test, followed by the PPH test and finished with the 
carotid sinus massage (CSM). Before testing and at each time point during tests (OH test 
every minute and PPH test every 5 min), BP and HR were determined. The reported BP values 
are averages of 20 heartbeats (10 before and 10 after each time point). For CSH testing, BP 
values were determined by taking the average of 3 heartbeats around the lowest BP value 
during or in a 30-s period after CSM. From the ECG registration, the R–R interval before and 
the longest interval during or in a 30-s period after CSM were documented. At each time 
point, symptoms of possible cerebral hypoperfusion, like dizziness, light-headedness, fatigue, 
or loss of consciousness were noted. 
Orthostatic hypotension test 
After a 10-min resting period in the supine position, patients were asked to stand up and 
remain standing for 10 min. Baseline values of BP and HR were defined as the average during 
the 60 s before rising. OH was defined as a SBP decline of 20 mmHg or more or a DBP decline 
of 10 mmHg or more within 3 min of standing from supine [13]. 
10 
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Postprandial hypotension test 
The patient was asked to drink a test meal within 10 min in sitting position. The test meal is a 
solution of 100 mL glucose syrup and 100 mL lactose-free milk, containing 292 kcal, 
65 g carbohydrates, 2 g fat and 4 g protein. The meal temperature was 20 - 25°C [21]. After 
drinking the meal, BP and HR were monitored during 75 min. PPH was defined as a SBP 
decline of 20 mmHg or more within 75 min after a meal [7, 9]. 
Carotid sinus massage 
CSM was performed in supine position after 5 min rest. Firm, longitudinal massage was 
performed for 5 s over the site of maximal pulsation of the right carotid artery and repeated 
on the left side when SBP and HR were normalized. If no significant response in SBP or HR was 
obtained with supine CSM, the procedure was repeated with the patient tilted at 70° on a tilt 
table with footplate. CSH is defined as an interruption of heart beat more than at least 3 s or 
as a decrease of SBP of 50 mmHg or more. 
Assessment of HRV, BPV and BRS 
Data were analysed with custom-written software in Matlab (version R2010b, the MathWorks 
Inc., Natick, Massachusetts). The 10-min resting period in supine position was used to select 
an appropriate period to determine the measures of HRV, BPV and BRS. Not necessarily, the 
same periods were used to calculate HRV, BPV, or BRS. 
Heart rate variability 
The standard deviation of all normal beat intervals (SDNN-HRV) and the square root of the 
mean-squared difference of successive beat intervals (RMSSD-HRV) were used for 
conventional time domain measurements [1]. The data were linearly detrended and filtered 
with a third-order Butterworth filter with a cut-off frequency of 0.03 Hz and resampled to 4 
Hz using linear interpolation. Artefact-free data series of 100 s were used. With spectral 
analysis, the power of HRV was calculated in the low (LF-HRV; 0.04 - 0.15 Hz) and high (HF-
HRV; 0.15 - 0.4 Hz) frequency band as conventional frequency domain measurements [1]. 
Also, the ratio of LF-HRV and HF-HRV was determined (LF/HF-HRV). 
Blood pressure variability 
The BPV was also analysed in the time and frequency domain. Only the systolic BP was used. 
The standard deviation of BP (SD-SBP) and the square root of the mean-squared difference of 
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successive BP beats (RMSSD-SBP) were used for conventional time domain measurements. 
The data were linearly detrended and filtered with a third-order Butterworth filter with a 
cut-off frequency of 0.05 Hz and resampled to 1 Hz using linear interpolation. Only 
uninterrupted data series of at least 50 s were used for the spectral analysis. With spectral 
analysis, the power of BPV was calculated in the low (LF-SBP; 0.05 - 0.15 Hz) and 
high (HF-SBP; 0.15 - 0.4 Hz) frequency band. These frequency bands were defined largely in 
line with the standards of the European Society of Cardiology for HRV, 
meaning  LF = 0.04 - 0.15 Hz and HF = 0.15 - 0.4 Hz [1]. However, because a filter with cut-off 
frequency 0.05 Hz was used as recommended by Bernardi et al. [22], LF for BPV was chosen 
between 0.05 and 0.15 Hz. 
Baroreflex sensitivity 
BRS was quantified in the time domain with the sequence and the standard deviation method 
(SD-BRS) and in the frequency domain with spectral analysis. The sequence method was 
applied for positive (SQ-BRS+) and negative (SQ-BRS−) sequences [23]. The SD-BRS method 
calculates the BRS by dividing the standard deviation of the heartbeat interval by the 
standard deviation of SBP (SD-BRS). The SD-BRS is an easy, robust and reliable method to 
calculate BRS [22]. 
The data were linearly detrended and filtered with a third-order Butterworth filter with a 
cut-off frequency of 0.05 Hz and resampled to 1 Hz using linear interpolation. Data series of at 
least 50 s were used. In the frequency domain, BRS is calculated in the low (0.05 - 0.15 Hz) 
and high (0.15 - 0.4 Hz) frequency band by dividing the spectral power of the heartbeat 
interval through the spectral power of SBP, only if the coherence is more than 0.5 [24]. 
Heartbeat intervals were derived from the BP peaks to overcome artefacts in the ECG [25]. 
STATISTICAL ANALYSIS 
We compared the patients with and without OH, PPH and CSH, respectively. We used only 
those patients who completed all three tests. Because there is frequent coexistence of 
multiple hypotensive syndromes in the same patient, we also compared patients with no 
single hypotensive syndrome versus one, two or three hypotensive syndromes. We also 
compared patients with and without falls, dizziness or syncope as presenting symptom. 
Finally, we made a comparison between patients who presented with falls and patients who 
presented with syncope. 
10 
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Baseline characteristics of the patients were compared with independent sample Student’s t 
tests or one-way analysis of variance and chi-square (χ2) statistics. Results are presented as 
mean ± SD or percentages. 
Normality of HRV, BPV and BRS measures was tested with the Kolmogorov–Smirnov test. If 
the data were not normal distributed they were logarithmically transformed and tested again 
for normality. None of the HRV, BPV and BRS measures had a normal distribution. After 
logarithmic transformation, all data were normal distributed except for the SQ-BRS+, SQ-BRS− 
and SD-SBP data. Means were compared with independent sample Student’s t tests or 
one-way analysis of variance for normal distributed data; otherwise, Mann-Whitney’s U tests 
or Kruskal-Wallis tests were used. Because we compared 14 different measures of 
cardiovascular autonomic function, we choose an alpha of 0.01, instead of 0.05 to correct for 
multiple testing. Results for HRV, BPV and BRS measures are presented as medians with the 
25th - 75th percentile range. All analyses were performed using the SPSS software version 16 
for windows (SPSS Inc., Chicago, Illinois). 
RESULTS 
Baseline Characteristics 
Of the 242 patients, 203 (84 %) patients completed all three tests. CSM was not performed in 
34 patients because they met the exclusion criteria. Of five other patients, there was no value 
for OH and/or PPH tests due to unreliable measurements (no good signal). Of these 
203 patients, 53 %, 57 % and 50 % were diagnosed with OH, PPH and CSH, and 87 % patients 
were diagnosed with at least one or more hypotensive syndromes. 
Baseline characteristics of patients with and without different hypotensive syndromes were 
compared (Table 1). Compared with the patients without OH, the patients diagnosed with OH 
had lower BMIs and had higher mean baseline SBP (p < .05). The patients with PPH were 
older, had higher baseline SBPs, and had more frequently a medical history of CVD (p < .05). 
The patients with CSH had lower BMIs, presented less often with dizziness and used less 
angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists compared 
with those without CSH (p < 0.05). There were no differences in comorbidity (CIRS-G) nor the 
number of drugs used. 
 
222  
 
Table 1. Comparison of the baseline demographic and clinical characteristics of the patients with and without 
orthostatic hypotension, postprandial hypotension, and carotid sinus hypersensitivity.  
The results are reported as means ± standard deviations or numbers (percentages). OH, orthostatic hypotension; 
PPH, postprandial hypotension; CSH, carotid sinus hypersensitivity; age(years); BMI, body mass index(kg/m2); 
SBP, systolic blood pressure(mmHg); DBP, diastolic blood pressure(mmHg); HR, heart rate(beats per minute); 
CIRS-G, Cumulative Illness Rating Scale for Geriatrics; COPD, chronic obstructive pulmonary disease; CVD, cardio-
vascular disease; ACE/AT2, angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists; CCB, 
calcium channel blockers. * significant differences (p<0.05) between patients with and without OH; † significant 
differences (p<0.05) between patients with and without PPH; ‡ significant differences (p<0.05) between patients 
with and without CSH.  
Variable OH– OH+ PPH– PPH+ CSH– CSH+ 
  (n=95) (n=108) (n=87) (n=116) (n=102) (n=101) 
Age 76.9±8.6 78.4±7.4 75.6±8.0 79.3±7.6† 76.7±9.0 78.7±6.7 
BMI 27.3±4.9 26.0±4.2* 27.3±4.7 26.1±4.4 27.2±4.8 26.0±4.2‡ 
Female, n (%) 55(58%) 74(69%) 59(68%) 70(60%) 63(62%) 66(65%) 
Baseline SBP 162±24 171±25* 160±22 172±26† 164±25 169±25 
Baseline DBP 78±11 80±13 79±12 79±12 79±12 79±12 
Baseline HR 67±11 68±12 68±12 67±11 68±12 68±11 
CIRS-G total score 10.6±4.6 11.3±4.4 10.5±4.3 11.3±4.6 10.9±4.4 10.9±4.5 
Presenting symptom       
Falls 79(83%) 96(90%) 74(86%) 101(87%) 90(89%) 85(84%) 
Dizziness 48(51%) 55(51%) 41(48%) 62(53%) 61(60%) 42(42%)‡ 
Syncope 29(31%) 37(35%) 28(33%) 38(33%) 36(36%) 30(30%) 
Symptomatic - 67(62%) - 46(40%) - 51(51%) 
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Variable OH– OH+ PPH– PPH+ CSH– CSH+ 
  (n=95) (n=108) (n=87) (n=116) (n=102) (n=101) 
Medical history       
Dementia 6(6%) 6(6%) 4(5%) 8(7%) 4(4%) 8(8%) 
Depression or anxiety 15(16%) 21(19%) 20(23%) 16(14%) 19(19%) 17(17%) 
COPD 16(17%) 19(18%) 15(17%) 20(17%) 16(16%) 19(19%) 
Diabetes mellitus 13(14%) 16(15%) 9(10%) 20(17%) 18(18%) 11(11%) 
Parkinson(ism) 4(4%) 6(6%) 3(3%) 7(6%) 7(7%) 3(3%) 
CVD 31(33%) 42(39%) 20(23%) 53(46%)† 37(36%) 36(36%) 
Hypertension 42(44%) 50(46%) 37(43%) 56(48%) 53(52%) 40(40%) 
Malignancy 15(16%) 25(23%) 14(16%) 26(22%) 19(19%) 21(21%) 
Medication use       
Polypharmacy 64(67%) 76(70%) 59(68%) 81(70%) 67(66%) 73(72%) 
Beta blockers 35(37%) 44(41%) 34(39%) 45(39%) 46(45%) 33(33%) 
ACE/AT2 26(27%) 43(40%) 26(30%) 43(37%) 43(42%) 26(26%)‡ 
CCB 11(12%) 19(18%) 13(15%) 17(15%) 16(16%) 14(14%) 
Diuretics 31(33%) 39(36%) 30(35%) 40(35%) 39(38%) 31(31%) 
Nitrates 10(11%) 15(14%) 8(9%) 17(15%) 15(15%) 10(10%) 
Table 1. Continued 
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Table 2. Comparison of heart rate variability, blood pressure variability and baroreflex sensitivity measures 
between patients with and without orthostatic hypotension, postprandial hypotension and carotid sinus hyper-
sensitivity. 
Results are reported as medians(25th-75th percentiles).  
Heart rate variability: SDNN = standard deviation heart rate(ms); RMSSD = root mean square successive diffe-
rence of heartbeats(ms); LF = low frequency power HRV(1x103ms2); HF = high frequency power HRV
(1x103ms2); LF/HF = ratio of LF-HRV and HF-HRV(-);  
Blood pressure variability: SD = standard deviation systolic blood pressure (SBP) (mmHg); RMSSD = root mean 
square successive difference SBP(mmHg); LF = low frequency SBP(mmHg); HF-SBP = high frequency SBP
(mmHg); 
Baroreflex sensitivity (BRS): SQ+ = sequence method BRS for positive sequences(ms/mmHg); SQ - = sequence 
method BRS for negative sequences(ms/mmHg); SD = standard deviation BRS(ms/mmHg); LF = low frequency 
BRS(ms/mmHg); HF = high frequency BRS(ms/mmHg).*:p<0.01  
  Heart rate variablity 
  SDNN RMSSD LF HF LF/HF 
OH– 60(37-86) 51(26-86) 0.7(0.2-1.6) 0.7(0.1-1.9) 0.9(0.7-2.0) 
n 86 86 84 84 84 
OH+ 49(30-88) 37(21-84) 0.4(0.1-2.3) 0.3(0.1-1.6) 1.2(0.6-1.8) 
n 93 93 88 88 88 
PPH– 50(27-72) 48(23-79) 0.8(0.1-1.4) 0.4(0.1-2.0) 1.0(0.7-2.5) 
n 74 74 71 71 71 
PPH+ 53(34-89) 43(24-83) 0.4(0.2-1.7) 0.5(0.1-1.7) 1.0(0.7-2.0) 
n 105 105 101 101 101 
CSH– 56(31-90) 51(23-89) 0.8(0.1-1.8) 0.6(0.1-2.6) 1.0(0.7-2.3) 
n 92 92 89 89 89 
CSH+ 49(33-76) 40(23-73) 0.4(0.2-1.2) 0.4(0.1-1.5) 1.0(0.7-1.9) 
n 87 87 83 83 83 
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  Baroreflex sensitivity 
  SQ+ SQ- SD LF HF 
OH– 5.5(2.4-8.2) 9.3(4.0-13.3) 7.7(5.1-14.3) 7.0(3.6-12.7) 7.6(4.7-15.0) 
n 95 95 95 50 61 
OH+ 3.5(1.5-5.5) 7.1(3.3-11.7) 7.4(3.8-13.7) 5.7(3.5-9.0) 5.7(3.4-10.6) 
n 108 108 108 39 56 
PPH– 3.6(1.3-7.2) 7.2(3.3-12.0) 7.9(4.3-14.3) 6.5(3.3-13.3) 7.0(3.2-17.4) 
n 87 87 87 38 44 
PPH+ 4.6(2.2-7.2) 8.4(4.2-12.1) 7.3(4.1-13.7) 6.2(3.6-9.1) 6.3(3.8-11.3) 
n 116 116 116 51 73 
CSH– 4.9(2.2-8.3) 7.8(3.7-13.0) 8.3(5.2-14.0) 6.6(3.3-13.7) 6.6(3.6-15.5) 
n 102 102 102 42 55 
CSH+ 3.8(1.8-5.9) 7.8(3.8-11.8) 6.9(3.4-14.2) 6.1(3.7-10.2) 6.8(3.8-11.0) 
n 101 101 101 47 62 
Table 2. Continued 
  Blood pressure variability 
  SD RMSSD LF HF 
OH– 11.1(8.3-13.8) 6.2(4.3-8.7) 3.0(1.5-5.2) 3.2(1.7-8.3) 
n 95 95 68 68 
OH+ 10.7(8.9-15.4) 7.2(5.3-11.3) 3.4(1.9-7.9) 4.9(2.5-10.2) 
n 108 108 81 81 
PPH– 11.5(9.0-15.2) 6.6(4.7-9.3) 2.5(1.5-5.4) 3.0(1.8-7.0) 
n 87 87 67 67 
PPH+ 10.6(8.4-14.3) 6.7(4.8-9.9) 3.5(1.9-7.6) 4.9(2.5-10.8) 
n 116 116 82 82 
CSH– 11.0(8.0-14.5) 6.5(4.5-9.0) 3.5(1.7-7.9) 4.5(2.1-9.8) 
n 102 102 81 81 
CSH+ 10.7(9.2-15.3) 7.2(4.9-10.3) 2.9(1.4-5.2) 3.9(1.9-7.7) 
n 101 101 68 68 
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Table 3. Comparison of heart rate variability, blood pressure variability and baroreflex sensitivity measures 
between patients with and without falls, dizziness and syncope  
Results are reported as medians(25th-75th percentiles).  
Heart rate variability: SDNN = standard deviation heart rate(ms); RMSSD = root mean square successive diffe-
rence of heartbeats(ms); LF = low frequency power HRV(1x103ms2); HF = high frequency power HRV
(1x103ms2); LF/HF = ratio of LF-HRV and HF-HRV(-);  
Blood pressure variability: SD = standard deviation systolic blood pressure (SBP) (mmHg); RMSSD = root mean 
square successive difference SBP(mmHg); LF = low frequency SBP(mmHg); HF-SBP = high frequency SBP
(mmHg); 
Baroreflex sensitivity (BRS): SQ+ = sequence method BRS for positive sequences(ms/mmHg); SQ - = sequence 
method BRS for negative sequences(ms/mmHg); SD = standard deviation BRS(ms/mmHg); LF = low frequency 
BRS(ms/mmHg); HF = high frequency BRS(ms/mmHg).*:p<0.01  
  Heart rate variablity 
  SDNN RMSSD LF HF LF/HF 
OH– 50(33-111) 44(27-89) 0.4(0.2-1.9) 0.4(0.2-2.0) 1.2(0.6-2.5) 
n 23 23 22 22 22 
OH+ 53(32-86) 43(23-82) 0.6(0.1-1.5) 0.4(0.1-1.9) 1.0(0.7-2.1) 
n 155 155 149 149 149 
PPH– 58(37-91) 55(28-84) 0.7(0.2-1.6) 0.7(0.1-1.9) 1.0(0.6-2.5) 
n 87 87 84 84 84 
PPH+ 48(30-77) 39(21-71) 0.4(0.2-1.6) 0.3(0.1-1.8) 0.9(0.7-1.9) 
n 91 91 87 87 87 
CSH– 51(34-84) 45(24-82) 0.6(0.2-1.4) 0.4(0.1-1.6) 1.0(0.7-2.1) 
n 121 121 115 115 115 
CSH+ 59(26-88) 37(20-86) 0.4(0.1-1.6) 0.5(0.1-2.7) 1.0(0.7-2.3) 
n 57 57 56 56 56 
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  Baroreflex sensitivity 
  SQ+ SQ- SD LF HF 
OH– 5.2(2.4-7.8) 9.0(5.4-11.5) 7.6(4.2-11.7) 5.4(3.7-14.3) 7.4(5.2-17.9) 
n 27 27 27 14 19 
OH+ 4.3(1.8-7.1) 7.6(3.7-12.1) 7.6(4.2-14.3) 6.6(3.5-10.2) 6.4(3.3-12.1) 
n 175 175 175 75 98 
PPH– 3.9(1.8-7.1) 7.4(3.9-11.2) 7.6(4.1-14.3) 7.0(3.7-12.5) 6.6(3.3-13.4) 
n 99 99 99 43 57 
PPH+ 4.5(2.1-7.4) 8.6(3.7-13.3) 7.6(4.9-14.1) 5.4(3.2-10.3) 6.8(4.0-10.9) 
n 103 103 103 46 60 
CSH– 4.4(2.1-7.1) 7.7(3.9-12.2) 7.2(4.1-12.8) 7.0.6(3.7- 6.8(3.7-12.2) 
n 136 136 136 61 81 
CSH+ 4.3(1.8-8.0) 8.1(3.3-11.6) 8.1(5.5-14.4) 5.9(3.3-9.1) 6.1(3.7-15.9) 
n 66 66 66 28 36 
Table 3. Continued 
  Blood pressure variability 
  SD RMSSD LF HF 
OH– 11.2(7.8-16.3) 6.4(3.9-8.8) 2.8(1.6-5.3) 3.2(1.7-5.9) 
n 27 27 18 18 
OH+ 10.8(9.0-15.1) 6.7(4.9-9.9) 3.3(1.7-6.7) 4.2(2.1-9.3) 
n 175 175 130 130 
PPH– 10.8(9.2-14.1) 6.6(4.9-9.2) 2.9(1.4-7.6) 4.0(1.9-8.6) 
n 99 99 71 71 
PPH+ 11.0(8.3-15.6) 6.4(4.5-10.6) 3.4(1.9-5.9) 4.1(2.1-9.9) 
n 103 103 77 77 
CSH– 11.2(9.4-14.9) 6.7(4.9-9.3) 3.0(1.6-5.9) 3.9(1.9-8.6) 
n 136 136 102 102 
CSH+ 9.8(7.4-15.8) 6.6(4.5-11.6) 4.4(1.7-9.6) 5.3(2.2-10.8) 
n 66 66 46 46 
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Measures of HRV, BPV and BRS 
No differences were found in the different measures of HRV, BPV and BRS between patients 
with or without OH, PPH and CSH, respectively (Table 2). Similar results were found when 
patients with no versus one, two or three hypotensive syndromes were compared (data not 
shown). Also, no differences were found in the different measures of HRV, BPV and BRS 
between patients with or without falls, dizziness and syncope, respectively (Table 3). There 
were also no differences between patients who presented with falls and patients who 
presented with syncope (data not shown). 
Finally, 20 patients had delayed OH, defined as onset of OH after the third minute. These 
patients were categorized among the “no OH” patients (n = 94) in our study. Compared with 
the n = 74 patients without OH and without delayed OH, they did not differ in HRV, BPV and 
BRS (data not shown). 
DISCUSSION 
The main finding of this study is that there were no differences in HRV, BPV and BRS between 
geriatric patients with and without hypotensive syndromes. We used extensive non-invasive, 
easy available and state-of-the-art indices of HRV, BPV and BRS [1, 22-24]. Most of these 
indices reflect primarily vagal activity, but LF-HRV and LF/ HF-HRV are also thought to reflect 
sympathetic activity or to reflect the sympathovagal balance [1]. 
Previous studies which examined the relationship between hypotensive syndromes and 
measures of HRV, BPV and BRS have reported conflicting results. In older persons, there was 
an association between diminished BRS with BP fall during OH testing [26, 27]. However, no 
difference in spectral measures of HRV and BPV was found between patients with normal and 
poor orthostatic tolerance [28]. During intraduodenal glucose administration for PPH testing, 
an association between diminished BRS with SBP fall was found [29]. Spectral measures of 
HRV were lower [30] and systolic BPV [31] was higher in patients with versus without PPH, 
but the latter study could not replicate the differences in HRV measures [31]. BRS was found 
to be higher [8], the same [32], or lower [33] between patients with and without CSH. 
Spectral measures of HRV were higher in patients with CSH compared with patients without 
CSH [8]. In another study, no differences were found in systolic BPV measures between 
patients with and without CSH [34]. An explanation for these conflicting data is the difference 
in used methods and in diagnoses, severity of illnesses and functional capacity between study 
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populations. Another explanation is the diversity of methods used to measure HRV, BPV and 
BRS in either the time or frequency domain [35]. Age-related normal values for different 
measures of HRV, BPV and BRS are lacking, which makes comparison between populations 
difficult [1]. 
Our data add to the literature because for the first time all three hypotensive syndromes are 
meticulously characterized together in one population of consecutive older patients who 
visited a geriatric outpatient falls and syncope clinic. Cardiovascular autonomic dysfunction, 
as measured with multiple, non-invasive measures of HRV, BPV and BRS, was not a sufficient 
cause to explain the occurrence of these hypotensive syndromes. An explanation for our 
findings might lie in the fact that hypotensive syndromes, especially in elderly patients, are 
multifactorial in genesis [36-38]. The lack of an association between HRV, BPV and BRS and 
hypotensive syndromes does not prove that cardiovascular autonomic control has no role in 
the pathophysiology of these hypotensive syndromes. However, it is unlikely that 
cardiovascular autonomic dysfunction is a sufficient factor, as other redundant regulatory 
mechanisms are able to compensate for diminished cardiovascular autonomic function and 
thus determine if hypotensive syndromes occur. Cardiovascular autonomic dysfunction 
probably is just a component cause with high frequency in geriatric patients and therefore 
there is no difference to be found between these groups. The conflicting data from literature 
can easily be explained by the geriatric syndrome causative model, which can be filled with 
different combinations of factors in different subgroups [36-39]. 
Strengths and Limitations 
This study has some limitations. Firstly, this study was a cross-sectional analysis. Secondly, we 
have no complete assessment of all 14 different measures of autonomic function in all 203 
patients. However, for 10 measures, there is approximately 15% or less missing data, which is 
acceptable. Of the four variables, the percentage of missing data was higher because for 
frequency analysis consecutive data series of 50-100 s are necessary which was sometimes 
not possible because the BP measurement was interrupted by calibrations, and ECG signals 
were sometimes disturbed through artefacts. Moreover, the calculation of the BRS with the 
spectral method requires that the coherence is more than 0.5, which explains the high 
portion of missing data for BRS-LF and BRS-HF. Data sets of 50–100 s are rather short to 
perform frequency domain analysis in which it is advisable to have data set lengths of at least 
128 consecutive beats [40]. Hereby, the estimation especially of the LF measures might be 
less accurate. However, despite these shortcomings, all the results of the frequency domain 
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analysis are in line with the other determined variables of HRV, BPV and BRS. 
Thirdly, this study investigated a selective patient population and did not have a control 
group. All patients were referred to an out-patient geriatric falls and syncope clinic, because 
of syncope, falls and/or dizziness. This has the disadvantage of a specific selection and 
therefore our sample is not a representative for the general population, but only for 
populations referred to similar outpatient clinics. On the other hand, this is the geriatric 
population with the highest relevance of hypotensive syndromes. 
Finally, there is evidence that postural and postprandial BP responses vary during the day and 
therefore should be measured more than once [12, 31, 41]. It would be possible that we 
falsely classified patients to be without OH, PPH, or CSH, who might in fact have the same 
degree of autonomic dysfunction as those patients with OH, PPH, or CSH. We found a high 
prevalence of syndromes, comparable to other studies, which reduces the likelihood that we 
missed patients. Also, when comparing patients with and without syncope or falls, there still 
was no difference in autonomic function. Misclassification is therefore less likely. 
This study has several other strengths. Firstly, the BP measurements and tests in our study 
were performed under standardized circumstances, with a beat-to-beat finometer (FinaPres), 
which is an accurate way to measure BP variability [20]. 
Secondly, we limited as much as possible the confounding effects of medication on our 
assessment of hypotensive syndromes and on our estimates of autonomic function. To do 
this, all medication was withheld from midnight the night before the tests. Nonetheless, 
biological effects of these drugs might persist longer than the period of abstinence, especially 
for beta-blockers. However, in aging beta-adrenoreceptor responsiveness decreases by 
several mechanisms and the effects of beta-blockers are therefore less pronounced [42]. 
Moreover, we found no differences in the use of beta-blockers or other medication between 
patients with and without hypotensive syndromes, with exception of lower use of angiotensin
-converting enzyme inhibitors and angiotensin-II receptor antagonists in patients with CSH. 
Thirdly, a strength of this study is that we investigated all three hypotensive syndromes in the 
same patients, where other studies only looked at one type of hypotensive 
syndrome [8, 26-34]. 
Finally, we investigated a rather large group of 203 geriatric patients on the presence of three 
common hypotensive syndromes, and this study addresses a potential mechanism underlying 
these common hypotensive syndromes. 
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CONCLUSIONS 
In geriatric patients with hypotensive syndromes, cardiovascular autonomic function as 
measured by HRV, BPV and BRS is comparable to patients without such syndromes. These 
findings may favour a multifactorial pathophysiology of geriatric hypotensive syndromes and 
argue against a single or dominant etiological factor, that is, cardiac autonomic dysfunction. 
For clinical practice, our data underline that in the initial diagnostic work-up of elderly 
patients with falls, dizziness and syncope should follow the structured approach as proposed 
in the evidence-based syncope guidelines, which recognizes a multifactorial ae-
tiology [13, 43]. 
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ABSTRACT 
Background 
Sepsis, the systemic host response to a severe bacterial infection, is often complicated by 
brain dysfunction. Many indicators, such as reduced global perfusion, disruption of the blood-
brain barrier and cerebral edema, point towards a link between cerebral perfusion and brain 
dysfunction in sepsis. An important factor in this relationship may be cerebral autoregulation. 
The endotoxemia model has been used to study inflammatory-induced changes in cerebral 
autoregulation. Surprisingly, in contrast to observations in septic patients, an improved 
cerebral autoregulatory performance was observed during endotoxemia at 3-4 hrs after LPS 
infusion. This suggests that cerebral autoregulatory performance may change over time, with 
improvement at an early stage, but possible deterioration at a later stage. In the present 
study we investigated these temporal changes in dynamic cerebral autoregulation in healthy 
volunteers during experimental endotoxemia. 
Method 
Cerebral autoregulation was tested using transcranial Doppler ultrasound in healthy 
volunteers (n = 16) before and at several time points after LPS infusion (-2, 2, 4, 6 and 8 
hours). Correlation coefficient analysis and transfer function analysis were used to quantify 
cerebral autoregulation. 
Results 
All subjects showed a marked systemic inflammatory response similar to that of the very 
early stages of sepsis, with progressive fever, leukocytosis and elevated TNF-α and IL-6 levels, 
after LPS infusion. In contrast to the hypothesis, no deterioration of the cerebral 
autoregulatory performance was found after LPS infusion. 
Conclusion 
Endotoxemia-induced systemic inflammation is associated with an overall preserved cerebral 
autoregulatory performance at an early stage after LPS infusion, with no deterioration up to 8 
hrs. 
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INTRODUCTION 
Sepsis, the systemic host response to a severe bacterial infection, is a potentially deadly 
medical condition, characterized by a widespread state of inflammation, often complicated by 
organ dysfunction or failure. Potentially irreversible acute cerebral dysfunction occurs in 
approximately 70 % of septic patients and may manifest as sepsis-associated delirium [1-3]. 
These changes in cerebral functioning are associated with increased rates of persistent 
cognitive dysfunction [4] and increased mortality rates after hospital discharge [5].  
Despite the fact that the exact mechanisms of sepsis-induced encephalopathy remain 
obscure, many indicators, such as reduced global perfusion, disruption of the blood-brain 
barrier and cerebral edema, point towards a link between cerebral perfusion and brain 
dysfunction in sepsis [6, 7]. An important factor in this relationship may be cerebral 
autoregulation. Cerebral autoregulation refers to the physiological mechanism that maintains 
an adequate cerebral blood flow during changes in blood pressure. As blood pressure drops 
may frequently occur during the course of sepsis, disturbed cerebral autoregulation likely 
causes the brain to be excessively sensitive to hypoperfusion, resulting in ischemic damage. 
The few studies performed during sepsis have shown that cerebral autoregulation is indeed 
impaired in the great majority of patients and is associated with delirium [8, 9]. However, 
these observational association studies in patients lack the possibility to directly relate 
inflammation to the observed changes in cerebral autoregulation from a baseline situation.  
Experimental human endotoxemia is an established human in vivo model of the systemic 
inflammatory response that occurs during early sepsis, including changes in renal 
function [10], vascular function [11, 12], as well as cerebral perfusion [8, 13]. In this model a 
low dose of purified E.coli lipopolysaccharide (LPS) is administered intravenously to healthy 
volunteers. LPS is one of the principal bacterial components that interact with the host during 
Gram-negative sepsis [14]. The endotoxemia model has been used to study inflammation-
induced changes in cerebral autoregulation [8, 13]. Surprisingly, in contrast to observations in 
septic patients, an improved cerebral autoregulatory performance was observed during 
endotoxemia at 3-4 hrs after LPS infusion [8, 13]. This suggests that cerebral autoregulatory 
performance may change over time, with improvement at an early stage, but possible 
deterioration at a later stage. In the present study we investigated these temporal changes in 
dynamic cerebral autoregulation in healthy volunteers during experimental endotoxemia.  
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METHOD 
Design and subjects 
This study was part of a larger trial that was registered under trial number NCT01522794. The 
study protocol was approved by the Ethics Committee of Radboud university medical center 
and complied with the Declaration of Helsinki including current revisions and the Good 
Clinical Practice guidelines. Sixteen healthy men, aged 21 ± 2 (mean ± standard deviation) 
years, participated in this study after providing written informed consent. Screening of the 
subjects within 14 days before the test revealed no abnormalities in medical history and/or 
physical examination. Routine laboratory tests and electrocardiogram were normal. 
Subjects received a 20-gauge arterial catheter (Angiomat, Becton Dickinson, Sandy, UT, USA) 
for continuous intra-arterial blood pressure monitoring and blood sampling. Hemodynamic 
data were continuously monitored for safety. A venous cannula was placed to permit infusion 
of 1.5 L 2.5 % glucose/ 0.45% NaCl in one hour preceding LPS infusion (prehydration), 
followed by 150 mL/h until 6 h after LPS infusion and 75 mL/h until the end of the experiment 
to ensure an optimal hydration status [15]. At T=0 h subjects received a single intravenous 
dose of 2 ng/kg purified E. Coli LPS (Escherichia coli O:113, Clinical Center Reference 
Endotoxin, National Institute of Health (NIH), Bethesda, MD, USA) by slow injection 
administered over 1 min. The LPS infusion was followed by infusion of 5 ml isotonic saline to 
ensure complete delivery. 
Dynamic cerebral autoregulation measurements 
Dynamic cerebral autoregulation was assessed in the time domain using correlation 
coefficient analysis and in the frequency domain using transfer function analysis [16, 17], two 
widely used methods to quantify cerebral autoregulation from spontaneous fluctuations in 
blood pressure and cerebral blood flow velocity.  
Cerebral blood flow velocity was estimated bilaterally in the middle cerebral arteries (MCA) 
by transcranial Doppler ultrasonography at time points: 2 h prior to LPS administration and 2, 
4, 6 and 8 h after LPS administration. The left and right MCA were insonated by placing a 
2-MHz Doppler probe (Multi-Dop, Compumedics DWL, Germany) over the temporal bone. 
The MCA were identified according to their signal depth, velocity, and wave characteristics 
[18]. After identification of the MCA, Doppler probes were locked at a constant angle and 
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position during data collection with a customized headband (Spencer technologies, Seattle, 
Wa, USA). If only one signal was available due to one-sided temporal window failure, we 
included this available signal for analysis. At each time point five minutes of beat-to-beat 
changes in mean blood pressure and cerebral blood flow velocity were obtained 
synchronically using a 4th order low-pass Butterworth filter. The consecutive beat-to-beat 
data of blood pressure and cerebral blood flow velocity were resampled at 10 Hz to create 
equidistant data sampling over time for spectral analysis. 
Correlation coefficient analysis 
Correlation coefficient analysis was performed in accordance with several investigations that 
showed that fluctuations on long time scale in cerebral blood flow velocity correlated with 
fluctuations in blood pressure [19, 20]. First, mean blood pressure and cerebral blood flow 
velocity were averaged over 3-second periods. Then, 20 consecutive 3-second averages of 
mean blood pressure and cerebral blood flow velocity were used to calculate single Pearson’s 
correlation coefficients. Finally, the collected 5-minute mean correlation coefficients were 
averaged over the whole measurement period and labeled as the autoregulatory index. 
Transfer function analysis 
The transfer function analysis assumes that autoregulation mechanisms can be described by a 
linear dynamic system with blood pressure as input and cerebral blood flow velocity as 
output [17, 21]. Cerebral autoregulation was evaluated using the gain, phase and coherence 
obtained by transfer function analysis at the respective time points: 2 hours prior to LPS 
administration and 2, 4, 6 and 8 hours after LPS administration. Transfer function gain, phase 
and coherence were estimated using the cross-spectral method which has been described in 
detail previously [17, 21]. The time series of mean blood pressure and cerebral blood flow 
velocity were first subdivided into 950-point segments with 50 % overlap for spectral 
estimation. This process resulted in five segments of data for the segment periodogram 
average. Fast Fourier transforms were implemented with each Hanning-windowed segment 
and averaged to quantify the transfer function. The coherence spectrum is defined as the 
normalized modulus of the cross-spectrum; the phase spectrum is the argument of the 
(complex-valued) cross-spectrum; and the gain is the regression coefficient of cerebral blood 
flow velocity on blood pressure.  
The transfer function parameter gain quantifies the damping effect between blood pressure 
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and cerebral blood flow velocity. A low gain indicates an efficient autoregulation, whereas an 
increase in gain represents a diminished efficiency of the dynamic process of cerebral 
autoregulation. The phase shift represents the time lag between changes in blood pressure 
and cerebral blood flow velocity. A larger phase shift (i.e. cerebral blood flow velocity 
oscillations precede blood pressure oscillations) indicates better cerebral autoregulation. 
Finally, coherence reflects whether the changes in cerebral blood flow velocity can be linearly 
explained by the changes in blood pressure. To ensure reliable TFA outcomes, a cut-off value 
of 0.5 for coherence was used. For quantification of cerebral autoregulation the positive 
phase shift and the gain between blood pressure and cerebral blood flow velocity were 
quantified as means of the following frequency bands: very low frequency (VLF): 0.02-0.07Hz; 
low frequency (LF): 0.07-0.15Hz; high frequency (HF): 0.15-0.4Hz [17, 21].  
Laboratory tests 
EDTA anti-coagulated blood for the determination of tumor necrosis factor alpha (TNF-a), 
interleukin-6 (IL-6), IL-10, IL-1ra and C-reactive protein (CRP), was drawn one hour before 
endotoxin administration, and at t=0, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours afterwards. Blood 
samples were immediately centrifuged at 2.000 g for 10 minutes at 4°C and supernatants 
were stored at -80°C and until batch wise determination of cytokine concentrations using a 
simultaneous Luminex assay according to the manufacturer’s instructions (Bio-plex cytokine 
assay; Bio-Rad, Hercules, California, USA). 
STATISTICAL ANALYSIS 
Statistical analysis was performed using PASW Statistics software version 18.0 (SPSS Inc., 
Chicago, IL, USA). Comparisons between T = -2 hours and the different time sets (2, 4, 6 and 8 
hours) after LPS dosing were performed using mixed model analysis. Statistical significance 
was set at p<0.05. Data are presented as mean and standard deviation. 
RESULTS 
Subject characteristics 
Figure 1 shows the systemic inflammatory response and the cardiovascular parameters of the 
subjects after LPS infusion. The injection of LPS caused flu-like symptoms including fever, 
which peaked at 4 h after LPS infusion (increase of 1.5 ± 0.5 ˚C), and 
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Figure 1. Systemic inflammatory response and cardiovascular parameters of the subjects after LPS infusion.  
X-axes show time after LPS infusion in hours. Y-axes represent for the graphs A to J: IL-6, TNF-α, CRP, 
leukocytes count, temperature, pCO2, pO2, heart rate, mean blood pressure, mean cerebral blood flow 
velocity, successively. Stars indicate a significant difference with respect to 2 hours before LPS infusion.  
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Figure 1. Continued 
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leucocytosis  (13 ± 2 x109/L). All subjects had increases in plasma TNF-α, IL-6, IL-10 and 
IL-1RA. pCO2 and pO2 decreased after LPS infusion. It was not always possible to record 
cerebral blood flow velocity, due to discomfort caused by the Doppler headband in 
combination with the severity of the endotoxemia-associated symptoms. Recordings of blood 
pressure and cerebral blood flow velocity were completed in 14, 11, 15, 14 and 14 subjects at 
the time sets -2, 2, 4, 6 and 8 hours after LPS administration, respectively. Heart rate was 
maximal at T = 4 to 6 hours (increase of 33 ± 9 bpm). Mean blood pressure and mean cerebral 
blood flow velocity decreased after LPS infusion with a minimum around 6 hours after LPS 
infusion (decrease of 16 ± 7 mmHg and 16 ± 15 cm/s, respectively). 
Correlation coefficient analysis 
Pearson’s correlation coefficients were calculated for the different time sets (-2, 2, 4, 6 and 8 
hours after LPS dosing). Figure 2 illustrates the average group results of the correlation 
coefficient analysis. The correlation coefficient decreased at t = 4, representing a lower 
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Figure 2. Outcomes of the correlation coefficient analysis in mean ± standard deviation of the subjects for -2, 2, 
4, 6, and 8 hours after LPS infusion. Stars indicate a significant difference with respect to 0 hours after LPS 
infusion. 
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correlation between blood pressure and cerebral blood flow velocity indicating an improved 
cerebral autoregulation at 4 h after LPS infusion (p < 0.01). After 6 h after LPS infusion, the 
correlation coefficient did not differ from before LPS infusion anymore (p>0.05). 
Transfer function analysis 
Transfer function analysis was used to assess the cerebral autoregulation performance in the 
frequency domain. Figure 3 shows the results of the transfer function analysis after LPS 
infusion. Overall, results were consistent with the high-pass filter model of dynamic cerebral 
autoregulation (17) with highest phase values in VLF and decreases in phase from VLF to LF to 
HF, and lowest gain in VLF increasing from VLF to LF to HF. This pattern was present at all 
time points, suggesting preserved dynamic cerebral autoregulation. Within each frequency 
band (VLF, LF, HF), transfer function gain was stable over time. Phase showed more variation 
over time, but there were no significant reductions or increases over time in VLF or LF. Phase 
increased modestly in HF at 2 and 4 h (p < 0.05). No differences in transfer function metrics 
were found after 6 h after LPS infusion (p > 0.05). 
DISCUSSION 
This study confirms that controlled systemic inflammation in healthy volunteers is associated 
with overall preserved autoregulatory performance. In addition, serial measurements over 
time revealed that autoregulation was stable over time, with a possible short-term 
improvement 4 hours after endotoxin administration, whereas no deterioration could be 
found at a later stage. 
Sepsis is defined by a systemic response to infection that includes fever, rapid heartbeat and 
respiration, and may result in hemodynamic instability and organ dysfunction. Acute brain 
dysfunction is often one of the first symptoms of organ dysfunction in septic patients and is 
associated with an unfavourable neurocognitive outcome [22]. An important precipitating 
factor for the neurocognitive decline may be a reduced cerebral blood flow due to a reduced 
capacity of cerebral autoregulation to compensate for the reduction in and instability of 
cerebral perfusion pressure (i.e. blood pressure). 
Two previous studies have evaluated cerebral autoregulation in a human experimental model 
of the systemic inflammatory response [8, 13]. Both studies used transfer function analysis to 
investigate cerebral autoregulation in healthy volunteers before and after LPS infusion and 
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Figure 3. Transfer function results of the subjects for -2, 2, 4, 6, and 8 hours after LPS infusion in mean ± 
standard deviation. Stars indicate a significant difference with respect to 0 hours after LPS infusion.  
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concluded that cerebral autoregulation was enhanced at an early stage after LPS 
infusion (3 and 4 hours after LPS infusion). This conclusion was in contrast to the observed 
autoregulatory performances in septic patients where an impaired cerebral autoregulation 
was found. Berg et al. speculated that one of the reasons that they found a difference in 
autoregulatory performance between patients and volunteers originates from the shortly 
lived inflammatory response during experimental endotoxemia. As it is possible that the 
autoregulatory performance improves at an early stage, but deteriorates at a later stage after 
LPS infusion, we studied the autoregulatory performance at several time points after LPS 
infusion, up to 8 hours after LPS infusion. In addition to the previous studies, we also 
expanded the methodology for the quantification of the cerebral autoregulatory performance 
by investigating the transfer function metrics over three frequency bands (VLF, LF and HF) 
instead of only using the LF band, and by using a second, frequently used method to analyze 
the data (correlation coefficient analysis). 
Confirming the previous studies, we found an overall preserved cerebral autoregulation 
during systemic inflammation evoked by experimental endotoxemia. Importantly, we 
established that no deterioration of the cerebral autoregulatory performance occurred at a 
later stage. The findings of the previous [8, 13] and present study in healthy volunteers 
subjected to endotoxemia are in contrast with reports of impaired cerebral autoregulatory 
performance in septic patients [8, 23, 24]. An explanation for this discrepancy may be that, 
although the endotoxemia model has been shown to be a valuable model to study some 
aspects of sepsis, it may not be an appropriate model to study the changes in cerebral 
autoregulatory performance observed during sepsis. A number of physiological and 
pathophysiological mechanisms may be involved in the deterioration of autoregulatory 
performance during sepsis, such as a comprised circulatory state [25], use of medication that 
may interfere with autoregulatory function like vasopressors [26], or a changed oxygen 
extraction due to mitochondrial dysfunction [27]. Studies on the effect of the above 
mentioned mechanisms on cerebral autoregulatory performance are warranted to elucidate 
their role in the deterioration of the cerebral autoregulatory performance in septic patients, 
giving more information on the occurrence of cerebral dysfunction at various stages of the 
disease. In addition, there are methodological reasons that may suggest that cerebral 
autoregulatory performance is not relevantly impaired in patients with sepsis. To date only 
three studies are published investigating dynamic cerebral autoregulation in septic patients 
[8, 23, 24]. Pfister et al. and Steiner et al. used correlation coefficient analysis to quantify 
cerebral autoregulation [23, 24]. Impaired cerebral autoregulation was indicated as a 
correlation coefficient index >0.3 and >0, respectively. Using these cutoff values for 
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correlation coefficient analysis would indicate our healthy subjects to have impaired cerebral 
autoregulation at each time point, even before administration of endotoxin. Furthermore, 
studies have shown positive values for the correlation coefficient index in healthy subjects of, 
0.2±0.13 [28], 0.28±0.18 [29], and 0.23±0.1 [30]. Berg et al. quantified dynamic cerebral 
autoregulation using transfer function analysis [8]. Comparing cerebral autoregulatory 
functioning in septic patients with healthy volunteers, they found a maintained transfer 
function gain, albeit a lower transfer function phase, concluding an impaired autoregulatory 
functioning. However, they only included 6 patients in their transfer function analysis. 
Furthermore, they mention that the spectral power of the blood pressure was very low for 
the whole group of patients. Despite the fact that they left out those subjects with a transfer 
function coherence value below 0.4, this low variation in blood pressure make the transfer 
function results less reliable. These results indicate that transfer function analysis may not be 
an appropriate technique to quantify cerebral autoregulation in septic patients. 
The relative stability in the parameters of dynamic cerebral autoregulation were observed 
despite marked changes in blood pressure, heart rate, cerebral blood flow-velocity and end-
tidal pCO2. Mean blood pressure decreased with 13 mmHg (-13 %) between -2 and 4 h 
following LPS. Cerebral blood flow velocity was not stable, but decreased, despite absent 
recovery in blood pressure. This decline in cerebral blood flow velocity could suggest 
impaired static autoregulation. However, this interpretation would require stable pCO2 levels, 
which was not the case. Changes in CO2 strongly affect cerebral blood flow and the 0.5 kPa 
reduction in end-tidal CO2 may explain the 15 % reduction in CBF [31]. With prolonged 
changes in CO2, adaptation occurs however and cerebral blood flow may partially restore 
towards baseline. The reduction in etCO2 may also explain the finding of enhanced cerebral 
autoregulation with correlation analysis. Studies in healthy controls have shown augmented 
dynamic cerebral autoregulation with hypocapnia [32]. 
There are several limitations to the present study. First, the inflammatory insult may be too 
short and to mild to cause a deterioration of cerebral autoregulation. Endotoxin is 
administrated as bolus infusion, which results in a marked, but short-lived inflammatory 
response. Second, because of the relatively small study group, these preliminary results 
would need to be confirmed in a larger group of subjects, where the LPS dose should be 
administered as a continuous infusion over a few hours, rather than bolus administration. 
Third, the methodology used to quantify cerebral autoregulation is not sensitive enough to 
measure the changes in autoregulatory performance that occur after LPS infusion. Currently, 
no generally accepted gold standard test for cerebral autoregulation exists. Both correlation 
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coefficient analysis as transfer function analysis are based on the assumption of a linear 
relationship between blood pressure and cerebral blood flow velocity. As, in general, cerebral 
autoregulation is considered to be a non-linear phenomenon, these methods possibly 
produce misleading results when nonlinear properties are present. However, transfer 
function analysis has shown changes in cerebral autoregulation metrics in patients with 
sepsis. 
In conclusion we demonstrate that endotoxemia-induced systemic inflammation is associated 
with an overall preserved, possibly even enhanced, cerebral autoregulatory performance at 
an early stage after LPS infusion, with no deterioration up to 8 h. 
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General discussion 
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Over the past years, the interest in the effects of diseases on haemodynamics and vice versa 
the effect of changes in haemodynamics on the pathogenesis of diseases has been growing. 
This has led to important progress in techniques to estimate cerebral perfusion and analytical 
methods to evaluate regulation systems, such as baroreflex functioning and cerebral 
autoregulation. Worldwide, researchers from several disciplines, i.e. medicine, physiology, 
engineering and physics, are trying to get a grip on the haemodynamic regulation systems of 
the human body. A variety of measurement techniques are being employed in clinical and 
experimental settings. New publications with novel findings rapidly follow one another. 
Despite considerable scientific interest, currently a standardized test to assess cerebral 
haemodynamics is still lacking. This is one of the reasons why the monitoring of cerebral 
autoregulation is not yet included in clinical routines. Being able to measure and monitor 
cerebral autoregulation in a sensitive and robust way would provide clinically useful 
information and would permit a more individualized physiologically based therapy aimed at 
reducing the risk of secondary brain injury. The studies conducted in this thesis are part of the 
active, ongoing scientific debate on the best measurement technique for cerebral 
autoregulation. The aim of this thesis is to gain better insight in the quantification of cerebral 
autoregulation and how the perfusion regulation is affected in different pathophysiological 
conditions. The main research questions are: 
1) How is transfer function analysis applied for the quantification of cerebral autoregulation? 
2) Is the perfusion regulation impaired in patients with Alzheimer’s disease, frail elderly and/
or during systemic inflammation? 
With the outcomes of this thesis, we hope to stimulate the scientific community to step 
towards uniform use of quantification techniques for cerebral autoregulation. This chapter 
starts with the main findings of this thesis. Then the findings are discussed, ending with 
conclusions and future perspectives. 
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MAIN FINDINGS 
The first main research question of this thesis is: How is transfer function analysis applied for 
the quantification of cerebral autoregulation? Below, the main findings are summarized. 
 A strong diversity exists in the application of transfer function analysis. No standard 
protocol exists and most studies fail to report important settings that were used to 
calculate the transfer function. (Chapter 2) 
 When the transfer function results of different studies are pooled, despite the strong 
methodological diversity, the data still show the high pass filter behaviour for dynamic 
cerebral autoregulation. (Chapter 2) 
 When cerebral autoregulatory performance is quantified from the same dataset, but by 
different methods of analysis as used in different centres, metric outcomes show a large 
variability. (Chapter 3) 
 In contrast to the analysis of sit-stand manoeuvres and cerebral vasomotor reactivity 
tests, transfer function analysis seems less sensitive to detect subtle impairment in 
cerebral autoregulatory functioning in small populations. (Chapter 6) 
 Standardisation and validation of the quantification method for cerebral autoregulation 
is needed to improve the reliability and usefulness of cerebral autoregulation in clinical 
practice. (Chapter 2 and 3) 
 Transfer function settings and criteria for qualifying terms such as ‘impaired cerebral 
autoregulation’ should be defined to make comparison between different studies 
possible. (Chapter 3 and 4) 
 Haemodynamic analysis at a group level may already provide clinical useful information 
and is applicable in a variety of populations. (Chapter 6, 7, 8, 9, 10 and 11) 
The second main research question of this thesis is: Is the perfusion regulation reduced in 
patients with Alzheimer’s disease, frail elderly and/or during systemic inflammation? 
Hereafter the results for this research question are given. 
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 Patients with Alzheimer’s disease have an impaired cerebral autoregulation, cerebral 
vasomotor reactivity and baroreflex functioning. This might cause chronic mild 
hypoperfusion, which may contribute to the brain atrophy seen in Alzheimer’s disease. 
(Chapter 6 and 7) 
 Aging is accompanied by a decline in slow oscillations of cerebral haemodynamics and 
blood pressure, possibly due to less spontaneous activity in microvascular smooth 
muscle cells and increased vessel stiffness. (Chapter 8) 
 In geriatric patients with hypotensive syndromes cardiovascular autonomic function is 
comparable to patients without such syndromes. (Chapter 10) 
 Endotoxemia-induced systemic inflammation does not deteriorate the cerebral 
autoregulatory performance. (Chapter 11) 
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DISCUSSION 
Quantification of cerebral autoregulation 
The first part of this thesis deals with the research question: ‘How is transfer function analysis 
applied for the quantification of cerebral autoregulation?’. Transfer function analysis is, 
currently, the most used non-invasive method for the quantification of cerebral 
autoregulation. The method is based on frequency analysis between spontaneous changes in 
blood pressure and cerebral blood flow velocity. Cerebral autoregulation is evaluated by 
dividing the cross spectra between blood pressure and cerebral blood flow velocity by the 
auto spectra of the blood pressure. To estimate these spectra several parameter settings 
need to be chosen, such as sample frequency, window length, overlap percentage and 
filtering. Together, these settings determine how the relationship between blood pressure 
and cerebral blood flow velocity will be approached. By performing a review of the literature 
(Chapter 2), we investigated how the transfer function analysis has been applied for the 
quantification of cerebral autoregulation, and the effect of different approaches of transfer 
function analysis was investigated in a multi-centre study (Chapter 3). 
Overall, we found that, while at first sight transfer function seems straight-forward, the 
standardization of the methodology was weak. It was found that most studies fail to report 
important settings that were used to calculate the transfer function. This may be due to the 
fact that some of the investigators were not aware of the existence of different options for 
settings or did not see the need for mentioning them. However, the review did also not show 
any consistency in the well reported settings. Overall, the approach for transfer function 
analysis seemed a matter of personal preference of the investigators; a high diversity existed 
and no standardization could be found. This was an important observation as it was shown, 
with the multi-centre study described in Chapter 3, that the outcomes for cerebral 
autoregulation of the transfer function analysis do depend on the choice of transfer function 
settings. In this multi-centre study, the same dataset was analyzed by 15 different centres, 
using their own methodological approach for transfer function analysis. And although the 
same dataset was analyzed, a high diversity in outcome values was found between the 
centres.  
From this, we can conclude that interpretation of the transfer function outcomes for cerebral 
autoregulation can only be done with care, taking into account the parameter settings used 
for the quantification. As many studies presented in literature have not well documented 
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their transfer function approach, one should also be careful when comparing study results.  
Despite all this, we still believe that transfer function analysis may be of potential use in 
clinical research, since also encouraging results were found. First, in spite of a high variability, 
it was also shown in Chapter 2 that combining the results of different studies does reveal 
multi-centre frequency plot trends for phase and gain that are consistent with the original 
high pass filter model for cerebral autoregulation. This suggests that, even when transfer 
function analysis is approached differently, the same physiological phenomenon is being 
investigated by the different centres. Furthermore, the multi-centre study showed that most 
centres were able to distinguish between normal cerebral autoregulation and modified 
cerebral autoregulation (using hypercapnia). Even the poorest performing centre had a ROC 
AUC higher than 0.75. 
However, as the effect of many transfer function settings on the outcome for cerebral 
autoregulation is still unclear, we believe that standardization of the methodology is 
necessary to reduce inter-centre variability and to make comparisons between studies 
possible. A first step to standardization is set by the proposed guideline for the usage of 
transfer function analysis for the quantification of cerebral autoregulation described in 
Chapter 4. This preliminary guidelines is set up for the purpose of uniformity in use of 
transfer function analysis and future revisions in the light of new evidence may be necessary. 
Furthermore, it needs to be emphasized that this guideline does not intend to endorse 
transfer function analysis as the ‘best’ method for the quantification of cerebral 
autoregulation. Many other techniques exist which may be just as good or even better. Below 
some methodological considerations of transfer function analysis will be discussed, which 
certainly should be kept in mind when transfer function analysis is being employed. 
First, transfer function analysis requires relatively long recordings (5 minutes or more) of 
blood pressure and cerebral blood flow velocity [1, 2]. This can be quite difficult in, for 
example, unstable patients. 
Secondly, transfer function analysis between blood pressure and cerebral blood flow velocity 
is only reliable when the blood pressure contains sufficient variation. In the previous 
mentioned studies, we only used recordings of spontaneous blood pressure and cerebral 
blood flow velocity. These spontaneous blood pressure variations have the advantage not to 
depend on active patient cooperation or physiological interference through for example 
medication. More powerful oscillations, i.e. provoked by sit-stand manoeuvres [3], may 
enhance clinical significance as they further challenge cerebral autoregulation functioning. 
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Substantial short‑term manipulations of blood pressure, are, however, not suitable in cases 
of severe illness. 
Third, transfer function analysis is based on the assumption of a linear relationship between 
blood pressure and cerebral blood flow velocity as it models a linear input-output system 
with the blood pressure signal as the input and the cerebral blood flow velocity signal as the 
output. In general, cerebral autoregulation is considered to be a non-linear phenomenon 
because of the nonlinear responses of key physiologic parameters [4], such as 
cerebrovascular resistance and arteriolar diameter, to changes in blood pressure [5]. Despite 
that the assumption of linearity may be justified in the case of spontaneous changes in blood 
pressure, because these changes are relatively small [6], transfer function analysis has the 
potential to produce misleading results in a system with nonlinear properties. It is arguable 
that a non-linear model may be more appropriate for assessment of autoregulation [7]. We 
described a new non-linear analysis method, convergent cross mapping, to assess these 
nonlinear dynamics of cerebral autoregulation. 
Furthermore, it is questionable whether, even when non-linear effects are left out, it is 
accurate to assume that transfer function analysis wholly reflects cerebral autoregulation. 
Although the relationship between blood pressure and cerebral blood flow is influenced by 
dynamic cerebral autoregulation, it is important to recognise that other physiological factors 
such as baseline blood pressure, pCO2 [8, 9], brain metabolic activity, and sympathetic tone 
[10] are also influential. Because transfer function analysis considers only the blood pressure 
(input) and cerebral blood flow (output) relationship, the approach is clearly a simplification 
of a highly complex physiological system. 
The last methodological issue that will be discussed is that the settings used for transfer 
function analysis possibly depend on the signals used as input. For our review and multi-
centre study we focused on using cerebral blood flow velocity measured with transcranial 
Doppler. Although transcranial Doppler offers the temporal resolution necessary to study 
dynamic cerebral autoregulation, velocity is not necessary equal to flow. Changes in the 
measured flow are proportional to the changes in mean velocity only if the diameter of the 
middle cerebral artery remains constant. Numerous studies have shown that middle cerebral 
artery diameter in humans remains relatively constant under a variety of haemodynamic 
conditions [11-13]. However, small changes in diameter may cause large variations in velocity, 
leading to a higher spread in transfer function outcomes. Other surrogates, i.e. obtained with 
near-infrared spectroscopy (Chapter 8), may provide better estimates of cerebral blood flow, 
however when used, the settings for transfer function analysis should possible be adopted. 
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Clinical application of haemodynamic analysis 
From the previous paragraph it is clear that methodological improvements have to be made 
before quantification of cerebral autoregulation as a clinical test in an individual is possible. In 
the second part of this thesis, haemodynamics were evaluated in different patient groups. 
The chapters in this part of the thesis show that, in the current state, haemodynamic analysis 
at a group level may already provide clinical useful information. Furthermore, it shows that 
haemodynamic analysis is applicable in a variety of populations, such as in the very old and 
critically ill. In this section, the clinical applications of haemodynamic analysis, as it was 
performed in this thesis, will be discussed. 
Alzheimer’s disease 
Alzheimer’s disease is a progressive neurodegenerative disorder and is the leading cause of 
dementia. At this moment, there is still limited understanding of this disease and its 
underlying cause, which is reflected in the lack of an effective curative treatment. 
A growing body of evidence suggests a strong link between Alzheimer’s disease and affected 
vascular function. However, the exact relationship between vascular functioning and 
Alzheimer’s disease remains poorly understood. We investigated whether cerebral 
autoregulation (Chapter 6), cerebral vasomotor reactivity (Chapter 6) and baroreflex 
functioning (Chapter 7) are impaired in patients with Alzheimer’s disease. 
Momentarily, three studies have investigated dynamic cerebral autoregulation in patients 
with Alzheimer’s disease [14-16], but found no evidence for impairment of cerebral 
autoregulatory performance. These studies assessed cerebral autoregulation using transfer 
function analysis. However, as shown in the first part of this thesis, this method may be less 
sensitive to detect more subtle impairment in cerebral autoregulatory performance in small 
samples. Therefore, in our study, next to transfer function analysis to assess the cerebral 
autoregulatory performance, subjects were asked to perform a single sit-to-stand protocol 
and repeated sit-stand manoeuvres. These sit-stand manoeuvres provide a straight-forward 
measure for cerebral autoregulation. Changes in cerebral blood flow velocity and 
cerebrovascular resistance are investigated during reductions and increases in blood pressure 
without the necessity of a pharmacological intervention. Analysis of the manoeuvres did 
indeed show less effective damping by cerebral autoregulation. 
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Cerebral vasomotor reactivity was evaluated by studying changes in cerebral blood flow 
velocity, blood pressure and cerebrovascular conductance index during transitions from 
hypocapnia (induced by 30 s of coached hyperventilation) to normocapnia and from 
normocapnia to hypercapnia (induced by the inhalation of a gas mixture containing 7% CO2). 
Like two previous studies, we have found an impaired cerebral vasomotor reactivity in 
Alzheimer patients. 
Baroreflex functioning was quantified using a bivariate causal model (ARXAR model), which 
was first introduced by Nollo et al. (2001) [17]. In contrast to widely used non-invasive 
methods to quantify baroreflex functioning, such as heart rate variability and systolic blood 
pressure variability, this method has the advantage of describing the causal relationship from 
systolic blood pressure to the beat-to-beat interval of the heart rate and separates it from the 
mechanical pathway (from R-R interval to systolic blood pressure). The method revealed 
distinct lowered baroreflex functioning in patients with Alzheimer’s disease compared with 
age‑matched control subjects. In addition, the performance of the baroreflex functioning in 
the studied subjects with mild cognitive impairment was in between that of the Alzheimer 
patients and the controls. Moreover, we were able to confirm both these observations in an 
independent validation sample. Despite these clear results, we have to keep in mind that this 
is the first report in which a bivariate causal model is used to estimate baroreflex functioning 
in patients with Alzheimer’s disease. Therefore, further evidence must be obtained before the 
method can be widely used in clinical settings, i.e. against important differential diagnoses in 
memory clinics. 
Overall, we have found impaired cerebral autoregulation, cerebral vasomotor reactivity and 
baroreflex functioning in patients with Alzheimer’s disease. The diminished baroreflex 
functioning, which was also observed in the patients with mild cognitive impairment, may 
imply that early in Alzheimer’s disease besides cognition also blood pressure regulation is 
affected. This affected blood pressure regulation may lead to higher fluctuations in blood 
pressure. As impaired cerebral autoregulation means that the ability to stabilize cerebral 
blood flow during blood pressure fluctuations is reduced, the results of these studies point 
towards a higher risk for hypo- and hyperperfusion in patients with Alzheimer’s disease. 
Despite the fact that the observed impairments are subtle, and do not directly lead to severe 
hypoperfusion, and may thus not lead to cerebral ischemia, it is not unthinkable that chronic 
mild hypoperfusion does contribute to brain atrophy in Alzheimer’s disease. It can be argued 
that the observed impairments are caused not by Alzheimer’s disease but by comorbid 
vascular disorders that may be more prevalent in Alzheimer’s disease. Indeed, even though 
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we tried to match for hypertension, the patients with Alzheimer’s disease did have a higher 
blood pressure. Still we believe that hypertension alone does not explain our results, as the 
study described in Chapter 9 reveals no distorted cerebral autoregulatory performance in 
patients with hypertension. 
Frail elderly 
Longevity increases worldwide. Currently, about 11 % of the Dutch population is aged 70 
years or older and this number is expected to be doubled by 2014. Currently, cardiovascular 
diseases are the most common cause of death among elderly patients in the Western World 
and almost 70% of the population over the age of 70 has some degree of hypertension. 
Furthermore, medications such as beta blockers and angiotensin converting enzyme 
inhibitors are commonly used in this age group, and the resultant drug interactions may 
compromise haemodynamic stability and lead to untoward events. Understanding 
haemodynamic changes that accompany the aging process is therefore becoming increasingly 
relevant. In this part of the thesis, we have shown that it is possible to measure systemic and 
cerebral haemodynamics in (frail) elderly. 
In Chapter 8, blood pressure and oxygenated- and deoxygenated haemoglobin 
concentrations were continuously measured in healthy elderly aged over 63 years to 
investigate age-related changes in blood pressure and cerebral haemodynamics. The 
oxygenated- and deoxygenated haemoglobin concentrations were measured using near-
infrared spectroscopy. Near-infrared spectroscopy is a promising non-invasive alternative for 
transcranial Doppler. Like transcranial Doppler, near-infrared spectroscopy has, in contrast to 
CT, MRI and PET, a high temporal resolution. Therefore it is more suitable to measure 
dynamic changes. Near infrared spectroscopy provides continuous quantification of regional 
changes in oxygenated and deoxygenated haemoglobin in the outermost layers of the 
cerebral cortex. The technique is based on near-infrared light absorption changes that 
depend on concentration changes of the chromophores oxygenated and deoxygenated 
haemoglobin in the tissue under investigation. Changes in total haemoglobin, defined as the 
sum of the changes in oxygenated and deoxygenated haemoglobin, can be used as a cerebral 
blood flow surrogate. The main advantage of near-infrared spectroscopy compared to 
transcranial Doppler is that the sensors are placed on the forehead and do not require precise 
location. In a survey reviewing transcranial Doppler results from 60 laboratories in the United 
States, percentages for failure to measure cerebral blood flow velocity due to inadequate 
access of the temporal window ranged between 0% and 65% (mean, 16%) [18]. Furthermore, 
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studies have shown that with advancing age assessing cerebral blood flow velocity through 
the temporal window becomes more and more difficult. Therefore, near-infrared 
spectroscopy may be a promising alternative. 
However, the difficulties with using near‑infrared spectroscopy as a surrogate of cerebral 
blood flow are that blood oxygenation is influenced by multiple factors, such as cerebral 
metabolism, arterial saturation and haematrocrit and that the “normal range” has yet to be 
defined. Furthermore, this study showed that the slow oscillations in near‑infrared 
spectroscopy metrics decline with aging, presumably due to aging-related changes in the 
microvasculature such as vessel stiffness. Effects of age should therefore be taken into 
account when studying non age-related effects in near‑infrared spectroscopy data. Further 
studies on the applicability of near‑infrared spectroscopy for investigating haemodynamics 
are warranted. 
Chapter 9 presents a case report on three patients (1 man and 2 women) over the age of 70 
years, with hypertension, before and after anti-hypertensive treatment. Anti-hypertensive 
treatment is believed to be harmful in elderly patients. As organs in hypertensive elderly are 
accustomed to perfusion at higher pressures, decreasing blood pressure toward the “low-
normal range” of healthy adults may be detrimental. Studying changes in systemic and 
cerebral haemodynamics due to medication use is of great importance. 
All three patients completed an extensive test protocol, consisting of a baseline 
measurement, a sit-stand protocol and a cerebrovascular motor reactivity test, during which 
blood pressure (using photoplethysmography), cerebral blood flow velocity (using 
transcranial Doppler) and oxygenated- and deoxygenated haemoglobin concentrations (using 
near-infrared spectroscopy) were measured. 
In the three elderly patients with hypertension described in this case report it was shown that 
blood pressure lowering did not result in a lowering of the cerebral blood flow. In contrast, 
even a rise in cerebral blood flow was observed. Furthermore, cerebral autoregulatory 
functioning was preserved in all three patients. 
Overall, the findings of this case report have clinical significance since they suggest that it is 
save to apply anti‑hypertensive treatment in elderly patients, with the benefit of reducing 
the development of (new) coronary events, stroke and congestive heart failure. However, as 
these results are only obtained in a small sample of three patients, a larger observational trial 
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is needed to confirm our findings. 
In Chapter 10 cardiovascular functioning was tested in 203 patients who visited the geriatric 
outpatient falls and syncope clinic of the Radboud university medical centre. These patients 
belong to a frail population, with a history of falls, dizziness and syncope. Furthermore, 6% of 
the patients was also diagnosed with a form of dementia. Fourteen different non-invasive 
autonomic function indices were used for heart rate variability, blood pressure variability and 
baroreflex sensitivity. No differences were found in autonomic function indices between the 
patients with hypotensive syndromes and those without such syndromes. These results argue 
against autonomic dysfunction as the sole or dominant factor in the pathophysiology of these 
syndromes and underline the need for a multifactorial approach in diagnostic studies of 
elderly people with problems as falls and syncope. 
Endotoxemia-induced systemic inflammation 
Experimental human endotoxemia is a human in vivo model, which, at least partially, mimics 
the inflammatory response that occurs during early sepsis. It is a well established model, 
which has been extensively studied. In Chapter 11, 16 healthy young men received a bolus 
injection of E. coli lipopolysaccharide to study the effect of inflammation on cerebral 
autoregulatory performance. Blood pressure and cerebral blood flow velocity were measured 
at different time point, 2 hours before and 2, 4, 6 and 8 hours after administration of 
endotoxin. This study shows that it is even possible to measure haemodynamic functioning in 
critically ill patients. However, as the E. coli lipopolysaccharide caused severe endotoxemia-
associated symptoms, such as fever, nausea, shivering, muscle and back pain and headache, it 
was not always possible to record the cerebral blood flow velocity and thus quantify cerebral 
autoregulatory performance. This was mainly due to discomfort caused by the Doppler 
headband, which could also be a problem in other clinical settings. Still, in contrast to 
conventional imaging modalities, such as MRI and CT, which require transferring patients to 
imaging facilities, transcranial Doppler is an easy to use, safe technique. 
These study results point towards an overall preserved cerebral autoregulatory performance 
and two opposite conclusions could be drawn. First, it is possible that - in contrast to previous 
studies - the cerebral autoregulatory performance is not impaired in patients with sepsis and 
therefore not a cause of sepsis-associated cerebral dysfunction. Second, it could be that 
cerebral autoregulatory performance is impaired, but the endotoxemia model is not an 
appropriate model to study the changes in cerebral autoregulatory performance observed 
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during sepsis. Unfortunately, our study is inconclusive in this regard. As it is not ruled out that 
impaired cerebral autoregulatory functioning is one of the causes of sepsis-associated 
cerebral dysfunctioning, further studies on cerebral autoregulation in patients with sepsis are 
recommended. 
PERSPECTIVES OF CEREBRAL AUTOREGULATORY TESTING 
From the results of this thesis it is clear that cerebral autoregulatory testing may be of great 
clinical benefit. However, optimization of the methods to quantify cerebral autoregulation is 
needed before they can implemented in the clinical arena.  
The first observation of cerebral autoregulation was described by Fog in 1937 [19]. Fog 
investigated the cat’s pial vessels during manipulations of the blood pressure and observed 
that the pial autoregulatory vasomotor responses were independent of neurogenic stimuli. 
The concept of cerebral autoregulation in terms of blood flow constancy during perfusion 
pressure changes was finally established by Lassen in 1959 [20]. From then on there has been 
an increasing scientific and clinical interest in the quantification of cerebral autoregulation 
and the role that impairment of the cerebral autoregulatory functioning might play in the 
causation, progression and risk of disorders such as intracranial haemorrhage, stroke and 
neurodegenerative diseases. 
Over the last 20 years, a wide variety of techniques has been developed and adopted for the 
assessment of cerebral autoregulation, but without providing a gold standard [6]. Transfer 
function analysis was first applied in 1990 for the quantification of cerebral autoregulation 
[21] and has been used in many different clinical populations ever since. However, the 
findings of this thesis show that the transfer function outcome is highly dependent on the 
application form. The lack of application consistency between research centres is clinically 
problematic because inappropriate conclusions may be drawn depending on the application 
chosen for the quantification of cerebral autoregulation. For example, when used in 
individual care, transfer function in one way may classify the individual as having normal 
cerebral autoregulatory functioning, while another application format will classify the patient 
as having deficient cerebral autoregulatory functioning. 
Thus, the findings of this thesis clearly question whether it is appropriate to continue the use 
of transfer function analysis as a reflective of cerebral autoregulation, without knowing the 
exact effects of transfer function settings on outcome metrics. Therefore, before getting 
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transfer function analysis to the clinical arena, further experimental validation of the transfer 
function metrics is needed. 
However, this does not necessarily invalidate previous research or preclude the future 
application of transfer function analysis. Transfer function analysis, in its various ways, may 
predict cerebral autoregulatory performance on a population level but provide nonspecific 
physiological information on an individual patient basis. This is also true for metrics as blood 
pressure and heart rate variability which are predictive of cardiovascular outcomes in large-
scale clinical trials [22, 23], but their physiological basis is poorly understood [24, 25]. 
Overall, our findings highlight the need for better understanding of the physiological 
information that each way of application of transfer function analysis may or may not convey. 
Therefore, many steps have to be taken before transfer function analysis can be considered 
to represent a valid standard for the assessment of cerebral autoregulation in individuals in 
clinical practice. Until such time, it is important that researchers use uniform settings for their 
cerebral autoregulation studies to ascertain that variations found in outcome metrics 
between studies are not caused by methodological differences. In this thesis, a guideline is 
provided for uniform application of the transfer function analysis (Chapter 4). This guideline 
contains directions for the data acquisition, measurement protocol and application of 
transfer function analysis. While there might be arguments for not adopting the proposed 
settings, we believe that when researchers stick to these directives (even if only as additional 
results) reproducibility and implementation of study results will improve. 
We emphasize that currently the evidence in support of some of the proposed settings is still 
weak, therefore arguments against the use of the current guideline and new insights from 
future research should be used in order to shape and improve the guideline. This is an 
important ongoing process, as until a global consensus is reached transfer function analysis 
can only be applied as a scientific tool to predict outcome on a population level and 
physiological interpretation of past and future research using transfer function analysis 
should be done with caution. 
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  PHASE I           PHASE II         PHASE III 
Figure 1.  
At this moment, the cerebral autoregulatory research is still in its first stage, in which different methods are 
tested to investigate whether they can be used as reflective of the cerebral autoregulatory functioning.  Before, 
cerebral autoregulatory testing can finally be implemented in the clinical arena, further experimental validation 
of the methods is needed. The methods should be tested in several clinical populations to investigate their 
sensitivity, specificity and robustness. And a global consensus should be reached on the application of the 
method and the interpretation of the method outcomes.  
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CONCLUSION 
Monitoring cerebral autoregulatory performance can help in the early detection of an 
increased risk of brain damage, due to hypo- or hyperperfusion. Many situations exist in 
which a repeatable and safe method to assess the autoregulatory capacity would be useful, 
such as in the care of patients with head injury, suffering from sepsis, intracranial 
haemorrhage or stroke, but it can also play a role in early detection of neurodegenerative 
diseases. However, due to the lack of standardization no normative values exist and therefore 
comparison between study results of different centres is difficult. Methodological 
improvements need to be made before cerebral autoregulation testing may become a 
clinically applicable diagnostic test in the individual. However, the results in this thesis do 
show that it is possible to measure haemodynamic functioning in a broad range of patients, 
such as frail elderly and critically ill patients. Using the proposed guideline for transfer 
function analysis, will make it possible to perform large multi-centre trials with reproducible 
results in the different centres. It provides a solid standard for comparison between studies 
performed in different research institutes or at different times, making it possible to pool 
data and to define clear criteria for ‘normal’ and ‘impaired’ cerebral autoregulatory 
functioning. 
Overall, there is a need for signal analysis software programs that describe and analyze 
systemic and cerebral haemodynamics with ‘sense and simplicity’, but still in a reliable and 
valid manner. For further implementation of haemodynamic analysis in both research and 
clinical practice, the interface between outcome metrics currently used and clinically 
recognizable results needs to be improved, standardized and simplified as well. 
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Future research 
Outlining the directions in which future research could be most useful, the following research 
questions should be considered: 
Quantification of cerebral autoregulation 
Research question 1. How can the proposed guideline for transfer function analysis be 
further optimized? 
The proposed guideline provides a standard which makes it easier to reproduce, compare and 
implement study results. The guideline reflects what is currently considered best, based on 
existing literature and expert opinions. However, the evidence in support of some of the 
proposed settings is still weak and the effect of the usage of different settings for transfer 
functioning analysis should be further explored. Furthermore, the proposed guideline is only 
set up for usage in awake and cooperating patients. As cerebral autoregulatory monitoring 
may also be of benefit in other clinical settings, such as critically ill patients in the intensive 
care, the guideline should also be adapted to these situations. 
 
Research question 2. Do other methods than transfer function analysis provide better 
estimates for cerebral autoregulation? 
While transfer function analysis is the most applied method for the quantification of cerebral 
autoregulation in resting state, other methods are available which may provide better 
estimates for cerebral autoregulation. Different linear methods, i.e. time domain analysis, 
should be considered, but also the non-‑linear nature of cerebral autoregulation should be 
further explored. A number of studies have already shown that the process of cerebral 
autoregulation contains non‑linear dynamics [26], but whether the quantification of the 
cerebral autoregulatory performance improves when these non-linear dynamics are taken 
into account has not (yet) been shown. 
 
Research question 3. How can reference values of cerebral haemodynamics in specific 
populations, such as children, adults, elderly and patients with specific clinical conditions be 
defined? 
Qualifying terms for the interpretation of outcome metrics, for example criteria for “impaired 
CA”, have never been strictly defined. Reference values for specific populations will make it 
possible to monitor the quality of cerebral haemodynamics in the individual patient and to 
investigate the diagnostic usefulness. 
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Research question 4. How is the cerebral autoregulatory functioning related to other 
mechanisms, such as the baroreflex functioning? 
Cerebral autoregulation is not the only mechanism involved in the control of cerebral 
perfusion, the exact relationship between cerebral autoregulation and other mechanisms, 
such as the baroreflex functioning, should be investigated. And, if possible, these mechanisms 
should be incorporated in the haemodynamic analysis. 
 
Research question 5. How should we define cerebral autoregulation? 
While this thesis focused on the measurement techniques for haemodynamic analysis, one 
should not overlook the fact that, currently, no clear definition on cerebral autoregulation 
exists. Maybe the concept of cerebral autoregulation, as currently studied, is too limited to 
cover the whole mechanism at work. Further studies are warranted on what parts of the 
regulation mechanism should or should not be incorporated within the concept of cerebral 
autoregulation and a clear definition should be formed. 
Clinical application of haemodynamic analysis 
Alzheimer’s disease 
Research question 6. Are the blunted perfusion regulation mechanisms (impaired baroreflex 
functioning, cerebral autoregulation and cerebrovasomotor reactivity) caused by the 
pathology of Alzheimer’s disease or do they contribute to (accelerate) the pathology of 
Alzheimer’s disease? 
In this thesis, we showed that patients with Alzheimer’s disease had a blunted vasodilatatory 
response to hypercapnia (impaired cerebrovasomotor reactivity), an insufficient 
vasodilatatory and vasoconstrictor responses to decreases and increases in blood pressure 
(impaired cerebral autoregulation) as well as a lowered baroreflex functioning (Chapter 6 and 
7). However, both studies used a cross-sectional design, which makes it impossible to 
establish whether the blunted perfusion regulation mechanisms are the effect or the cause of 
neurodegeneration. Knowing more about the causality, may provide useful information 
toward the understanding, and ultimately, treatment, of Alzheimer’s disease. 
Frail elderly 
Research question 7. Is, in elderly patients with hypotensive syndromes, an impaired 
cerebral autoregulatory functioning the cause of symptoms such as falls and syncope? 
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We found that in geriatric patients with hypotensive syndromes, cardiovascular autonomic 
was not a sufficient cause to explain the occurrence of these hypotensive syndromes (Chapter 
9). As symptoms associated with these hypotensive syndromes such as dizziness, 
lightheadedness, blurred vision and loss of consciousness may point towards insufficient 
cerebral perfusion, impairment of the cerebral autoregulatory functioning may play a role in 
these hypotensive syndromes. Investigating the cerebral autoregulatory functioning in 
patients with hypotensive syndromes may provide important knowledge as cerebral 
hypoperfusion may place the patient at significant risk to health and may cause injury. 
Furthermore, as patient complaints can be vague or nonspecific, impaired cerebral 
autoregulation may be an objective indicator of impaired cerebral perfusion. 
 
Research question 8. Is anti-hypertensive treatment save for elderly patients with 
hypertension? 
Anti‑hypertensive treatment can reduce morbidity and mortality risks in hypertensive 
patients. However, there is an alarming lack of evidence to guide treatment decisions for 
elderly with hypertension. Therefore, it is difficult for the physician to balance the assumed 
benefits of treatment against possible risks. This is reflected in the fact that only a small part 
of hypertensive patients aged >80 years receive adequate treatment. In three hypertensive 
patients aged between 70 and 80 years, we showed that blood pressure lowering with 
anti‑hypertensive treatment did not result in a reduction of baseline brain blood flow. 
Validating this finding in a larger group of elderly, will stimulate physicians to treat elderly 
patients, improving not only the health of the patient but also lowering health expenses as 
medical interventions which may be needed as hypertension goes untreated can be 
prevented. 
Endotoxemia-induced systemic inflammation 
Research question 9. Is the perfusion regulation impaired in septic patients? 
The few studies performed during sepsis have shown that cerebral autoregulation is indeed 
impaired in the great majority of patients. However, in this thesis, we showed that controlled 
systemic inflammation in healthy volunteers is associated with overall preserved 
autoregulatory performance at short term and at a later stage. This discrepancy may be 
caused by the fact that we used the endotoxemia model to study sepsis, but it is also possible 
that the methods used to quantify cerebral autoregulation (correlation coefficient analysis 
and transfer function analysis) in the studies using patients with sepsis are not appropriate 
for this patient group. To rule out that impaired cerebral autoregulatory functioning is one of 
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the causes of sepsis-associated brain dysfunction, further study on the perfusion regulation in 
septic patients is needed. 
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SUMMARY 
Part 1. Quantification of cerebral autoregulation 
The term cerebral autoregulation stands for an important concept in cardiovascular 
regulation, namely that brain circulation is preserved at all cost. Cerebral autoregulation 
refers to the properties of the brain vascular bed to maintain cerebral perfusion despite 
changes in blood pressure. Whereas classic studies have assessed cerebral autoregulation 
during changes in blood pressure that have a gradual onset, dynamic studies quantify the fast 
modifications in cerebral blood flow in relation to rapid alterations in blood pressure. A large 
number of methods have been proposed to assess the quality of dynamic cerebral 
autoregulation. Transfer function analysis is the most frequently used method in the 
literature to quantify cerebral autoregulation using spontaneous fluctuations in blood 
pressure and cerebral blood flow velocity. Transfer function analysis is based on analysis of 
frequency gain, phase and coherence components of oscillations in blood pressure and the 
resultant degree to which these changes are reflected in cerebral blood flow. One of the 
advantages of this method is that it only takes a baseline measurement without the need for 
any pharmacological or physiological manipulation of blood pressure. 
In this part of the thesis, the following research question was raised: 
How is transfer function analysis applied for the quantification of cerebral autoregulation? 
Chapter 2 provides an overview of different ways of execution and implementation of the 
transfer function in the assessment of cerebral autoregulation. A thorough search of the 
literature was performed, which yielded 113 studies that had used transfer function to assess 
cerebral autoregulation for spontaneous oscillations in blood pressure and cerebral blood 
flow velocity. It was concluded from these studies that there exists a high diversity in settings 
and criteria used for transfer function analysis. Notable was also the high number of studies 
with sparse information about the settings of transfer function analysis. The high diversity in 
the implementation of the transfer function made it difficult to compare the results of the 
different studies. As a consequence, pooling the data of the different studies for each type of 
transfer function metric showed an expectedly large between-centre variability. However, the 
pooled data did reveal multi-centre frequency plot trends for phase and gain that were 
consistent with the original high pass filter model for dynamic cerebral autoregulation. This 
implies higher values for phase in the lower frequencies, decreasing with increasing 
frequency, and lower values for gain in the lower frequencies, increasing with higher 
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frequency. 
To further investigate the between-centre variability, a multi-centre study was performed 
(Chapter 3) to investigate the between-centre variability in transfer function analysis 
outcome metrics. In this multi-centre study a single, uniform database with healthy patients 
with blood pressure and transcranial Doppler recordings was analyzed by different research 
centres, each using their own transfer function settings. A large non-homogeneous variation 
was found in transfer function outcome metrics between the centres. To evaluate how 
differences in usual routine settings of the centres might have influenced the outcome of the 
transfer function analysis, several settings were compared using artificial generated datasets. 
Results show an urgent need for detailed standardisation of the signal processing methods 
used for transfer function analysis. Without such standardisation, additional uncertainty is 
added to any comparison between studies of autoregulation carried out at different centres. 
To come to a consensus on the standardisation of transfer function analysis, Chapter 4 
provides preliminary guidelines for the use of transfer function analysis. With these 
guidelines, we hope to establish more uniformity in the use of transfer function analysis in 
future literature. 
Despite the fact that transfer function analysis is the most widely used method to non-
invasively evaluate cerebral autoregulation performance, it is not necessarily the best 
available method. Transfer function analysis provides an estimate of cerebral autoregulatory 
performance, but other methods may be equally well or even better able to describe the 
complex physiological process of cerebral autoregulation. As transfer function analysis is 
based on the assumption that the relation between blood pressure and cerebral blood flow 
velocity is linear, while physiologically cerebral autoregulation exhibits nonlinear dynamics, it 
may be possible that this method oversimplifies the nature of cerebral autoregulation. 
Chapter 5, uses a new non-linear analysis method, convergent cross mapping, to assess these 
non-linear dynamics of cerebral autoregulation. Convergent cross mapping determines 
causality between variables by investigating if historical values of the blood pressure can be 
used to predict the states of the cerebral blood flow velocity. As outcome measure the 
Pearson correlation between the cerebral blood flow velocity predicted from the blood 
pressure and the measured cerebral blood flow velocity is used. We have validated this 
method in 19 healthy adults by comparing normocapnic data with hypercapnic data, which is 
a model for impaired cerebral autoregulation. The correlation was found to be higher in the 
hypercapnic state compared to normocapnia, making convergent cross mapping a promising 
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technique for cerebral autoregulation estimation. 
Part 2. Clinical application of haemodynamic analysis 
In this part of the thesis, the focus was shifted to haemodynamics in clinical practice. Inspired 
by the clinical background of the department of geriatric medicine where this thesis research 
was performed, conditions that are of relevance for an elderly population were investigated. 
The following research question was investigated: 
Is the perfusion regulation impaired in patients with Alzheimer’s disease, frail elderly 
and/ or during systemic inflammation? 
Part 2.1. Alzheimer’s disease 
Alzheimer’s disease is a frequent occurring progressive neurodegenerative disorder which 
places a huge burden on society and individual caregivers. Despite tremendous research 
efforts aimed at understanding and curing Alzheimer’s disease, there are still no simple 
diagnostic tests for Alzheimer’s disease and existing therapies only treat symptoms, but do 
not actually stop the disease. Recent studies have provided evidence that vascular factors 
contribute to the neuronal degeneration in Alzheimer’s disease and are even considered 
responsible for the initiation and progression of the neuropathology of Alzheimer’s disease. 
Vascular pathology may impair cerebral autoregulation and lead to cerebrovascular 
insufficiency, which in turn may contribute to the progression of Alzheimer’s disease. Animal 
studies show strong evidence for impairment of cerebral autoregulation by Alzheimer’s 
disease. However, the exact relationship remains poorly understood. Knowledge about the 
vascular involvement in the pathogenesis of Alzheimer’s disease could lead to the 
development of adequate techniques for the diagnosis and maybe even effective treatments. 
Therefore, in Chapter 6, the association of Alzheimer’s disease with cerebral autoregulation 
and cerebral vasomotor reactivity was studied. In this chapter, cerebral autoregulation and 
cerebral vasomotor reactivity were studied in 12 patients with mild to moderate Alzheimer’s 
disease and 24 controls matched for age and history of hypertension. While transfer function 
analysis revealed no differences in cerebral autoregulation between the patients with 
Alzheimer’s disease and the controls, the sit-stand manoeuvres showed that Alzheimer 
patients have insufficient vasodilatatory and vasoconstrictor responses to decreases and 
increases in blood pressure. Furthermore, a blunted vasodilatatory response to hypercapnia 
was seen in the patients with Alzheimer’s disease, indicating impaired cerebral vasomotor 
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reactivity. 
In Chapter 7, we studied whether the baroreflex was less effective in patients with 
Alzheimer’s disease. Baroreflex functioning was assessed in 18 patients with mild to 
moderate Alzheimer’s disease, 11 patients with mild cognitive impairment and 19 age and sex 
matched healthy controls. We found that the baroreflex functioning was reduced in 
Alzheimer’s disease compared to healthy controls. Baroreflex functioning of patients with 
mild cognitive impairment was between those with Alzheimer’s disease and the healthy 
controls. Results were confirmed in an independent validation sample of 16 patients with 
Alzheimer’s disease, 18 patients with mild cognitive impairment and 19 age- and sex matched 
healthy controls. Furthermore, in 18 patients with Alzheimer’s disease it was found that 
treatment with acetylcholinesterase inhibitor increased baroreflex sensitivity with 66%. 
The clinical implications of the observed impairments in cerebral autoregulation, cerebral 
vasomotor reactivity and baroreflex functioning are still unclear and need further research. 
Part 2.2. Frail elderly 
Age-associated physiological changes in heart rate and blood pressure regulation, comorbid 
medical conditions such as hypertension and atherosclerosis, and the concurrent use of 
medication that affect the regulation systems may make elderly highly vulnerable for cerebral 
hypo- and hyperperfusion. In the three studies, described in Chapter 8 to 10, we evaluated 
haemodynamic changes in elderly patients. Studying healthy elderly (Chapter 8), patients 
with hypertension before and after antihypertensive treatment (Chapter 9) and patients with 
hypotensive syndromes (Chapter 10). 
Healthy aging 
Aging itself leads to a degeneration of the vascular system. Cerebral blood flow decreases, 
which may influence the vasoregulatory capacity, and vessel stiffness is enhanced. 
Furthermore, the aging brain shows a compromised microvascular anatomy, which may 
interact with cerebral brain perfusion and metabolism, contributing to a suboptimal cognitive 
performance in the elderly. In Chapter 8 the effect of aging and cognitive load on cerebral 
haemodynamics is examined using near-infrared spectroscopy, which is a non-invasive tool to 
measure cortical haemodynamics and metabolism. Fourteen healthy young (>22 years) and 
14 healthy older adults (>63 years) performed a verbal n-back working-memory task. It was 
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found that very low- and low-frequency oscillations of both cerebral haemodynamics and 
blood pressure were reduced in the older compared to the young adults during task 
performance. The very low frequency oscillations were also reduced in the group of young 
persons with increased cognitive load. These results indicate that it is important to take the 
factors age and cognitive load into consideration for the analysis and interpretation of 
haemodynamic neuroimaging data. Furthermore, transfer function analysis was used to gain 
more insight into the relationship between the task-induced oscillations in oxygenated 
haemoglobin concentration and blood pressure. A clear relationship was found in accordance 
with the known properties of cerebral autoregulation, which did not change under influence 
of age and cognitive load. 
Hypertension 
The prevalence of hypertension in elderly people is increasing. Multiple mechanisms, 
including stiffening of large arteries, endothelial dysfunction, cardiac remodelling, autonomic 
dysregulation and renal aspects, contribute to the high prevalence of hypertension in the 
elderly. Long-standing hypertension may result in structural changes of the cerebral vessels, 
such as thickening of the vessel walls with narrowing of the lumen and hyalinosis of the 
media resulting in stiffness. Several studies have demonstrated that antihypertensive drug 
therapy reduces the development of new coronary events, stroke and congestive heart 
failure in elderly persons. However, at short term antihypertensive drug therapy may also 
have disadvantages. Indications exist that hypertension impairs the mechanism of cerebral 
autoregulation itself plus it could attenuate orthostatic hypotension. Chapter 9 represents a 
case report of three hypertensive patients. Haemodynamic changes after antihypertensive 
treatment in these patients were studied. It was found that cerebral perfusion (regulation) is 
preserved in hypertensive elderly before and after antihypertensive treatment. 
Hypotensive syndromes 
Three other disorders of the blood pressure regulation which are highly prevalent in the 
elderly are orthostatic hypotension, postprandial hypotension and carotid sinus 
hypersensitivity. These hypotensive syndromes are characterized by a fall in blood pressure 
when a person assumes a standing position, a drastic decline in blood pressure after eating a 
meal and an exaggerated response to carotid sinus baroreceptor stimulation, respectively. 
Though highly prevalent, the underlying pathophysiology is not clearly understood. In 
Chapter 10, several non-invasive cardiovascular function indices to assess heart rate 
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variability, blood pressure variability and baroreflex functioning were studied in 203 patients, 
who visited the falls and syncope outpatient clinic of the Radboud university medical centre 
because of falls, dizziness and/or syncope. No differences were found in cardiovascular 
function indices between patients with and without hypotensive syndromes. Symptoms, such 
as falls, dizziness or syncope, could also not be related to changes in cardiovascular 
functioning. These findings argue against a single pathological factor, such as autonomic 
dysfunctioning, causing these hypotensive disorders. It is more likely that these syndromes, 
especially in the elderly, are multifactorial in genesis. 
Part 2.3. Endotoxemia-induced systemic inflammation 
Sepsis is an adverse systemic response to infection that includes fever, rapid heartbeat and 
respiration, low and unstable blood pressure and organ dysfunction associated with 
compromised circulation. Acute brain dysfunction is often one of the first symptoms of sepsis 
and may herald an unfavourable neurocognitive outcome. An important precipitating factor 
for the neurocognitive decline may be a reduced cerebral blood flow due to a reduced 
capacity of cerebral autoregulation to compensate for the reduction in and instability of 
cerebral perfusion pressure (i.e. blood pressure). 
In Chapter 11, cerebral autoregulation was studied during endotoxemia-induced systemic 
inflammation in 16 healthy young men. Blood pressure and cerebral blood flow velocity were 
assessed 2 hours before and 2, 4, 6 and 8 hours after infusion of a low dose of purified E. coli 
lipopolysaccharide. At each time point, cerebral autoregulatory performance was quantified 
in the time domain and frequency domain using correlation coefficient analysis and transfer 
function analysis, respectively. Despite the marked systemic inflammatory response after LPS 
infusion similar to that of the very early stages of sepsis, the serial measurements over time 
revealed no deterioration of the cerebral autoregulation. 
13 
289  
Su
m
m
ary 
 
 
Chapter 14. 
Nederlandse samenvatting (Summary in Dutch) 
Dankwoord (Acknowledgments) 
Curriculum Vitae 
List of publications 
 
 
 
 
292  
 
14 
293  
N
ed
e
rlan
d
se sam
en
vatti
n
g (Su
m
m
ary in
 D
u
tch
) 
NEDERLANDSE SAMENVATTING (SUMMARY IN DUTCH) 
De hersenen, die twee procent van het lichaamsgewicht uitmaken, verbruiken twintig 
procent van alle zuurstof die in een lichaam wordt opgenomen. De zuurstofvoorziening van 
de hersenen is afhankelijk van de hoeveelheid zuurstof in het bloed en de hoeveelheid bloed 
die naar de hersenen stroomt. Onderbreking van de bloedtoevoer van enkele seconden kan 
al leiden tot een verlies van bewustzijn en uiteindelijk zelfs tot hersenschade. De hersenen 
zijn dus sterk afhankelijk van een goede en zo stabiel mogelijke toevoer van bloed met 
zuurstof en glucose. Omdat de bloeddruk ook onder gezonde omstandigheden varieert 
(bijvoorbeeld doordat we schrikken of ineens opstaan), kent het lichaam verscheidene 
mechanismen om de bloedstroom naar de hersenen op peil te houden. De belangrijkste 
regulatie mechanismen van het lichaam om de doorbloeding van de hersenen te reguleren 
zijn de controle van de bloeddruk via de baroreflex en die van de hersendoorbloeding zelf via 
de cerebrale autoregulatie (BOX 1). De baroreflex zorgt ervoor dat het hart sneller gaat slaan 
en vaten vernauwen wanneer de bloeddruk daalt en visa versa het hartritme vertraagd en 
vaten verwijden wanneer de bloeddruk stijgt. Het is een feedbacksysteem dat de bloeddruk 
op peil houdt. Naast het baroreflex zorgt de cerebrale autoregulatie voor een demping van 
overdracht van de schommelingen in bloeddruk op de daadwerkelijke doorbloeding van de 
hersenen. De cerebrale autoregulatie reguleert de locale bloedtoevoer door aanpassingen 
van de diameter van de  vaten in de hersenen.  
Wanneer deze regulatie mechanismen falen wordt de doorbloeding van de hersenen sterk 
afhankelijk van de bloeddruk. Hierdoor daalt de hersendoorbloeding bij bijvoorbeeld een 
daling van de bloeddruk (vb. bij het opstaan) en dit is niet zonder gevaar, maar kan onder 
andere leiden tot het ontstaan van hersenschade. Het goed functioneren van de 
regelmechanismen is dus van groot belang. De literatuur laat echter zien dat verschillende 
aandoeningen, zoals beroerte, dementie en hoofdtrauma, deze belangrijke regelsystemen 
kunnen beïnvloeden. Dit kan zorgen voor een verhoogd risico op hersenschade in patiënten 
met deze aandoeningen.  
In de kliniek kan het meten van het functioneren van de baroreflex en cerebrale autoregulatie 
dus een grote meerwaarde hebben voor de behandeling van patiënten met bijvoorbeeld 
hersenschade, meningitis of beroerte. Maar het kan ook van belang zijn voor de vroege 
detectie van neurodegeneratieve ziekten zoals dementie. Vooruitgang in meettechnieken en 
rekenmethoden hebben het mogelijk gemaakt om stabiele en dynamische veranderingen in 
hartritme, bloeddruk en hersendoorbloeding te bestuderen. Helaas is er momenteel nog 
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BOX 1.  
Baroreflex 
De baroreflex is een belangrijk regelmechanisme, welke zorgt voor instandhouding van de adequate bloeddruk 
in het lichaam. Deze reflex werkt zeer snel en komt in actie bij plotselinge drukveranderingen, waarbij door 
middel van aanpassingen van de vaatdiameter en het hartritme de bloeddruk gecorrigeerd. De baroreflex 
werkt door middel van baroreceptoren, rekgevoelige vezels in bijvoorbeeld de wand van de aorta. Wanneer 
iemand plotseling opstaat vanuit liggende houding, dan wordt het bloed door de zwaartekracht in de richting 
van de benen getrokken. De daling van de bloeddruk zorgt dat de baroreceptoren signalen van een 
verminderde uitrekking afgeven signalen af welke via de hersenen uiteindelijke resulteren in een verwijding 
van de bloedvaten en een versnelling van het hartritme.  
Cerebrale autoregulatie 
Cerebrale autoregulatie is een mechanisme waarbij de hersenen de doorbloeding zo stabiel mogelijk houden 
door dynamische aanpassing van de vaatweerstand aan wisselingen in de bloeddruk. Daalt de bloeddruk dan 
worden de hersenvaten verwijd, waardoor deze meer bloed kunnen verwerken, en bij een stijging van de 
bloeddruk vindt vernauwing van de vaten plaats. Op deze wijze kunnen geleidelijke veranderingen in bloeddruk 
tussen de 50 en 150 mmHg opgevangen worden. Buiten deze range worden bloeddruk schommelingen passief 
doorgegeven aan de hersendoorbloeding, doordat de hersenvaten niet verder in staat zijn te vernauwen of te 
verwijden. De aanpassingen van de vaten op geleidelijke veranderingen wordt 'statische autoregulatie' 
genoemd en wordt vaak onderzocht door grote bloeddrukschommelingen te induceren, bijvoorbeeld door 
toediening van geneesmiddelen, en de mate van verandering in hersendoorbloeding te meten. Naast de 
statische autoregulatie zorgt de zogenaamde dynamische autoregulatie voor aanpassingen van de vaten op 
plotselinge veranderingen (binnen secondes) in de bloeddruk. Een goud standaard voor het meten van de 
dynamische autoregulatie bestaat momenteel nog niet. 
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geen goud standaard techniek om de kwaliteit van de cerebrale autoregulatie te meten.  
Dit proefschrift is opgedeeld in twee delen, waarvan het eerste deel gewijd is aan de 
kwantificatie van cerebrale autoregulatie. Hierbij ligt de focus op de meest gebruikte niet-
invasieve methode op dit moment, genaamd overdrachtsfunctie analyse. De toepassing van 
deze methode is in kaart gebracht door middel van een review van de literatuur en een multi-
center studie. Om tot standaardisatie van de techniek te komen, hebben we een voorstel 
gedaan voor richtlijnen omtrent de toepassing van de overdrachtsfunctie analyse voor het 
meten van cerebrale autoregulatie. Het tweede deel bevat studies naar het functioneren van 
de doorbloedingsregulatie in verschillende patiënten populaties. Geïnspireerd door de 
klinische achtergrond van de afdeling waar de studies beschreven in dit proefschrift werden 
uitgevoerd, werden aandoeningen die van belang zijn voor de oudere, waaronder de ziekte 
van Alzheimer, hypertensie en orthostatische hypotensie, onderzocht. 
Dit hoofdstuk bevat een samenvatting van de bevindingen in dit proefschrift. 
Deel 1. Kwantificatie van cerebrale autoregulatie 
In dit deel van het proefschrift staat de volgende onderzoeksvraag centraal: Hoe wordt 
overdrachtsfunctie analyse toegepast voor de kwantificering van cerebrale autoregulatie? 
Ondanks de grote meerwaarde welke het meten van de cerebrale autoregulatie in de 
klinische praktijk kan hebben, bestaat er op dit moment nog geen goud standaard methode 
hiervoor. Overdrachtsfunctie analyse is momenteel de meest gebruikte niet-invasieve 
methode om cerebrale autoregulatie te kwantificeren. Om de overdrachtsfunctie analyse te 
kunnen toepassen is een simultane meting van de bloeddruk en hersendoorbloeding nodig. 
Zowel de bloeddruk als de hersendoorbloeding kunnen niet-invasief worden gemeten (zie 
Figuur 1A). Zowel de bloeddruk als de hersendoorbloeding zijn opgebouwd uit 
schommelingen met verschillende frequenties. Met behulp van de overdrachtsfunctie analyse 
kan in kaart worden gebracht hoe (vb. versterking en vertraging) verschillende 
schommelingen in de bloeddruk worden doorgegeven aan de hersenendoorbloeding. Het is 
bekend dat de cerebrale autoregulatie werkt als een hoog-doorlaatfilter, dit betekent dat 
langzame schommelingen in de bloeddruk (lage frequenties) worden gedempt en snelle 
schommelingen in de bloeddruk (hoge frequenties) passief worden doorgegeven aan de 
hersendoorbloeding (Figuur 1B). Wanneer de overdrachtsfunctie niet het kenmerkende hoog-
doorlaatfilter weergeeft is er sprake van een verstoring van de cerebrale autoregulatie. Een 
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van de voordelen van deze methode is dat er geen farmacologische of fysiologische 
manipulatie van de bloeddruk nodig is, maar dat een rustmeting voldoende is. 
Om te onderzoeken of de overdrachtsfunctie analyse gebruikt zou kunnen worden als goud 
standaard voor de kwantificering van cerebrale autoregulatie, hebben we een review van de 
literatuur (Hoofdstuk 2) en een multi-center studie  (Hoofdstuk 3) uitgevoerd.  
Met het review hebben we een overzicht gemaakt van hoe de overdrachtsfunctie voor de 
kwantificatie van de cerebrale autoregulatie momenteel wordt toegepast in de literatuur. Van 
113 studies werd de wijze van uitvoering van de overdrachtsfunctie in kaart gebracht. Het 
review laat een grote diversiteit aan wijze van uitvoering van de overdrachtsfunctie analyse 
en criteria voor de interpretatie van de uitkomsten zien tussen de studies. Daarnaast was 
opvallend dat een groot deel van de studies niet hun gehele procedure beschreven hadden in 
het artikel. Ondanks dat de studies hun resultaten dus allen presenteerden onder de noemer 
‘verkregen met overdrachtsfunctie analyse’ verschilde de wijze van overdrachtsfunctie dus 
onverklaarbaar veel. Omdat het effect van de wijze waarop de overdrachtsfunctie wordt 
uitgevoerd op de uiteindelijke uitkomsten voor cerebrale autoregulatie onbekend is, maakt 
deze grote diversiteit in de uitvoering van de overdrachtsfunctie het moeilijk om de 
resultaten van de verschillende onderzoeken te vergelijken. Het doel van de multi-center 
studie (beschreven in Hoofdstuk 3) was te onderzoeken of de wijze van uitvoering van de 
overdrachtsfunctie analyse invloed heeft op de uitkomst voor cerebrale autoregulatie. Voor 
deze studie werden 15 centra gevraagd dezelfde 80 datasets te analyseren met hun eigen 
instellingen voor de overdrachtsfunctie analyse. Grote verschillen in uitkomsten voor de 
cerebrale autoregulatie van de 80 datasets tussen de centra werden waargenomen. Hierdoor 
werd duidelijk dat uitvoering van de overdrachtsfunctie op de ene wijze de patiënt zou 
diagnosticeren als hebbende een goede cerebrale autoregulatie, terwijl een andere wijze op 
een verstoorde cerebrale autoregulatie uit zou komen.  
Om verschillende studies met elkaar te kunnen vergelijken is standaardisatie van de 
uitvoering van de overdrachtsfunctie analyse dus van belang. In Hoofdstuk 4 wordt een 
eerste voorzet gegeven voor een richtlijn omtrent het gebruik van de overdrachtsfunctie 
analyse. Met deze uniforme methode kan internationaal vervolgonderzoek worden gedaan 
met de grote winst dat uitkomsten nu te vergelijken en combineren zijn. Daarnaast maakt 
standaardisatie van de methode het mogelijk om de sensitiviteit, specificiteit en robuustheid 
van de overdrachtsfunctie te vergelijken met andere beschikbare methoden.  
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Ondanks dat de overdrachtsfunctie analyse de meest gebruikte niet-invasieve methode is om 
cerebrale autoregulatie te kwantificeren is op dit moment nog onbekend of het ook de beste 
methode is. Het feit dat de overdrachtsfunctie analyse gebaseerd is op de veronderstelling 
dat er een lineaire relatie is tussen bloeddruk en hersendoorbloeding, maakt dat 
verscheidene onderzoekers de accuraatheid van de methode in twijfel trekken en voorkeur 
geven aan een niet-lineaire methode.   
In Hoofdstuk 5 wordt een nieuwe niet-lineaire analyse methode, genaamd convergend cross 
mapping, voor de cerebrale autoregulatie beschreven. Convergend cross mapping bepaalt de 
causaliteit tussen schommelingen in hersendoorbloeding en bloeddruk door te onderzoeken 
of de waarden van de bloeddruk in het verleden kunnen worden gebruikt om de 
hersendoorbloeding te voorspellen.  
Deel 2. Toepassing van haemodynamische analyses in de klinische praktijk 
In dit deel van het proefschrift ligt de focus op haemodynamica in de klinische praktijk. De 
volgende onderzoeksvraag werd onderzocht:  Is de regulering van de hersenperfusie 
aangetast in patiënten met de ziekte van Alzheimer, kwetsbare ouderen en / of tijdens een 
systemische ontsteking? 
Deel 2.1. De ziekte van Alzheimer 
De ziekte van Alzheimer is een frequent voorkomende progressieve neurodegeneratieve 
ziekte. Ondanks de grote hoeveelheid onderzoek die gedaan wordt op het gebied van 
Alzheimer, zijn er nog geen eenvoudige diagnostische testen beschikbaar voor de ziekte van 
Alzheimer. Daarnaast behandelen bestaande therapieën alleen de symptomen, maar stoppen 
niet daadwerkelijk de ziekte. Recent hebben studies aangetoond dat ook vasculaire factoren 
bijdragen aan de neuronale degeneratie bij de ziekte van Alzheimer en mogelijk zelfs 
verantwoordelijk zijn voor de initiatie en progressie van de neuropathologie. Vasculaire 
pathologie kan de cerebrale autoregulatie beïnvloeden en leiden tot cerebrovasculaire 
insufficiëntie, welke weer kan bijdragen aan de progressie van de ziekte van Alzheimer.  
Kennis over de vasculaire betrokkenheid in het ontstaan van de ziekte van Alzheimer kan 
helpen bij de ontwikkeling van betere diagnostische technieken en mogelijk zelfs effectievere 
behandelingen. In de studies beschreven in Hoofdstuk 6 en 7 hebben we onderzocht of de 
cerebrale autoregulatie, cerebrale vasomotore reactiviteit en/of het baroreflex functioneren 
verminderd zijn in patiënten met de ziekte van Alzheimer. 
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In Hoofdstuk 6 is de cerebrale autoregulatie en cerebrale vasomotore reactiviteit onderzocht 
in 12 patiënten met milde tot matige Alzheimer en 24 controles welke gematched waren voor 
leeftijd en op voorgeschiedenis van hypertensie. Met behulp van zit-sta manoeuvres toonden 
we aan dat Alzheimer patiënten grotere schommelingen in hersendoorbloeding laten zien in 
reactie op schommelingen in de bloeddruk dan de controles. Dit wijst op onvoldoende 
vasodilatatoire en vasoconstrictoire en is dus een teken van een verstoorde cerebrale 
autoregulatie. De vasomotore reactiviteit werd gemeten door de proefpersonen een 
gasmengsel met een verhoogde CO2 concentratie te laten inademen voor ongeveer 30 sec. 
De verhoogd CO2 concentratie zorgt ervoor dat de hersenvaten verwijden en de 
hersendoorbloeding stijgt. In de patiënten met de ziekte van Alzheimer werd een 
verminderde vasodilatatoire reactie waargenomen, wat aangeeft dat ook de vasomotrische 
reactiviteit verminderd is.  
Hoofdstuk 7 laat zien dat, naast de cerebrale autoregulatie en de cerebrale vasomotore 
reactiviteit, ook het baroreflex minder effectief werkt bij patiënten met de ziekte van 
Alzheimer. Het baroreflex functioneren is onderzocht in twee onafhankelijke centra waarbij 
patiënten met milde tot matige ziekte van Alzheimer, patiënten met milde cognitieve 
stoornissen en gezonde controles zijn geïncludeerd. In beide centra werd een verminderd 
functioneren van het baroreflex gevonden bij patiënten met milde cognitieve stoornissen ten 
opzichte van de gezonde controles. Daarnaast werd ook een verminderde baroreflex functie 
gevonden in de groep patiënten met de ziekte van Alzheimer ten opzichte van de patiënten 
met milde cognitieve stoornissen. Dit suggereert dat naast de cognitie ook de regulering van 
de bloeddruk al in een vroeg stadium van de ziekte van Alzheimer verstoord raakt. Naast dat 
de verstoring van het baroreflex functioneren meer verteld over het verloop van de ziekte 
van Alzheimer, kan de baroreflex functie mogelijk ook worden gebruikt als diagnostisch 
middel voor het opsporen van de ziekte van Alzheimer in een vroeg stadium. 
Omdat de waargenomen stoornissen in hersenperfusie regulering subtiel zijn, leiden ze 
waarschijnlijk niet direct tot ernstige hypoperfusie en daarmee niet tot (ernstige) cerebrale 
ischemie. Toch is het niet ondenkbaar dat chronische milde hypoperfusie bijdraagt aan de 
atrofie van de hersenen bij de ziekte van Alzheimer en is het van belang om de klinische 
implicaties van de waargenomen stoornissen verder te onderzoeken. 
Deel 2.2. Kwetsbare ouderen 
Het aantal ouderen neemt toe. In Nederland zullen er in 2040 naar schatting 4,6 miljoen 65-
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plussers zijn. Dat ouderen een hoger risico hebben op cerebrale hypo- en hyperperfusie is aan 
verschillende oorzaken toe te schrijven, zoals leeftijdsgeassocieerde fysiologische 
veranderingen in de hartslag en bloeddruk regulatie, comorbide medische aandoeningen 
zoals hypertensie en atherosclerose en het gebruik van medicatie. In dit deel van het 
proefschrift hebben we de haemodynamiek bestudeerd van gezonde ouderen (Hoofdstuk 8), 
oudere patiënten met hypertensie voor en na de behandeling met antihypertensiva 
(Hoofdstuk 9) en van oudere patiënten met een hypotensieve syndromen (Hoofdstuk 10). 
Gezond ouderen 
Tijdens het ouder worden gaat de kwaliteit van het vasculaire systeem langzaam achteruit. 
De hersendoorbloeding neemt af, hetgeen de vasoregulatoire capaciteit kan beïnvloeden, en 
de vaatstijfheid neemt toe. Bovendien tonen de ouder wordende hersenen een verminderde 
microvasculaire anatomie. Samen zorgen deze factoren ervoor dat de cognitieve prestaties 
van ouderen achteruitgaan. In Hoofdstuk 8 hebben we het effect van veroudering en 
cognitieve belasting op de cerebrale haemodynamiek onderzocht. Hiervoor is gebruik 
gemaakt van near-infrared spectroscopy. Door middel van deze techniek kan niet-invasief een 
meting van de cerebrale oxygenatie worden verricht op basis van het verschil in lichtabsorptie 
tussen geoxygeneerd en gedeoxygeneerd hemoglobine in het brein.   
Veertien gezonde jonge (> 22 jaar) en 14 gezonde oudere volwassenen (> 63 jaar) deden mee 
aan het onderzoek. Een verminderde hoeveelheid langzame schommelingen in zowel de 
bloeddruk als de cerebrale oxygenatie werd waargenomen in de groep gezonde ouderen. 
Wanneer de jongeren verhoogd cognitief belast werden, door middel van een verbale 
werkgeheugentaak, werd ook bij hen een vermindering van de hoeveelheid langzame 
schommelingen waargenomen. Dit suggereert dat ouderen al eerder een stadium van hogere 
cognitief belasting bereiken. De cerebrale autoregulatie bleek niet aangetast te worden door 
de veroudering zelf.  
Hypertensie 
Hypertensie is een aandoening waarbij er sprake is van een te hoge bloeddruk. Door 
leeftijdsgeassocieerde fysiologische veranderingen, zoals een verhoogde vaatstijfheid van 
grote slagaders, endotheliale dysfunctie en autonome ontregeling kampt een groot gedeelte 
van de ouderen met hypertensie. Langdurige hypertensie is echter niet zonder nadelige 
gevolgen. Het kan leiden tot structurele veranderingen van de hersenvaten. Verschillende 
studies hebben aangetoond dat medicatie om de bloeddruk te verlagen het risico op 
bijvoorbeeld een beroerte en hartfalen vermindert. Echter, is er de kans dat op korte termijn 
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bloeddrukverlagende medicatie ook nadelige effecten hebben. Aanwijzingen bestaan dat 
hypertensie de functie van de cerebrale autoregulatie vermindert en orthostatische 
hypotensie (een sterke bloeddruk daling bij het opstaan) versterkt. Het verlagen van de 
bloeddruk met medicatie kan daarom leiden tot hypoperfusie van de hersenen. Om te 
bekijken of dit het geval is, hebben we in een case studie van drie oudere patiënten met 
hypertensie (Hoofdstuk 9) onderzocht of er  haemodynamische veranderingen gepaard gaan 
met bloeddrukverlagende medicatie in oudere patiënten met hypertensie. Uit deze case 
studie kwamen geen aanwijzingen voor een vermindering van de hersendoorbloeding na het 
gebruik van bloeddrukverlagende medicatie naar voren.  Dit suggereert dat het veilig is om 
bloeddrukverlagende medicatie voor te schrijven in deze patiënten groep.  
Hypotensieve syndromen 
Drie veel voorkomende andere aandoeningen in ouderen die te maken hebben met de 
bloeddruk regulering zijn orthostatische hypotensie, postprandiale hypotensie en sinus 
carotis hypersensitiviteit. Deze zogenaamde hypotensieve syndromen worden gekenmerkt 
door een flinke daling van de bloeddruk. Bij orthostatische hypotensie vindt deze 
bloeddrukdaling plaats na het gaan staan, bij postprandiale hypotensie na het eten van een 
maaltijd en bij sinus carotis hypersensitiviteit ontstaat de bloeddrukdaling als gevolg van een 
overdreven reactie op de stimulatie van sinus carotis baroreceptor. Ondanks dat de 
syndromen veel voorkomen, is de onderliggende pathofysiologie nog onduidelijk. In de studie 
beschreven in Hoofdstuk 10 hebben we daarom onderzocht of er verstoringen zijn in de 
cardiovasculaire regelsystemen die gepaard gaan met deze syndromen. Hiervoor hebben we 
gekeken naar de hartslag variabiliteit, bloeddruk variabiliteit en het functioneren van het 
baroreflex in 203 patiënten, wie vanwege klachten van vallen, duizeligheid en/of syncope 
onze val en syncope polikliniek van het Radboud universitair medisch centrum bezochten. 
Geen verschillen in de reguleringsmaten werden waargenomen tussen patiënten met en 
zonder hypotensieve syndromen. Ook symptomen, zoals vallen, duizeligheid en syncope, 
konden niet worden gerelateerd aan de werking cardiovasculaire systemen. Deze resultaten 
geven aan dat het onwaarschijnlijk is dat er één pathologische factor is, zoals autonome 
disfunctie, welke de aandoening deze aandoeningen zou veroorzaken. Het is waarschijnlijker 
dat vele verschillende factoren samen ten grondslag liggen aan deze syndromen en dat 
daarom een verschillen in de enkele maten gevonden konden worden. 
Deel 2.3. Endotoxemia geïnduceerde systemische ontsteking 
Sepsis (in de volksmond ook wel ‘bloedvergiftiging’) is een ontstekingsreactie van het gehele 
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lichaam, als reactie op een infectie. Het is een ernstig verlopend ziektebeeld welke 
gekenmerkt wordt door een snelle hartslag en ademhaling, lage en instabiele bloeddruk en 
orgaan disfunctie. Sepsis leid in veel gevallen tot de dood. Eén van de eerste symptomen van 
sepsis is acuut hersenfalen, wat vaak een ongunstige neurocognitieve toestand tot gevolgd 
heeft. Een belangrijke factor in het ontstaan van een verminderde neurocognitieve toestand 
kan een verlaagde hersenperfusie zijn. Deze verlaagde hersenperfusie kan een gevolg van een 
verminderd functioneren van de  cerebrale autoregulatie. Om te onderzoeken hoe de 
cerebrale autoregulatie functioneert tijdens sepsis, hebben we de cerebrale autoregulatie 
onderzocht tijdens een endotoxine-geïnduceerde systemische ontsteking in 16 gezonde jonge 
mannen (Hoofdstuk 11). 
De bloeddruk en cerebrale bloeddoorstromingssnelheid werden 2 uur voor en 2 , 4 , 6 en 8 
uur na infusie van een lage dosis van gezuiverde E. coli lipopolysaccharide gemeten. Op elk 
tijdstip werd het functioneren van de cerebrale autoregulatie gekwantificeerd in het 
tijdsdomein en het frequentiedomein middels correlatie coëfficiënt analyse en 
overdrachtsfunctie analyse. Ondanks de sterke systemische ontstekingsreactie (vergelijkbaar 
met de symptomen die voor komen in de zeer vroege stadia van sepsis)  die werd 
waargenomen in de proefpersonen vonden we geen verslechtering van de cerebrale 
autoregulatie.   
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DANKWOORD (ACKNOWLEDGMENTS) 
Piglet: 
‘How do you spell love?’ 
Pooh: 
‘You don’t spell it, you feel it.’ 
 
Het is eindelijk zover...  
Je bent aangekomen bij het dankwoord. Heb je het hele proefschrift doorgeploeterd of is dit 
de eerste bladzijde die je openslaat? Het maakt ook niet uit, iedereen weet dat dit het meest 
gelezen deel van ieder proefschrift. En ergens is dit maar goed ook. Want die 35 maanden 
waarin ik meer dan 46.000 kilometer heb gereisd tussen Ede en Nijmegen (laten we het niet 
over het aantal uren dat dit heeft gekost hebben), ongeveer 140 uur aan besprekingen met 
(co-) promotoren heb gehad, uiteindelijk 9 publicaties heb weten te creëren en zeker 20 
presentaties op congressen en symposia heb gehouden, waren natuurlijk erg leerzaam, maar 
vooral leuk en enthousiasmerend dankzij tientallen collega’s van de afdeling Geriatrie en de 
steun van veel vrienden en familie.  
 
Drie jaren zijn in vogelvlucht voorbij gegaan, met momenten waarop stress hoogtij vierde 
maar ook momenten waarop er heerlijk gerelaxt kon worden (met een pizza bijvoorbeeld). 
Promoveren is uitdagend, het maakt je kritisch, het vergroot je wereld, je schrijfvaardigheid 
verbetert, maar het is toch vooral een traject waarin je jezelf leert kennen op een weg vol 
obstakels en omwegen. Gelukkig heb ik de weg niet in mijn eentje hoeven te bewandelen. 
Want ook al leiden meerdere wegen naar Rome, zonder de hulp van anderen had ik het 
eindpunt niet bereikt. 
 
Allereerst mijn co-promotor Jurgen. Je uitgebreide onderzoekservaring, je onverzadigbare 
werklust en zeker ook je begeleiding tijdens de afrondende fase van dit proefschrift, 
waardeer ik zeer. Bedankt dat je me steunde in mijn ambitie om een promotieonderzoek te 
starten en daar de nodige potjes geld voor bij elkaar wist te sprokkelen. Je hebt me altijd de 
ruimte gegeven om zelfstandig onderzoek te verrichten en ik ben je daar ontzettend 
dankbaar voor. Je hebt me met een open blik steeds gestimuleerd buiten de kaders te denken 
en hier ook aan vastgehouden. 
 
Joep, onder jouw supervisie startte ik met een klinisch-wetenschappelijke stage op de 
afdeling Geriatrie. Jouw enthousiasme voor technisch onderzoek in de ouderenzorg, heeft er 
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uiteindelijk voor gezorgd dat ik ben blijven hangen voor een promotietraject. Ik ben trots dat 
ik jouw eerste promovendus mag zijn die haar proefschrift gaat verdedigen. 
Beste Kees, bedankt voor alle uurtjes dat ik bij jou aan je bureau mocht verschijnen of dat jij 
bij ons op de afdeling in een bedompt geurig vergaderhokje met mij kwam overleggen. De 
overleggen met jou hebben me altijd enthousiast gemaakt over mijn eigen werk en je hebt 
mij het belang van de onderzoeken kunnen laten inzien.  
 
Marcel, bedankt dat je mijn promotor wilde zijn. Je hebt mij laten zien hoeveel er komt kijken 
bij het managen van een afdeling en het begeleiden van zoveel promovendi. Maar ondanks 
het feit dat je agenda erg volgeboekt zit maak je tijd voor ons. Jouw enorme 
onderzoekservaring heeft de discussie van mijn proefschrift echt een extra dimensie gegeven.  
 
Zonder manuscriptcommissie en corona geen promotie. Bedankt dat jullie bereid waren deze 
taak op jullie te nemen. 
 
Co-auteurs, jullie wil ik bedanken voor de kritische input. Zonder jullie was het eindresultaat 
minder goed geworden. In het speciaal wil ik Arenda bedanken voor het lezen van alle 
abstracts voor het review, maar ook vooral voor het helpen richting te geven aan het review. 
Als je mij niet had geholpen om een strak plan te trekken was ik nog een hele tijd bezig 
geweest. Natuurlijk ook bedankt voor alle schattige baby kleertjes die ik mocht lenen voor 
Livia. 
  
Stagiaires, jullie hielden me scherp en lieten me zien dat het lastig kan zijn om aan anderen 
precies uit te leggen waarom en hoe je dingen doet. Linda, super dat jouw stage onderdeel 
van dit proefschrift is geworden. 
  
Mijn collega-onderzoekers: bedankt! Andere onderzoekers, stafleden, aios, 
laboratoriummedewerkers en secretaresses van de afdeling geriatrie van het Radboudumc: 
allen bedankt voor de gezelligheid en prettige samenwerking! 
 
Lieve Geke, m’n mattie van de afdelingskamer bij de binnentuin (en daar buiten). Als mijn 
meest directe collega heb je mij de kneepjes van het veldwerk geleerd. Af en toe lekker 
klagen keeps you going, toch? We hebben samen hard gewerkt, maar (gelukkig) ook veel lol 
gehad. 
 
Lieve Malou, ook al hebben we niet veel direct samengewerkt, de gezellige lunch uurtjes in 
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Nijmegen, het weekendje Belgie hebben me vaak goed gedaan en je bent gewoon een goed 
vriendinnetje geworden. Het was fijn om je als sparringspartner te hebben tijdens de zware 
loodjes! Hopelijk blijven we elkaar veel zien. 
Lieve vriend(inn)en! Wat ben ik gezegend met jullie. Het combineren van promotie, en 
daarnaast ook nog jullie willen zien, is lastig. Dank voor al jullie gezelligheid, interesse, steun 
en ook flexibiliteit als ik weer eens afspraken wilde verzetten. Laten we er de 3e een mooi 
feestje van maken! 
 
Lieve Chantal, we hebben een vriendschap die teruggaat tot de prehistorie. Ook al zien we 
elkaar niet veel, we pakken altijd net zo makkelijk de draad weer op waar we gebleven waren. 
Geweldig dat je als paranimf wil optreden. 
 
Lieve Annelien. We kennen elkaar nu 2 jaar, maar wel 2 hele gezellige jaren. Als 
onderzoeksassistent (of moet ik zeggen personal assistant) van Geke kwam je onze kamer 
verrijken. En onze gezamenlijk habitat (Ede, the place to be) heeft ons vele gezellige 
gezamelijke treinreisjes opgeleverd. En natuurlijk niet te vergeten onze sportiviteit in het 
zwembad. Ik vind het heel leuk dat je tijdens mijn verdediging mijn back-up, als paranimf, wilt 
zijn.  
 
Lieve mama, misschien kon je af en toe niet meer bijbenen waar ik mee bezig was; 
onderzoek, opleiding, voorbereiden voor congres etc...... Maar je hebt me altijd gestimuleerd 
om het beste uit mezelf te halen. Samen hebben we al een heleboel meegemaakt. Leuke en 
minder leuke dingen. Maar we staan sterk. Ik hoop dat je net zo trots op mij bent als ik op 
jou. 
Lieve Eva, sis, ook al heb je het misschien niet altijd gemakkelijk met zo’n betweterige oudere 
zus, samen hebben we (bijna) altijd lol. Forever sisters! 
 
Lieve Daniël, je moest het allemaal aanhoren en meemaken; mijn gemopper als het niet wilde 
vlotten, de statistiekperikelen waar ik je mee opscheepte, de zenuwen als ik op een 
buitenland bezoek moest, alle keren dat ik weg moest voor een cursus of congres (in plaats 
van gezellig bij jou te zijn), alle presentaties waar je naar mocht luisteren. Dank je wel voor al 
je steun en liefde. Het is heerlijk samen met jou! 
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Aisha Meel-van den Abeelen (19 april 1987) groeide op in Hengelo (Overijssel). Na het 
behalen van het Gymnasium diploma op de Grundel te Hengelo, startte zij in 2005 met de 
studie Technische Geneeskunde aan de Universiteit Twente te Enschede. 
Na haar eerste masterstage op de afdeling klinische neurofysiologie van het Radboudumc, 
volgden vele stages in het Radboudumc (KNO, Geriatrie en NICU). In 2011 behaalde zij haar 
universitaire diploma, waarna ze verder ging als OIO op de afdeling geriatrie in het 
Radboudumc. Haar promotieonderzoek naar de kwantificatie en klinische toepassing van de 
cerebrale autoregulatie werd kort onderbroken voor de komst van een prachtige dochter 
Livia. Daarna heeft ze haar Ph.D. traject weer opgepakt. Sinds juni 2014 werkt ze als post-
doctoraal onderzoeker aan een onderzoek naar de toepassing van 3D-ultrasound voor 
borstkankerdiagnostiek.  
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‘Promise me you’ll always remember: 
you’re braver than you believe, 
and stronger than you seem, 
and smarter than you think.’ 
-Pooh- 
